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Abstract
To date, five cancer treatment modalities have been defined. The
three traditional modalities of cancer treatment are surgery, radio-
therapy, and conventional chemotherapy, and the two modern
modalities include molecularly targeted therapy (the fourth modal-
ity) and immunotherapy (the fifth modality). The cardiotoxicity
associated with conventional chemotherapy and radiotherapy is
well known. Similar adverse cardiac events are resurging with the
fourth modality. Aside from the conventional and newer targeted
agents, even the most newly developed, immune-based therapeutic
modalities of anticancer treatment (the fifth modality), e.g., immune
checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell
therapy, have unfortunately led to potentially lethal cardiotoxicity
in patients. Cardiac complications represent unresolved and poten-
tially life-threatening conditions in cancer survivors, while effective
clinical management remains quite challenging. As a consequence,
morbidity and mortality related to cardiac complications now
threaten to offset some favorable benefits of modern cancer treat-
ments in cancer-related survival, regardless of the oncologic prog-
nosis. This review focuses on identifying critical research-practice
gaps, addressing real-world challenges and pinpointing real-time
insights in general terms under the context of clinical cardiotoxicity
induced by the fourth and fifth modalities of cancer treatment. The
information ranges from basic science to clinical management in the
field of cardio-oncology and crosses the interface between oncology
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and onco-pharmacology. The complexity of the ongoing clinical
problem is addressed at different levels. A better understanding of
these research-practice gaps may advance research initiatives on
the development of mechanism-based diagnoses and treatments for
the effective clinical management of cardiotoxicity.
K EYWORDS
cancer therapy-induced cardiotoxicity, chimeric antigen receptor
(CAR) T-cell therapy, immune checkpoint inhibitors, molecularly tar-
geted therapeutics, research-practice gaps
1 INTRODUCTION
Currently available cancer treatments include the traditional surgery, radiotherapy, and conventional chemotherapy
approaches and have been extended with two new modalities in recent decades: molecularly targeted therapy (MTT)
and immunotherapy. Cardiac toxicities associated with conventional chemotherapy and radiotherapy are well known,
and to a certain degree, the cellular and molecular mechanisms leading to cardiotoxicity have been discovered.
Similar adverse cardiac events are encountered when applyingMTTs, which represent a new generation of anticancer
drugs.1–11 The MTTs that have received US FDA approval since their initiation in 2001 are listed in Tables 1 and2,
and 3. In addition, the recently developed immune-based therapeutic modalities, e.g., immune checkpoint inhibitors
(ICIs)12–29 and chimeric antigen receptor (CAR) T-cell therapy (CART),29–44 have also raised cardiovascular concerns
in patients, including lethal cardiotoxicity (Table 3). Cardiotoxicity reflects functional, structural or a combination of
both types of damage to the heart by various detrimental environmental insults,45 e.g., conventional chemotherapy,
radiotherapy, MTT, immunotherapy, and toxins. Cardiotoxicity manifests as electrophysiological disorder of the heart
(cardiac dysfunction) and a spectrum of myocardial damage (cardiomyopathy), with heart failure as the most severe
consequence. The clinical features are demonstrated by a wide range of cardiovascular manifestations or events,
including bradycardia, tachycardia, cardiomyopathy, widened pulse pressure, hypotension, arrhythmias, decreased left
ventricular ejection fraction (LVEF), troponinemia, QT prolongation, myocarditis, myocardial infarction, pericarditis,
acute coronary syndromes, and congestive heart failure.20,46–49 The clinical scenarios derived from these novel
anticancer approaches reflect new challenges to medical, pharmacological, and research communities because the
cardiotoxicity from new clinical entities are clinically and mechanistically different from the cardiotoxicity resulting
from traditional chemotherapeutic agents. Cardiotoxicity caused by these novel agents or modalities are diverse, and
many specific mechanisms of individual compounds or modalities underlying this toxicity remain to be elucidated.50
Some commonly conceptualizedmechanisms underlie toxicity, including on- and off-target toxicity, production of toxic
metabolites, harmful immune responses, unpredictable specificities of targeted tumor antigens, tumor lysis symptoms,
cytokine release syndrome, T-cell receptor (TCR)mispairing, TCR cross-reactivity, and idiosyncratic mechanisms.51–56
A primary goal of targeted therapy or more advanced immune-based modalities is to kill cancer cells more specif-
ically than traditional treatment modalities while maintaining an acceptable level of side effects and quality of life.
Unfortunately, the newer targeted agents or modalities exhibit a similar frequency and severity of toxicities as tra-
ditional cytotoxic agents do, albeit with differences in preference for the organs/tissues that are involved.57 Many
unanticipated short- and long-term adverse effects on multiple organs/tissues have shown the limitations of the
new therapies,7,30,56–59 although MTTs have improved the overall survival of cancer patients over the past two
decades,57,60,61 and advanced immunotherapies are promising to improve the outcomes of certain types of cancers
(ICIs62–70 and CART71–74). Cardiac complications associated with cancer treatment represent unresolved and poten-
tially life-threatening conditions in cancer survivors. As a consequence, morbidity and mortality related to cardiac
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TABLE 3 Immune checkpoint inhibitors and CART in oncology and the reported clinical cardiotoxicity/car-
diovascular events from 2011 toMay 2017
Generic/TradeName
Approval
Year Category Antigens Disease Indications
Cardiotoxicity/
Cardiovascular
Events
Yervoy (Ipilimumab) 2011 ICI CTLA-4 Metastatic melanoma SR16,134-136
Opdivo (Nivolumab) 2014,
2015,
2016
ICI PD-1 Metastatic melanoma,
metastatic SNSCLC,
ARCC
SR16,135-140
Keytruda (Pembrolizumab) 2014,
2015,
2016
ICI PD-1 Head and neck SCC SR16,135-
137,141-143
Tecentriq (Atezolizumab) 2016 ICI PD-L1 Urothelial carcinoma and
metastatic NSCLC
SR144
Bavencio (avelumab) 2017 ICI PD-L1 Merkel cell carcinoma SR160, SR161,
SR167
Imfinzi (durvalumab) 2017 ICI PD-L1 Advanced ormetastatic
urothelial carcinoma
SR162, SR167
CART Not yet CART CD19,MAGE-A3 Hematopoietic
malignancies,
melanoma
SR145-159
Abbreviations: CTLA-4 = Cytotoxic T-lymphocyte-associated antigen 4; ICIs = Immune checkpoint inhibitors;
ARCC = Advanced renal cell carcinoma; CHL = Classical Hodgkin lymphoma; SNSCLC =Metastatic squamous non-small cell
lung cancer; SCC = Squamous cell carcinoma; NSCLC = Non-small cell lung cancer; CART = Chimeric antigen receptor T cell
therapy; SR= Supplemental references.
complications now threaten to offset someof the favorable benefits of these novel cancer treatments in cancer-related
survival and strongly impact thequality of life regardless of the oncologic prognosis.75–77 Additionally, effective clinical
management remains quite challenging because no evidence-based approaches are currently available for the effec-
tive monitoring and treatment of these patients.78,79 This information is lacking because the risk of cardiovascular
toxicity greatly differs from one treatment to another according to the targeted pathways or antigens and the pres-
ence of co-morbid conditions.75,80 Because the novel drugs or modalities are highly cost-intensive,81–84 cardiotoxi-
city may add additional costs without improving the outcome of a life-limiting illness with a generally unpredictable
occurrence and uncertain cure.8,54,85,86 Clinical cardiotoxicity challenges not only sustainable cancer survivorship but
also precision oncology/medicine and affordable healthcare. Cost savings are a major incentive for the adoption of
biosimilars, and some biosimilars have been developed and used in clinical oncology trials.87,88 Biosimilars refer to
biologic products that demonstrate no clinically meaningful differences in terms of quality attributes, efficacy, safety,
and immunogenicity compared with an existing licensed, originator biologic.89 The incorporation of biosimilars into
healthcare systems worldwide may result in a 30–45% cost savings.87 A strategy to prevent clinical cardiotoxicity will
have significant impacts on the overall prognosis and survival of cancer patients. This strategy is part of the field of
cardiovascular safety, with multifaceted aspects at multiple levels involving improvement of preclinical models for
the study of chemotherapy-induced cardiotoxicity,90 appropriate preapproval investigations and monitoring during
clinical practice.91 In addition, it is important to realize that the approval decision following preapproval clinical tri-
als does not necessarily represent a singular moment of clarity about the risks and benefits associated with a drug;
thus, continuous post-marketing surveillance and vigilance for cardiotoxicity is required.91 The research gaps in novel
cancer treatment-related cardiotoxicity range from basic, translational, clinical, and epidemiologic sciences to can-
cer patients, medical professionals, research communities, pharmaceutical industries, regulatory bodies, and research
funding agencies. In response to ongoing clinical challenges, “cardio-oncology” or “onco-cardiology” represents a new
multidisciplinary discipline in recent decades92,93 and is a newer frontier in clinical medicine leading to advances in
clinical care, medical education, and dual subspecialist training programs.94–96 The subspecialty harbors more ques-
tions than answers; thus, enormous research opportunities are embedded in the field.76 The research is expected to
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address gaps from basic, translational, and clinical studies to epidemiological studies and to exploit the synergistic
interactions amongmultiple disciplines. A joint effort ofmultiple disciplines, including cardiology, oncology, and clinical
pharmacology is to lead advances in the field of cardio-oncology in hopes of ultimately eliminating cardiac diseases as a
barrier to effective cancer therapywhile providing affordable care to patients. This review focuses on the identification
of the current gaps between research and clinical practice and addresses the challenges and pinpoints current insights
of clinical cardiotoxicity induced by the fourth and fifthmodalities of cancer treatments.
2 FDA-APPROVED MTTS FOR ONCOLOGY
According to the latest reports,97–100 approximately 76 targeted anticancer drugs received approval from theUS FDA
from 2001 to May 2017; these drugs include small molecule kinase inhibitors, other types of agents (e.g., proteasome
and histone deacetylases targeting inhibitors) (Table 1), and therapeutic monoclonal antibodies (Tables 2 and 3). The
clinical patterns of toxicity associated with some of these agents have been addressed or discussed in detail in other
reviews.20,46–49 Many of the approved drugs are protein kinase inhibitors (PKIs), typically protein tyrosine kinase
inhibitors (TKIs).101–103 Only a few inhibitors affect serine/threonine kinases (e.g., Vemurafenib and Dabrafenib),102
andone is a lipid kinase inhibitor (idelalisib).104 This distribution is in linewith the fact that tyrosinephosphorylation is a
uniquebiochemicalmechanismutilizedby intra- and intercellular communicationpathways, and thesekinases regulate
important fundamental cellular processes, including cell proliferation, differentiation, migration, and metabolism.103
Protein kinases catalyze the transfer of the terminal phosphate of ATP to substrates that usually contain a serine, thre-
onine, or tyrosine residue; this phosphate then serves as a ubiquitous mechanism for cellular signal transduction.105
Thus, protein kinases are ATP-consuming enzymes with a high degree of conservation in their kinase domain,8,105,106
especially for those within the family of protein tyrosine kinases (PTKs).2,8,101 The ATP-consuming feature is unfor-
tunately associated with the ATP required for the vitality and viability of cardiomyocytes. Mitochondria are abun-
dant in heart tissue, constituting approximately 45% of themyocardial volume, which is high in comparison with other
tissues.107 The abundance is due to the high-energy demand of the heart, which is satisfied during mitochondrial res-
piration; thus, more than 90% of the ATP generated by the mitochondria is utilized by cardiomyocytes for myocardial
function and viability.107
The protein kinase family includesmore than 385 serine/threonine kinases andmore than 90PTKs.102,103,105 More
than 900 protein-encoding genes with kinase activity have been confirmed.108–110 Out of 90 PTKs, 58 are recep-
tors with an extracellular, transmembrane, and intracellular domain, and 32 are intracellular non-receptors.102,111,112
Kinases comprise one of the largest classes of proteins encoded by the human genome, and their signaling molecules
play an important role in regulating almost every aspect of cell function in many different tissue types and
organs,102,105,108,109 including the cell fate decisions of cardiac myocytes that lead to cardiac pathologies.7,113 Thus,
dysfunctional kinase activity disrupts the normal control of cellular phosphorylation signaling pathways and leads to
numerous pathologies beyond cancer through pathway affiliation,99 including immunological, neurological, metabolic,
infectious diseases, diabetes, osteoporosis, and otology.7,98,101,102,105,113–115 Consequently, the pharmacological util-
ity of kinase-targeting has been expanded for kinase-targeted therapies in a broad array of indications beyond
cancers.98 The selectivity of drug-kinase interactions has become a common concern in clinical pharmacology,116
and there is continuing debate surrounding target selection, mechanism of action, compound development prioriti-
zation, toxicity, and patient tailoring.116,117 Kinase inhibitors also provide additional opportunities to investigate and
elucidate kinase functions under various circumstances, both physiologically and pathologically.104 Intensive efforts
in the exploration of disease targets have significantly extended the coverage of druggable targets in the human
kinome from the tyrosine kinase family to several other families, such as calmodulin/calcium-regulated kinase, glyco-
gen synthase kinase (GSK), cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), CDC-
like kinase (CLK), and protein kinase C (PKC).98,104 In addition, targeting the ubiquitin-proteasome pathway is an
emerging concept in cancer therapy based on the hypothesis that many proteins in the proteasome are implicated
in the regulation of important processes of carcinogenesis and cancer cell survival.118 Several proteasome-targeting
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inhibitors (e.g., bortezomib,20,47,119–125 carfilzomib20,124,126–130) have been introduced in the clinic. A retrospective
analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma reported that
bortezomib-based treatment was associated with a low incidence of cardiac events.131 Epigenetic cancer therapy
using histone deacetylase inhibitors is also emerging,132–134 as epigenetic gene silencing is a hallmark of cancer cells.
Two important types of epigenetic changes are DNA methylation by DNA methyltransferases (DNMTs) and histone
modification by histone deacetylases (HDACs).133,134 DNMTs andHDACs have become attractive therapeutic targets,
and several HDAC inhibitors e.g., Romidepsin,47,57,135–140 Belinostat,141,142 and Panobinostat,137,140,143,144 have been
used in the clinic. Unfortunately, clinical cardiotoxicity has been induced by these types of drugs.47,57,135–144
3 KINASE INHIBITORS AND CARDIAC CONCERNS
Based on kinship in structure and activity (different binding modes), kinase inhibitors can be grouped into two classes:
irreversible and reversible.102,104,109,114,116,145 Irreversible inhibitors form covalent bonds with cysteine or other
nucleophilic residues in the ATP-binding pocket.105,116 The advantage of an irreversible inhibitor is its ability to block
the active site of the kinase, which might also block mutated versions of the kinase.101 Theoretically, irreversible
inhibitors may be superior to their reversible counterparts in several aspects. For example, they circumvent competi-
tionwith high ATP concentrations in the cell and are less affected by changes in the ATP-binding affinity, and they have
prolonged pharmacologic effects, high potency, and the ability to validate pharmacological specificity through muta-
tion of the reactive cysteine residue.103,105 However, progress in the implementation of irreversible kinase inhibitors
in the clinic remains slow because of safety and toxicity concerns,109,146 as covalently binding kinase inhibitors require
the intrinsic reactivity of cysteine-reactive groups, which can lead to non-selective reactions with off-target proteins
that increase toxicity.101,147–150
Kinase inhibitors are further categorized into four main types based on their binding mode to a target109,151: type
I inhibitors constitute the majority of ATP-competitive inhibitors and recognize the active conformation of the kinase;
type II inhibitors recognize the inactive conformation of the kinase; type III inhibitors bind next to the ATP-binding
pocket; and type IV (irreversible inhibitors) do not bind to the ATP or peptide substrate binding sites102,109,116,145,152
but characteristically form covalent bondswith their target enzyme.109,145 Thus, type III and IV inhibitors are allosteric
in nature.109,114,150 So-called allosteric sites refer to locations outside of the ATP-binding pocket, and allosteric
inhibitors blockprotein kinase catalytic activitywhile havingnoeffect onATPbinding.109 Allosteric inhibitors bindout-
side the ATP-binding site and thus induce a conformational shift in the target enzyme to block the kinase function.150
Currently, the vast majority of PKIs in the clinic are type I inhibitors that target the ATP-binding site in its active
conformation (reversible ATP-competitive inhibitors).101,102,105,108,114,150,153 With high relevance in cardiac safety
liabilities, kinases have one ATP-binding site, and thus, cardiotoxicity would theoretically be inevitable if a targeted
kinase was functionally expressed in the heart (on-target toxicity) when ATP-competitive inhibitors are used. Even
if a targeted kinase is not expressed in the heart, off-target toxicity is also a major issue for both ATP-competitive
kinase inhibitors154 and non-ATP-competitive kinase inhibitors (allosteric inhibitors).101,147–150 Assuming an ATP-
competitive case, an energy system dysfunction or energy deprivation of cardiomyocytes becomes a high risk. This
risk is in line with the fact that cardiac muscle tissue is highly energetic, and cardiac performance is typically reliant on
aerobic metabolism as a source of ATP; impairments in this process can rapidly induce cardiac dysfunction.155 Phar-
macologically, a theoretical solution to this problem is the development of covalent-allosteric kinase inhibitors (type
III and IV inhibitors),156 in which an active site-directed moiety is tethered to another ligand that targets a location
outside of the ATP-binding cleft. In principle, allosteric inhibitors should be superior to active-site-directed inhibitors
due to the high degree of kinase selectivity because these sites are highly divergent across the kinome and are unique
to a particular kinase.101,114,116,151 In contrast, the high sequence similarity in the ATP-binding site among members
of the kinase family often results in low selectivity and additional toxicities of these ATP-competitive inhibitors. Con-
sidering the superiority of allosteric inhibitors, the development of inhibitors that target sites other than the ATP cleft
has been the reality in clinic. Trametinib is the only type III inhibitor that has been approved thus far, although several
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promising allosteric kinase inhibitors are currently in different stages of clinical trials.104,109 Only a feware irreversible
ones (afatinib and ibrutinib)104 that have been approved by the FDA (Table 1). Currently, clinical cardiotoxicity induced
by irreversible inhibitors, e.g., Trametinib,20,57,124,157–159 Ibrutinib,20,160,161 and Afatinib162,163 has been reported.
Thus, novel mechanisms of action need to be further explored in type III and IV inhibitors.104 Despite the advantages
of covalent-allosteric kinase inhibitors versus orthosteric inhibitors (types I and II), whether allosteric kinase inhibitors
can radically overcome the non-selective problem (most importantly, considering clinical cardiotoxicity) while retain-
ing their potency or effectiveness on cancer cells104,164 in the clinical endpoint remains unclear. The ultimate answer to
this question, considering cardiac safety concerns and potency on cancer cells, will derive from the accumulated clini-
cal data in the future because the predictive values of success in the preclinical model systems are limited to the use of
homogenous cell lines and immune-compromised animals.101
Because protein kinases play a key role in all aspects of cancer, kinase inhibitors represent the largest family of
targeted agents that have entered or are entering the clinic.101 However, an important concern is that only a very small
percentage of kinases (approximately one-fifth of the human kinome) have been successfully targeted clinically.104,165
Thus, the field remains largely unexplored in the research of numerous undiscovered kinases, their respective
inhibitors, and their potential cardiotoxicity/toxicities. Moreover, approximately 10–20% of the kinases are classified
as pseudokinases109,166 because of the lack of one or several of the highly conservedmotifs involved in nucleotide (nt)
binding or catalytic activity of protein kinases.110,165,166 Many pseudokinases in the kinome have evolved from active
kinases by obtaining regulatory functions in which catalytic function is dispensable; however, a significant proportion
of pseudokinases have retained their ATP-binding ability.166 An important molecular property of pseudokinases is
that they serve as allosteric regulators of signaling pathways.109 Pseudokinases also play an important regulatory role
in cellular signaling, and the abnormal function of several human pseudokinases has been associated with human dis-
eases, including cancers.110,165–172 Pharmacological targeting of pseudokinases may be a possible alternative option
in this regard.165,173,174 For example, the receptor tyrosine kinase (RTK)-like orphan receptors (RORs) are RTK-like
pseudokinases in this context.175 ROR1 is a type 1 transmembrane protein expressed on the plasma membrane and
has an extracellular domain that is essential for ligand binding and signal transduction.176,177 Interestingly, ROR1
is selectively overexpressed in many hematologic malignancies and a number of solid tumors, while it is without
significant expression in normal adult tissues.176,178,179 The unique expression profile of ROR1 makes it a promising
candidate for novel drug targets,176 assuming that this expression pattern will maximize effectiveness and minimize
off-target toxicities. A monoclonal antibody (cirmtuzumab) was developed by binding to ROR1 on tumor cells and
inhibiting Wnt5a signaling, which is a pathway that is important for blocking tumor-cell proliferation, migration, and
survival.180 The antibody has been used in a phase I clinical trial for chronic lymphocytic leukemia.175,178,179,181,182
4 CAVEATS, CHALLENGES, AND INSIGHTS ON THE DIAGNOSIS
AND THERAPY OF MTT-INDUCED CARDIOTOXICITY
4.1 Caveats
An important caveat for clinicians is the fact that in many cases, the adverse cardiac events observed in the clinic were
unobserved in preclinical safety evaluations or insufficiently addressed in clinical trials; these events may not even be
mentioned on product labels when placed on themarket.2,8,58,154,183 Cardiotoxicitymay become apparent only in rou-
tine clinical practice.2 Therefore, it is important to identify new models or techniques in both preclinical and clinical
settings154 that can better predict adverse clinical outcomes with these agents. Some studies have shown that cancer
treatment-related cardiotoxicity is the third leading cause of treatment-associated mortality in survivors of pediatric
and adolescent cancers, with recurrence and second malignancies being the two leading causes.184 In adult patients,
cardiotoxicity is agent-dependent, and the incidence can be as high as 50%, depending on the cardiac conditions.185
The incidence of treatment-induced heart damage in pediatric cancer survivors increases over time186,187 and can
be identified many years post-launch or even 30 years after treatment, as shown in adult survivors of childhood
cancers.186,188–192 A constant vigilance for cardiotoxicity is required91 and is especially important for pediatric
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cancer patients. These pediatric patients have a higher risk of developing treatment-associated cardiotoxicity/
toxicities subject to age-associated, tissue-specific sensitivity to cancer therapeutics193 and can exhibit an insidious
onset (occult cardiotoxicity).194 Clinicians practice in a sea of uncertainty, with relatively few strategies leading to
the safe prescription of anticancer drugs or use of therapeutic modalities. This uncertainty poses a threat to mak-
ing life-altering decisions based on incomplete information in real-world practices. In addition, the so-called “break-
through therapy designation” (applied tomany novel anticancer therapies by the FDA since 2012) 195–208 refers to the
allowance of particular drugs to have an accelerated approval timeframe in order to provide new treatment options
for difficult diseases and conditions. Thus, the designation by no means guarantees an escape from cardiotoxicity
of any investigative or post-marketing drugs in clinical endpoints. Breakthrough “magic bullet” therapies have been
criticized by medical professionals who emphasize the importance of evidentiary requirements for meaningful clin-
ical data.209,210 Beyond cancer, treatment-related cardiotoxicity is a growing concern (not restricted to anticancer
agents), and almost all therapeutic drug classes haveunanticipated cardiotoxicities.154,211 Onemajor problem is chron-
ically administered drugs, such as neurologic/psychiatric agents and anticancer chemotherapeutic agents, because
toxicity may become evident only after long-term accumulation of the drug or its metabolites (toxicology-metabolic
activation)148 in the heart.135,136,193 Cancer has been transformed from a rapidly fatal disease into a chronic condition
due to advancements in detection and treatment.212,213 As such, both short- and long-term cardiotoxic effects result-
ing from cancer therapy are becoming more evident.213 The long-term adverse effects are typically seen in adult sur-
vivors of childhood cancer, but treatment-related cardiotoxicity can develop at any time after treatment initiation and
can occurwell into adulthood.188–192 Given the concern of cardiac safety liabilities in relation to non-anticancer drugs,
a particular caution should be takenwhen repurposing non-anticancer drugs for novel applications in oncology.214,215
4.2 Challenges, insights, and perspectives
4.2.1 Current diagnostic modalities and biomarkers
Preventing cardiac damage is far more important than using a therapeutic intervention to counteract ongoing damage
because in general, the heart is a terminally differentiated organ, and adult mammalian myocardium has very limited
regeneration potential after injury.45 Thus, prompt recognition of early signs of cardiotoxicity and initiation of appro-
priatemanagement prior tomajor clinical manifestations (i.e., the irreversible phases) is paramount for the substantial
recovery of cardiac function in the hope of preventing the development of irreversible cardiotoxicity.216–219 “Early
detection” theoretically refers to the identification of early functional cardiotoxicity – at this stage, no morphologi-
cal damage to cardiomyocytes is detectable, and the damage is usually reversible and clinically manifests as asymp-
tomatic or subclinical cardiotoxicity.185,220–222 Unlike functional cardiotoxicity, structural cardiotoxicity often appears
in late stages and is usually irreversible, with detectablemorphological and symptomatic damage.185,220 For the detec-
tion of cardiotoxicity and the initiation of therapeutic measures in the early stages, a set of diagnostic and prognostic
methods have been suggested, including clinical, imaging, serological, and molecular investigations.198–200,205 Unfor-
tunately, while 2D echocardiography or radionuclide angiography, ECG, and several bloodmarkers that are commonly
used in clinical practice allow the late diagnosis of cardiac dysfunction, these tests have a low sensitivity and insuf-
ficient predictive power in detecting subtle, incipient myocardial injury.216,223,224 A cardiac biopsy-based approach
is highly invasive and is not a suitable option for routinely diagnosing and monitoring cancer treatment-related car-
diotoxicity. Noninvasive or minimally invasive approaches should be considered first. Furthermore, the currently used
cardiotoxicity biomarkers provide few mechanistic insights into the underlying mechanisms that lead to the identifi-
cation of actionable and mechanistic biomarkers–-understanding these mechanisms is a fundamental effort to trans-
lational medicine. Circulating biochemical markers are alternative or synergistic tools for clinical diagnosis. However,
circulating biochemical markers harbor potential problems related to sensitivity and specificity with respect to sys-
temic disease because this type of biomarker could be significantly influenced by multiple microenvironmental fac-
tors both locally and systemically. Cancer is a systemic disease with local manifestations,225 and cancer cachexia of
multiple organs, including cardiac cachexia,226 is a typical reflection of its systemic nature. An ideal circulating
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biomarker is definedby two important characteristics: disease specificity anda linear relationship (sensitivity) between
the serum/plasma concentration and disease severity.227 For instance, cardiac troponin (cTn), B-type natriuretic pep-
tide (BNP), and its N-terminal fragment (NT-proBNP) are the best-studied circulating biochemical markers of cardio-
vascular diseases, including cardiotoxicity, and they have been used primarily in the clinic.228–230 However, cTn, BNP,
and NT-proBNP are elevated not only in patients with acute and chronic cardiovascular diseases but also in patients
with non-cardiovascular diseases,227,231 including untreated cancers.232–234 Therefore, these biomarker values may
reflectmore than the disease activity towhich they are applied.228,235 Moreover, a newconcern has been raised for the
potential impact of the tumor itself on cardiovascular health; the underlying cancer pathophysiology may also affect
cardiac biomarkers.233
4.2.2 Application and development of advanced diagnostic modalities and biomarkers
Advanced non-nuclear molecular imagingmodalities
The gap in relation to the early detection/diagnosis of cardiotoxicity should be filled by combined clinical and transla-
tional research. Advanced diagnostic imagingmodalities are gainingmomentum. Imagingmethods have the advantage
of in situ visualization of real-time cardiac performance with dynamic profiles to assess cardiac function. Currently,
advanced, non-nuclear molecular imaging modalities in the clinic mainly include 3D echocardiography, cardiac mag-
netic resonance (CMR) imaging, cardiac computed tomography (CT), 3D speckle tracking echocardiography (STE), and
cine images. Among these techniques, 3D echocardiography strain rate/deformation imaging, metabolic imaging, and
myocardial systolic velocities seemmore sensitive and should facilitate the identification of patients with more subtle
measures of cardiac function.236–240 Recently, CMR imaging241,242 and cardiacCT243 have been explored for their util-
ity in evaluating cancer treatment-induced cardiotoxicity. Cardiac CT has an excellent diagnostic performance for the
detection of subclinical atherosclerosis, coronary atherosclerotic plaque, and obstructive coronary artery disease,243
while CMRhas added value in characterizingmyocardial remodeling.241 Conceptually, left ventricular (LV) remodeling
is defined in response to myocardial injury or overload through chamber dilation and/or hypertrophy.244–246 Remod-
eling restores the contour of the chamber by removing poorly functioning areas to improve its efficiency.247 Classifi-
cation of such states can be achieved by evaluating LV mass, LV volume, the ratio of LV mass/volume (M/V), and rel-
ative LV wall thickness (RWT).248–250 Thus, the spectrum of LV geometric adaptation can be measured using these
geometric parameters. Ventricular hypertrophy (VH) is classified as concentric when the RWT is increased, while VH
is classified as eccentric when the RWT is not increased; a third pattern, termed concentric remodeling, occurs when
RWT but not ventricular mass is increased.244,248 Analysis of cardiac function is the major focus of echocardiogra-
phy, and measuring LVEF has been the clinical standard; however, LVEF has shown its limitations for early detection
of myocardial dysfunction.251,252 In the past decade, STE has become a novel clinical tool for the analysis of regional
and global myocardial function, and this tool has the potential to provide a more accurate assessment of overall and
regional myocardial function.251,253 Cine images are short movies that show heart motion throughout the cardiac
cycle, and the images can be very useful in studying cardiac and valvular function and the movement of blood through
the heart.254,255 As the myocardium contracts and thickens throughout the cardiac cycle, any abnormality in this wall
motion indicates a problem with the myocardium, such as ischemia or infarct.256 Cardiac cine images have already
beenused toevaluate cardiotoxicity in breast cancer patients treatedwith trastuzumab.257 Althougheachnon-nuclear
molecular imagingmodality has their different strengths andweaknesses, a common feature of thesemodalities is the
use of nonradioactive probes such as light or sound. In addition, these modalities are mainly used to detect changes in
the anatomical and physiological features of cardiac events rather than function at the cellular and molecular level. In
this regard, these diagnosticmodalities have less value for understanding disease processes than domolecular imaging
modalities (see the “Nuclear molecular imaging” section).
Nuclearmolecular imaging
In contrast to traditional imaging modalities, molecular imaging in the myocardium has great potential to contribute
to clinical cardiovascular medicine by improving the understanding of disease processes and therapeutic mechanisms
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or effects,258 enabling the visualization and interrogation of specific biologic targets and pathways that precede or
underlie changes in morphology, physiology, and function of the heart prior to the manifestation of gross anatomical
features or physiological consequences.258–261 Thus, the potential for molecular imaging is much greater than the
detection of changes in anatomical and physiological features using non-molecular imaging modalities, such as
blood flow or contractile function.262,263 In the preclinical setting, molecular imaging of the cardiovascular system
uses multiple modalities, including optical, nuclear, MR, CT, ultrasound imaging, and fluorescence imaging.258,263
However, clinical application in humans has beenmainly restricted to the use of nuclear imaging techniques,258,262 e.g.,
single photon emission computed tomography (SPECT) and positron emission tomography (PET). Nuclear molecular
imaging characterizes specific disease processes (functions) in different individuals (personalized patient care) using
the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in
humans and other living systems. Therefore, nuclear molecular imaging is different from routine X-rays, CT, MRI,
or echocardiography, which largely show how the body appears structurally rather than how it functions. However,
nuclearmolecular imaging uses radioactive pharmaceuticals and traces their progress through the body to “view” how
the body is functioning. The application of radioactive substances in the diagnosis and treatment of disease is a unique
feature for nuclear imaging. Currently, the clinical application ofmolecular cardiac imaging based on nuclear imaging is
largely limited to the imaging ofmetabolism and innervation.258 Activation of the cardiac sympathetic nervous system
is a cardinal pathophysiological abnormality associatedwith the failing human heart.264 Several SPECT and PET radio-
tracers can be used for imaging pre- and post-synaptic function.265,266 Among those radiotracers, the norepinephrine
analog123 Imetaiodobenzylguanidine (123IMIBG) is FDA approved and the most commonly used agent. This agent can
be used to investigate the activity of norepinephrine, which is the predominant neurotransmitter of the sympathetic
nervous system.267–269 The discovery and application of agents such as 123IMIBG are absolutely needed in clinical
nuclear imaging to provide better prognostic risk stratification, which, in heart failure,may include innervation imaging
(sympathetic imaging), because this imaging modality provides more accurate information than conventional markers
and mechanistic insights that drive therapeutic decisions.258,259,267 A reduced 123IMIBGmyocardial uptake or higher
washout rate can predict cardiac adverse events.123,267IMIBG imaging is more sensitive than decreased LVEF, which
has been frequently used in the clinic,268 because a decrease in LVEF is a late manifestation of cardiotoxicity.252
Moreover, with the imagingmodality, it is also possible to predictwhether LVEF recoverywill occur.269 Indeed, seeking
early predictors of cardiotoxicity is urgently needed so that treatment can be initiated earlier or that pre-emptive
intervention can be used270 to prevent irreversible cardiac damage.
Photoacoustic imaging
Radiotracer-free molecular imaging modalities may serve as alternatives to nuclear molecular imaging. However, an
important concern in the application of these imaging techniques in the clinic is the technical challenge of limited pen-
etration depth in contrast to nuclear molecular imaging using radiotracers.258,262 To overcome these technical chal-
lenges, some advances are being made to provide the required signal amplification in order to enable molecular imag-
ing with contrast agents, e.g., new nanoparticle contrast agents coupled with MRI and ultrasound.262 However, the
clinical safety of these contrast agents must be further evaluated in human studies.262 To date, no single parameter
or approach can accurately predict cardiotoxicity in the clinic. Multi-parameter test panels or modalities may be ben-
eficial for preclinical and clinical investigations or applications because they enable the acquisition of complementary
information from each panel/modality.271 Each imaging modality has its intrinsic advantages and disadvantages for
cardiovascular events,263 but none of the current clinically used modalities can simultaneously image both molecu-
lar events and anatomical and physiological features. Medical diagnosis and therapeutic options benefit greatly from
imaging technologies that combine molecular and microscopic parameters with clinical observations; such a combi-
nation is provided by photoacoustic imaging (also known as optoacoustic imaging).272–276 Photoacoustic imaging is
a label-free, non-ionizing, noninvasive, high-resolution optical imaging modality that uses optical absorption contrast
andultrasonic resolution.277–282 This technologyhas ahigh scalability andallows imagingof biological structures, rang-
ing frommolecules, organelles, cells, and tissues to entire organs and even entire small animal bodies.273,275,280,283–286
The anatomical, functional, metabolic, and histologic properties of tissues or organs can be solely revealed by
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endogenous contrast (e.g., hemoglobin, lipids, melanin, and collagen), while exogenous contrast agents are only used
to further increase the imaging contrast and specificity.273,283 Various exogenous probes with high contrast have also
been extensively developed, including inorganic and organic dyes,274 magneto-optical and photochromic probes,283
nanoparticles,282,287 and genetically encoded probes,281 to achieve improved resolution and sensitivity while pro-
viding multi-parametric photoacoustic imaging.283 This imaging modality has proven its clinical and preclinical value
in functional, structural, and molecular aspects of diseases and has been used for physiologically and pathologically
imaging various organs and tissues, including breast cancer,288–292 neural tissues,277,287,293–295 fingers,296 sentinel
lymph nodes,277,292,297 the cardiovascular system,298–302 the prostate,303,304 skin,305 cancer therapy,273,274,306 mus-
cle oxygenation,307 metabolic status,274,283 eyes,308,309 plaque pathophysiology,310 tumor microenvironment (pH,
enzymes, radical oxidation species (ROS), and metal ions, among others),274 and biomaterial-tissue interactions to
assess the functions of the engineered tissue/organ constructs.276 Although photoacoustic imaging is conceptually
different from some imaging modalities, it is complementary to many other imaging modalities. The major advan-
tages include deep tissue penetration, good spatial and temporal resolution, a highly scalable nature, and dynamic
imaging without ionizing radiation,272,275,276 thus enabling the potential acceleration of its clinical translation and
application.
Economically, ultrasound-based technologies are a valuable diagnostic tool for potential global adoption because of
their affordability, availability, and portability.273 Currently, photoacoustic imaging has three major implementations
with excellent scalability tomeet the application at different levels283–286,311: (1) photoacoustic microscopy (PAM), (2)
photoacoustic computed tomography (PAT) or multispectral optoacoustic tomography (MSOT), and (3) photoacous-
tic endoscopy (PAE). PAT and MSOT are seen as a future alternative to conventional scanning methods, such as MRI
and CT scan.311,312 These imaging modalities combine non-ionizing optical and ultrasonic waves via the photoacous-
tic effect, which provides in vivo multiscale functional, metabolic, and molecular imaging.313 Photoacoustic imaging
is starting to be used on patients, and the technology may revolutionize medical imaging in clinical practice.311–315
PAT/MSOTmay be an optimal imaging modality for the detection of clinical and experimental cardiotoxicity. Thus far,
PAT/MSOT has not been explored in clinical cardiac imaging to the best of our knowledge. However, experimental car-
diac imaging using PAT/MSOT or PAM has been reported.298,302,316–320 The imaging modality may yield new insights
into the cardiomyocytes and their life in vivo and further contribute to clinical imaging science and diagnosis.
Development of novel, non-invasive, and cost-effective biomarkers
Multiple diagnostic tools can assess cardiac abnormalities, and cardiac biomarkers may play a complementary role to
cardiac imaging in monitoring patients for cardiotoxicity.92 However, biomarkers that could help identify the risk for
cardiotoxicity at an earlier time point require further development.91 Identifying risks is the first and perhaps themost
important step in the riskmanagement process. If there is a failure to identify any particular risk, thenother steps in the
riskmanagement process cannot be implemented for that risk. The concept of ‘actionable’ and/ormechanistic biomark-
ers refers to biomarkers that are embedded or rooted in disease pathogenesis (pathogenetic pathways).321,322 Thus,
mechanistic/actionable biomarkers are more useful as predictive and/or pharmacodynamic (PD) biomarkers than as
descriptive biomarkers that are byproducts of the disease process with limited value of the diagnostic and prognostic
information.321,322 Generally, those molecules involved in disease pathways most likely serve as important mechanis-
tic/actionable biomarkers in the diagnosis andmanagement of diseases.322 Thus, circulating actionable andmechanis-
tic biomarkers of cardiotoxicity should be explored to identify cardiotoxicity risk factors.
An ideal biomarker in this context shouldmeet the baseline criteria (superior tissue specificity, early time of release,
a mechanistic association, and increased sensitivity with respect to bioanalysis).323 In addition, circulating biomark-
ers of cardiotoxicity should be able to distinguish myocardial from skeletal muscle or other tissue damage, such as
cancer cachexia-induced damage of skeletal muscle. MicroRNAs (miRNAs) are small, non-coding RNAs of approxi-
mately 22 bp in length that post-transcriptionally regulate gene expression by binding and inhibiting particular mRNA
targets.324 Due to the signature profiles of their tissue specificity and disease expression, miRNAs are being exten-
sively explored or profiled for use as disease biomarkers, including drug-induced cardiotoxicity.224,324 Several circu-
lating miRNAs (miR-1, miR-133a, miR-499, miR-208, and miR-423–5p) are promising cardiac injury biomarkers in
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cardiovascular diseases.324 miRNAs exhibit two significant characteristics: (1) they are secreted from the produc-
ing cells, and (2) they can deliver gene-silencing signals between living cells in vitro and in vivo.325 The secretory
mechanism of extracellular miRNAs has been explored, and the release of miRNAs into the circulation or body fluids
is actively controlled through a ceramide-dependent machinery that is associated with the secretion of small mem-
brane vesicles called exosomes or microvesicles as a versatile communication tool.326 Thus, the specific miRNA pro-
file of cardiac exosomes or microvesicles can also be utilized as a novel diagnostic tool for chemotherapy-induced
cardiotoxicity.
Regardless of the tremendous efforts made to discover novel biomarkers for clinical use, it remains unlikely that a
single biomarker will be able to predict all drug-induced cardiotoxicities; rather, an optimal panel of biomarkers that
reflects multiple aspects should be developed as a multiplex test for use in the laboratory and the clinic.211 Further
innovation is needed for the development of new noninvasive and cost-effective diagnostic biomarkers or modalities
to manage the early detection of drug-induced myocardial injury. Compared to traditional approaches, an integrated
mechanism-informed approach (advanced molecular and cellular cardiac imaging, ultrasensitive detection of subtle
electrophysiological phenotypes, circulating actionable or mechanistic biomarkers) may allow a more sensitive and
specific identification of in vivo cardiotoxicity and offer a better understanding of the fundamental mechanisms for
individual compounds. Identifying the early signs of cardiotoxicity would certainly be beneficial to the management of
oncologic patients and become essential for identifying patients who are at risk of irreversible heart disease and for
monitoring treatment outcomes. Such approaches involve the assessment of cardiac function in the broadest sense.
4.3 Novel therapeutic modalities in cancer versus cardiotoxicity
4.3.1 Chronotherapeutic strategies using the concept of chronobiology
Biological processes and functions are organized in both space, as a physical anatomy, and time, as a biological time
structure.327 The 24-hr cycle in physiological processes is known as the circadian rhythm in humans and many other
living organisms.328,329 Similarly, ultradian rhythm relates to hours, minutes, or seconds; infradian rhythms refer to
those spanning days or months, and longer rhythms.330 In general, the best-studied chronobiologic frequency is the
circadian rhythm, and cell physiology and functions are regulated along the 24-hr time scale by the circadian timing
system (CTS), which is composed of endogenous molecular clocks within each cell.331 The suprachiasmatic nucleus in
thebrain acts as the central pacemaker (a central coordination system) for thehumancircadian system.331–335 Chrono-
biology is the study of biological rhythms and the mechanisms of biological timekeeping, which is associated with the
fields of medicine, pharmacology, and drug delivery.327 Chronotherapy addresses the use of circadian, ultradian, infra-
dian, seasonal, or other rhythmic cycles in the application of therapy for various diseases330 and involves altering the
timing of medication administration to improve the overall control of a disease and tominimize treatment side effects.
This concept is emerging in the field of therapeutics.336 The initial idea in the development of chronotherapeutics was
to synchronize the in vivo drug bioavailability with the rhythms of the diseases to optimize therapeutic outcomes and
minimize side effects.330 Chronotherapeutics aim at improving treatment tolerability and efficacy through the adjust-
ment of drug delivery to the CTS327,328 based on the endogenous biologic rhythms.329 With relevance to cancer, the
CTS controls several criticalmolecular pathways of cancer processes and therapeutic effects over the 24 hours, includ-
ing drugmetabolism, cell cycle, apoptosis, andDNA damage repair mechanisms.337 The conventional concepts of drug
delivery mostly consider constant release rates to maintain drug concentrations in the human body and achieve con-
stant drug exposure at the sites of drug effects over time to optimize treatment efficacy,338 regardless of the patient's
physiological and biochemical conditionswithin the context of circadian rhythms.329 Drug deliverywith such concepts
(the homeostatic theory of drug delivery330) is being challenged with the advanced knowledge of the CTS; i.e., drug
effects predictably vary not only as a function of dose but also as a function of administration timing.328,337,339 If a drug
release profile mimics the circadian rhythms of a living system, it may improve drug efficacy and reduce the toxicity of
a specific drug administration schedule.329 This hypothesis is in linewith themain function of theCTS, which is to coor-
dinate bodily and cellular functions, down to the main pathways that are responsible for drug pharmacokinetics (PK)
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and drug metabolism over 24 hours.328,340 For example, circadian timing can improve drug tolerability and/or efficacy
up to several-fold in rodents and patients, regardless of administration routes.328,338 The tolerability of nearly 500
medications varies by up to five-fold according to circadian scheduling both in experimental models and patients.340
Thus, medication and treatments provided according to the body's circadian rhythms will result in better outcomes,
and the relevance of timingmay even exceed that of the dose.341 Improved patient outcomes on circadian-based treat-
ments (chronotherapy) have been demonstrated in randomized clinical trials, especially for cancer and inflammatory
diseases.340
With advancements in the field of chronobiology, the circadian rhythms and their influence on biologi-
cal systems have given rise to several mutually connected concepts beyond chronobiology, chronotherapy, and
chronotherapeutics.338,342 These concepts are extended to chronopharmacology, chronokinetics, chronodynamics,
chronesthesy, chronotoxicology, and chronoprevention.327,338,343 Chronopharmacology is the study of the circa-
dian dependencies in the PK and PD of drugs, PK-PD relationships, and their mechanisms.327,328,342 Chronoki-
netics refers to dosing-time, i.e., rhythm-dependent differences in the absorption, distribution, metabolism, and
elimination of medications.327 Chronodynamics refers to dosing-time, i.e., rhythm-dependent differences in the
effects of medications.327,344 Chronotoxicology is an aspect of chronodynamics that refers specifically to dosing-
time, i.e., rhythm-dependent differences in the manifestation and severity of adverse effects and, thus, the intoler-
ance of patients to medications.327,340,345 Chronesthesy refers to rhythm-dependent differences in the sensitivity
of target systems to medications that cannot be explained by corresponding administration-time differences in PK
phenomena.327,340 The mechanisms of chronesthesy have yet to be elucidated327,340 but may represent rhythms in
receptor number and conformation, second messenger dynamics, membrane permeability, or rate-limiting steps of
metabolic pathways in drug-targeted tissues.327 Chronoprevention is the timing ofmedications or other interventions
according to biological rhythm criteria as ameans of averting disease or a decline in health status.327 Themajor differ-
ence of the goals between chronoprevention and chronotherapeutics is that chronoprevention focuses on the avoid-
ance of disease, pathology, and other deleterious phenomena that compromise heath, while chronotherapeutics are
themanagement or reversal of existing acute or chronic medical conditions.
4.3.2 Chronotherapeutic strategies in the context of precision oncology and cardiotoxicity/toxicity
Cancer is considered a chronotherapeutic disorder332,346; thus, cancer can be a driver for system
chronotherapeutics.340 The chronotherapy principle has been explored in the context of cancer therapies, and
the results showed that circadian timing largely modifies the extent of toxicity of 40 anticancer drugs among agents
in all pharmacological classes in rodents328 and humans.338,347 Doxorubicin (DOX), cisplatin, 5-fluorouracil (5-FU)
and 5-fluoro-2′-deoxyuridine, irinotecan and oxaliplatin are representative anticancer agents that have been stud-
ied in the context of their circadian chronopharmacodynamics and chronotoxicologies.327,348 The results of both
laboratory animal and multicenter trials clearly show that the proper timing of cancer medications improves both
patient tolerance to therapy and clinical outcomes.327,340 For instance, the cytotoxic effect of 5-FU was minimal
for a circadian delivery peaking at 4 a.m. and maximal for a continuous infusion or a circadian pattern peaking at
4 p.m.328,349–351 The existence of a cancer-specific molecular clock can be used for the discovery and development
of novel, therapeutic approaches to treat cancer.352 A pharmacological modulation of clock-related proteins may
be a suitable strategy for the identification of innovative anticancer approaches.353 To date, chronotherapy has
been studied for some conventional anticancer agents, while data for MTT class and immunotherapies seem to
be lacking. In line with the beneficial effects of chronotherapy, there is a critical and urgent need to prevent MTT
and immunotherapy-induced cardiotoxicity of cancer patients who are also using chronopharmaceutics,338 which
may potentially improve the safety, efficacy, and patient compliance of the new generation of anticancer drugs or
modalities. Additionally, CTS robustness and phase varies among cancer patients, resulting in significant variabilities
in response to chronotherapy340 and indicating that the development of personalized chronotherapeutics is highly
expected through interdisciplinary systems approaches.337 Personalizing cancer chronotherapeutics requires an
extensive molecular knowledge of anticancer chronopharmacology and chronotoxicity, both in healthy and tumor
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tissues.340 Tumor tissues usually display a disrupted circadian organization relative to the circadian synchronization
(molecular clock) in healthy tissues,327,348 although the molecular basis of this difference remains unclear.340 More-
over, circadian disruption has been observed in up to 50% of patients with metastatic cancer, and such disruption
was associated with poor outcomes.337 Conceivably, the differential molecular clock between cancer and normal
tissues can be exploited in treatment timing to specifically shield healthy cells while targeting cancer cells.340,354,355
Indeed, a combination of mathematical, statistical, technological, experimental, and clinical expertise is now shap-
ing the development of dedicated delivery algorithms that enable treatment individualization (patient-tailored
chronotherapies).330
The concept of chronotherapy offers further potential for improving current cancer treatments and optimizing the
development of new anticancer or supportive agents.328 Clock modulators or mediators are often considered natural
candidates for a chronotherapeutic approach.352 One important mediator of circadian activity is the hormone mela-
tonin (MEL), which peaks at the end of dark periods in both diurnal and nocturnal mammals.356 Therefore, MEL has
been used to mimic the dark period in humans as a means of treating sleep disorders and jetlag.357. The determina-
tion of the circadian phase in individual patients throughmonitoring relevant CTS biomarkers could drive personalized
chronotherapy and improve treatment effects,337 with particular significance in cancer therapies.358 CTS biomark-
ers mainly involve circulatingMEL, cortisol, body temperature, and rest–activity rhythm.331 For example, DOX should
be given mid-morning when circulating MEL levels are low to further reduce cardiotoxicity from DOX treatment.359
Mitochondria are a common target for bothMEL and many anticancer agents.107 The heart is particularly susceptible
to oxidative damage induced by anticancer agents because it is abundant in mitochondria,107 which are both sources
and targets for ROS.360 Furthermore, the heart has an elevated rate of oxygen consumption and limited antioxidant
defense systemswhen comparedwith other tissues. Thus abnormalities inmitochondrial functionsmay be the primary
causative factors in the pathogenesis of anticancer drug-induced cardiotoxicity.107,361
In view of the abovementioned information, the general clinical approach to attenuate anticancer drug-induced
cardiotoxicity is to utilize natural antioxidants such asMEL. The dark hormone holds amphiphilic properties. The term
“amphiphilic properties” refers to a chemical compound possessing both hydrophilic and lipophilic properties. MEL
has shed light on this therapeutic avenue with being dually oncostatic and cardioprotective.107 Another appealing
and unique property of MEL, which other antioxidants do not possess, is that its metabolites also exhibit antioxidant
activity by scavengingROS and reactive nitrogen species (RNS).107 In addition,MEL concentrations in subcellular com-
partments (cell membrane, cytosol, nucleus, andmitochondria) fluctuate independently of the circadian rhythmduring
a 24-hr period.107 From a therapeutic perspective, clinicians should bear in mind that the subcellular levels ofMEL are
controlled by regulatory mechanisms; therefore, MEL has low toxicity when administered at high doses.362 MEL is the
first known natural antioxidant molecule that may have both curative and palliative actions in the treatment of human
neoplasms.363 Todate, studies regarding thedirect effect ofMELon themitochondrial respiratory chain and complexes
in relation to anticancer agent-induced cardiotoxicity, includingMTT, seem to be lacking.107,364 This crosstalk between
MEL and the mitochondria is quite important as it can enable to overcome these pharmacological hurdles for greater
clinical impact. Because almost all clinically usedantitumordrugs exhibit toxic side effects that affect heart function,365
the discovery of natural phytochemicals as chronopharmaceuticals for clinical use becomesmore andmore important.
Aside fromMEL, other natural phytochemicals such as coenzyme Q10, L-carnitine, resveratrol, curcumin, and ginkgo
biloba also counteract the cardiotoxic side effects of cancer chemotherapy.365 Thus, co-administration of these natural
cardioprotective agents seems promising to improve the clinical outcomes of cardiotoxicity.
In light of emerging chronotherapeutic approaches,366 various chronoprogrammable drug delivery systems
have been developed.329,339,367–381 These approaches include chronomodulating infusion pumps, controlled-release
microchip strategies, floating pulsatile systems, nanotechnology, press-coating approaches, micro-electrochemical
systems, osmotic pressure, microchips, liposomes, thermosensitive hydrogels, micro- and nanocarriers, and
microparticle-based systems. The development of programmable time pumps has enabled the safe and highly effective
delivery of combination chronotherapy protocols.337 Unfortunately, no current drug delivery system can satisfy all the
requirements of chronotherapeutics.330 From the applied and clinical perspectives, one of themost important issues is
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to consider the ease of manufacturing and cost-effectiveness during the selection of the appropriate chronopharma-
ceutical technology.
5 RESEARCH GAPS, CHALLENGES, PERSPECTIVES, AND OPPORTUNITIES
TO REDUCE MTT-INDUCED CARDIOTOXICITY
5.1 The gaps in cross-disciplinary research
The lack of a mechanism-based curative treatment of cardiotoxicity for many compounds is a treatment concern
in the clinic, and only general cardioprotective care or discontinuing cancer therapy (premature discontinuation
of chemotherapy) is currently applied to the patients. Each molecular drug or therapeutic modality may have a
unique biological mechanism of action because each drug shows a unique toxicity profile regardless of whether the
drugs are in the same class and exhibit structural similarity.382 This feature is also supported by the observation
that transcriptome-wide response profiles in cardiomyocytes using a cohort of KIs showed a limited overlap.383
Therefore, general cardioprotective strategies (ACE inhibitors, beta-blockers, digitalis, etc.) may not work effectively.
Disease-specific mechanisms must be addressed in preclinical research (basic and translational) for a mechanistic
understanding of the cardiotoxicity induced by novel anticancer therapies. Drug-induced cardiac dysfunction and
cardiomyopathies reflect serious, clinically adverse effects of drug actions, and they can be used in experimental
models to study the pathogenic mechanisms of these cardiac disorders, offering the advantage of precise control of
the onset time, and can often be studied in a longitudinal fashion.384 The gaps currently observed between clinical
observations and pharmacological innovation might be reduced by a better application of the concept of reverse
translational research with a bidirectional research paradigm - from practice (bedside) to research (benchside) - and a
back flowof information. This research paradigm aims to transfer clinical insights or observations into hypotheses that
can be investigated in the basic research laboratory and that can subsequently inform clinical practice. With such a
bidirectional research paradigm, clinical cardiotoxicity becomes an important source of observations and ideas to feed
into fundamental research for further mechanistic insights. In turn, these new mechanistic insights allow proposing
novel concepts regarding these drugs and accelerating clinical advances in knowledge to further bridge knowledge
gaps. Such a mechanistic approach should yield disease-onset, mechanism-based biomarkers that identify the initial
disease stages. These markers are valuable tools for developing strategies to prevent the progression of diseases that
can be translated into clinic for diagnosis and to measure disease progress and/or the effects of treatment. In line
with the expectations, using various modeling systems (in vitro, in vivo, computational biology or their combination)
to explore the underlying mechanisms that drive the cardiotoxicity is a high-priority research area in preclinical
research.
The development of new PD, prognostic, and surrogate biomarkers not only enhances the efficiency of cancer
treatment (e.g., targeting neoantigens) but also mitigates the risk of cardiotoxicity. Thus, this development is urgently
needed in this era of precision oncology.93 According to the hierarchical tree of various sources of biomarkers in nature
(genes and genetic variants, RNA,microRNA, proteins, andmetabolites), some caveats should be kept inmind: (1) each
category of markers is suited to a specific purpose, (2) caution should be taken regarding cross-species translatabil-
ity, and (3) biomarker values fluctuate in response to the pathophysiology of the organism over time. Taken together,
genomic and transcriptomic markers can provide information about a person's risk of developing a specific disorder
or how a patient may respond to treatment. Proteins and metabolites are more dynamic in a disease course and thus
carry more diagnostic information than DNA or RNA. It is important to note that DNA, RNA, and proteins are more
species-dependent; thus, these biomarkers should be best identified and characterized using humanmaterials. In con-
trast, small molecules or metabolites are less species-dependent,385,386 and miRNAs are also well conserved among
species, ranging from worms to humans; 324,387 therefore, many of these markers from animal studies can be trans-
lated into clinical practice.324,388 Metabolic biomarkers are subtly sensitive indicators of health status that provide
early profiles on drug efficacy, toxicity, and mechanism.45,389 miRNAs are sensitive and specific toxicity reporters as
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well.224,390 Considering the sensitivity and interspecies translatability, identifying metabolic biomarkers, especially
metabolic imaging biomarkers and/or circulating/tissue miRNA markers, should be prioritized in preclinical studies
using model organisms, allowing a direct comparison of animal models with human studies. Altered ionic homeosta-
sis is considered the foremost change in the early phase of responses of myocardium to environmental toxicants or
drugs.45 Preclinical research on the molecular basis of cardiac ion channels in relation to regulation and drug sensitiv-
ity of the cardiac ionic currents should be performed.
5.2 Modeling systems for clinical cardiotoxicity
5.2.1 Overview of livingmodeling systems
The next step is to select a proper modeling system for predicting clinical cardiotoxicity as precisely as possi-
ble. A proper model should encompass adequate sensitivity, predictability (similarity to human myocardial biology),
measurable functional parameters of cardiac dynamics/performance, real-time data acquisition over time, and high
throughput, all of which should be considered collectively. For example, in vitro assays that use primary animal car-
diomyocytes, human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes, hiPSC-derived endothelial cells,
and hiPSC-derived cardiac fibroblasts are primarily designed as electrophysiological models to assess the interac-
tion of drug candidates with the main ion channels that are involved in maintaining the cardiac action potential
(electrophysiology),391,392 contractility,392 kinase phosphorylation profiling392 and more. Complementary to these in
vitro assays, mathematical or computational approaches can model the propagation of the action potential and ion
concentration dynamics of the heart.393 Recently, the xCELLigence RTCA Cardio System was developed to monitor
cardiac contractility and arrhythmogenic properties in vitro basedon impedancemeasurement. This technology canbe
used for a high-throughput screening of functional cardiotoxicity.391 However,many in vitromodelsmay lack or incom-
pletely recapitulate important aspects of human biology in vivo,8,394 allowing certain toxicities to escape detection.
Cardiac performance is the result of an entire functioning organ, including electrophysiological function (rhythms or
heartbeats), pump function (cardiac output, stroke volume, strokework, ejection fraction) andmechanicalmuscle func-
tion (force velocity curve, maximum velocity of shortening (Vmax), LVEF, ventricular contractility (dP/dt)). Although ex
vivo experiments using isolated hearts from live animals (e.g., the Langendorff heart assay) can be used to assess car-
diac performance, these experiments present technical challenges because they are labor intensive and not amenable
to a high-throughput analysis. However, addressing in vivo cardiac effects ofMTTnecessitates a suitable animalmodel.
Thus, it is important to select themost appropriate animalmodel formechanistic studies and/or as a predictive preclin-
ical model.
5.2.2 Rodentmodel
In biomedical sciences,Musmusculus is themost commonlyused species for animalmodels due to its genetic, physiolog-
ical, and anatomical similarities to the human system in general. However, the expenses associated with the use of this
species limit its application in large-scale molecular and/or therapeutic screening or modeling. To date, using a mouse
model solely for drug screening (i.e., a single factor experimental study) is very rare, while multi-factorial experiments
have often been performed, for example, simultaneous evaluation of antitumor efficacy and cardiotoxicity of cancer
drugs,395–406 and/or studies of cardioprotective strategies after using cancer drugs.407–412 More importantly, many
drugs, including oncologic pharmaceuticals, can often lead to cardiotoxic electrophysiological effects (e.g., QT prolon-
gation, atrioventricular conduction blocks, and ventricular arrhythmias including torsades do pointes); thus, adverse
electrophysiological effects represent important phenotypes of drug-induced cardiotoxicity.75,391,413 In this regard,
the intrinsic species-specific differences of cardiac electrophysiology require attention during model selection. The
cardiac electrophysiological properties in mice are significantly different from their human counterpart.414 Further-
more, mice are nocturnal animals; therefore, this CTS of this species is mismatched with the human counterpart from
the perspective of chronobiology and chronopharmacology. These practical concernsmay lead one to considermice as
a second choicemodel organism for studying drug-induced cardiotoxicity.
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5.2.3 Zebrafishmodel
Zebrafish have filled a niche in the phylogenetic gap between invertebrates and mammals as one of the most suc-
cessful vertebrate models for studying human physiology and diseases.415 Approximately 70% of human genes have
at least one obvious zebrafish orthologue and mutations in homologous genes lead to similar phenotypes.416 The
genome of zebrafish is well conserved, and its physiology shows good resemblance to mammals in general. Addition-
ally, most zebrafish organs perform the same functions as their human counterparts.417 Regarding the cardiovascu-
lar system, zebrafish stand out for their highly conserved integrative physiology of the cardiovascular system and
a pharmacological response similar to that of human beings.417,418 The key morphological, functional, mechanobio-
logical, electrophysiological, metabolic, and molecular profiles, as well as many cardiac events, overlap with those in
humans,418–422 including the kinome profiles, wheremost kinase inhibitors interact with the kinases.423,424 Moreover,
the cardiac electrophysiological properties of the hearts of zebrafish larvae and adults resemble those of humans in
many aspects.413,425–428 It is of particular importance to evaluate the pharmacological response of cardiac function in
an animal model relevant to the human heart for an appropriate assessment of the safety (drug-induced cardiotoxic-
ity) and efficacy of drugs that target cardiovascular diseases (cardiopharmacology). Many human cardiovascular drugs
have identical effects on zebrafish physiology, and numerous human cardiovascular disorders have been recapitulated
in zebrafish genetic models.417,429 Importantly, many drugs that cause QT prolongation in humans consistently cause
bradycardia and AV block in zebrafish,413 suggesting that zebrafish are a rational, predictive model for cardiac safety
liability of chemicals/drugs and also a valued, mechanistic model of human cardiovascular diseases. The overall physi-
ology, genetics, and cardiovascular pharmacology similarities strongly support the use of zebrafish as themost reason-
able approach formodeling human cardiovascular diseases or events in vivo,420,428,430–433 monitoring drug-induced in
vivo cardiotoxicity,413,417,418,434–436 and in vivo cardiovascular drug discovery.429 Furthermore, zebrafish are a diurnal
vertebrate;437 thus, the zebrafish CTS is expected to be compatible with the human counterpart for studies of chrono-
biology and chronopharmacology.437–454 Recently, zebrafish have been increasingly recognized as a model for circa-
dian rhythm disorder.455 Lastly, the general advantages of the zebrafish model,456 e.g., convenience of drug delivery,
rapid development, ease of genetic manipulation, low cost of maintenance relative to other model animals, high fecun-
dity, transparency, small size, and the availability of various transgenic lines, make this animal model an almost ideal
complement to rodent-based biomedical research. This organism has been considered the “new mice” to replace the
so-called “higher vertebrates” (e.g., mice, rats) according to the 3R (replacement, reduction, and refinement) perspec-
tive for animals used for experimentation.456–458 Research in exploring the potential use of zebrafish as a mechanistic
model organism to study cancer treatment-induced cardiomyopathy andmyocardial dysfunction or to exploit the pre-
dictability of clinical cardiotoxicity, particularly for MTT, should be highly promoted. To date, extensive studies of the
mechanisms involved in relation to MTT have not yet been undertaken, and published data in the preclinical setting
using zebrafish remain highly limited.434 A research program is being started in our laboratory using zebrafish as a
predictive and mechanistic model to address clinical cardiotoxicity induced by MTT to identify potential mechanistic
biomarkers.
Regardless of the aforementioned merits, several important caveats in modeling kinase inhibitors on a zebrafish
model should be considered: (1) Confounding effects: transgenic fluorescent animals are genetically modified, and the
confounding effects of an inbred strain background may harbor compensatory mechanisms that can alter biological
events.459 Thus, any data obtained from transgenic lines must be further confirmed by wild-type fish lines. (2) Cardiac
regeneration: the zebrafish heart maintains the ability to regenerate throughout adulthood with scar-free regenera-
tion of a damaged heart. In contrast, the adult mammalian heart exhibits a limited signaling powerhouse and cell reser-
voir for regeneration.460,461 The limited cardiac regenerative capacity in humans iswitnessedby scar formation follow-
ing myocardial infarction. (3) The human kinome shares many catalytic domains of zebrafish homologs,423,462 which is
important for tyrosine kinases.462 However, small changes in the sequence of amino acids in a protein may reduce
or enhance certain inhibitor interactions, consequently leading to under- or over-estimation of toxicity.423 To extend
zebrafish utility as a functional model organism for toxicity and efficacy in studying kinase inhibitors, more knowl-
edge of these relationships may be required. (4) Phenylthiourea (PTU) is a well-known inhibitor of tyrosinase463 and
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is widely used in zebrafish research to suppress pigmentation in the developing embryos/larvae of small animals.464 In
modeling the toxicity of kinase inhibitors on zebrafish, PTU is not recommended to avoid potential synergistic effects
fromPTU and a test drug. (5) Pseudokinases are generally less conserved between zebrafish and humans.423 Thus, it is
unsuitable tomodel pseudokinases in a zebrafishmodel. (6) The drug exposuremethod for zebrafish is mainly bathing,
and caution should be taken with insoluble drugs and drug metabolism.465,466 Therapeutic antibodies are large thera-
peuticmolecules that differ fromsmallmolecule agents in absorption, distribution, andeliminationproperties between
the two classes of drugs in a systematic manner.467 (1) Absorption: the absorption of small and large molecules dif-
fers with respect to their common extravascular routes of delivery (oral for small molecule agents versus injection for
antibodies). (2) Elimination: small molecule agents are commonly distributed into the tissues but are eliminated pri-
marily by liver metabolism. Meanwhile, catabolism and target-mediated drug disposition are unique features of anti-
body distribution and elimination.468 The above knowledgemust be consideredwhen testing humanized antibodies in
animals.
5.3 Challenges, perspectives, and opportunities
5.3.1 Kinase inhibitors versus “precision oncology” on efficacy and cardiotoxicity/toxicity
Introduction of the “MTT for cancer” concept in the past 15 years has led to optimistic expectations that we can pre-
cisely target the molecular underpinnings or molecular drivers of a patient's disease, and this concept is hailed as a
revolutionizing approach in the treatment of cancer.469 Most impressively, the concept has served as the foundation
for personalized medicine or precision oncology/medicine to guide the selection of treatments in the clinic.470 Preci-
sion oncology aims to deliver the right therapy to the right patient at the right time through promising identification of
genetic alterations in human cancer and either the signaling pathways or specific biological processes that are essen-
tial for the development and progression of tumors, followed by therapy targeted to a patient's unique genetic or other
relevant characteristics.471–479 Many kinase inhibitors that target oncogenic mutations in protein kinases have been
developed under such theoretical expectations and perspectives.115,480 Consequently, most kinase inhibitors that are
currently developed and clinically used largely focus on anticancer effects. In real-world practice, an individually tai-
lored cancer treatment is determined or guided by specific molecular biomarkers based on a genetic understanding
of their diseases (biomarker-informed treatment).2,481 These biomarkers are somatic genomic alterations (mutated,
amplified, or overexpressed), often called “driver mutations,” and are considered responsible for the initiation and
progression of cancer. Thus, these “driver mutations” are optimal biomarkers for selecting patients with targeted
therapies.481 Because mutations and dysregulation of protein kinases play causal roles in cancers, kinase inhibitors
have become the largest class of new anticancer drugs, serving as the cornerstone of the development of molecu-
larly targeted therapeutics to date,2,109,472 although the effectiveness/potency and potential cardiotoxicity/toxicity
of those very recently approved therapeutics remains unclear.2 In light of the promise of precision oncology and based
on the concept of MTT over the past 15 years, many concerns and challenges have been raised in the real world, and
themedical, pharmacological, and research communitiesmust face those challenges. First, clinically, intrinsic (primary),
andacquired (secondary) resistance to targetedagents has emergedas aprimary challenge.471,482,483 This resistance is
typically reflected by the limited effectiveness of targeted therapies on long-term clinical benefits. Almost all patients
acquire resistance in less than two years from therapy initiation, and a small subset of patients (10–20%) simply fail
to respond at all, demonstrating intrinsic (primary) resistance.116,471,482,483 This resistance is because of alternative
oncogenic pathways taking over and/or other mechanisms (e.g., bypass pathways), leading to the occurrence of drug-
resistant variants.101,471,482,484–489 Cancer cells may become drug resistant much more rapidly than would be pre-
dicted from the rates of conventional mutation116 by differential utilization of genomic and epigenetic strategies at
various levels through point mutations, deletions, translocations, amplifications, altered microRNA levels, and epige-
netic anomalies (epimutations).134,490,491 Therefore, irreversible inhibitors may also need to be combined with other
targeted agents and/or chemotherapy to address drug resistance.101 In addition, secondary mutations in the ATP-
binding site, such as threonine to methionine at position 790, serve as a mechanism of resistance to ATP-competitive
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kinase inhibitors.492 The complex and adaptive nature of most tumors frustrates the optimistic predictions of MTT
for cancer.493 Second, most of these PKIs prolong survival in cancer patients only weeks or months longer than stan-
dard cytotoxic therapies.109 In other words, generally targeted therapies by inhibiting protein kinases or other molec-
ular events are usually not curative, even when combined with other chemotherapy or radiotherapy.101,494 Third, the
number of patientswho gained clinical benefits fromgenomic profiling or the analysis of their tumor genomes followed
usingMTTs against those “driver” mutations is currently quite small,470,495 and responsive patientsmay be designated
“exceptional responders” for largely unexplored reasons.494,496–500 To this end, inhibiting tumor growth through tar-
geting defects in cancer genetics does not seem working meaningfully, while life-threatening complications such as
cardiotoxicity are unavoidable, uncontrollable, and unpredictable. Fourth, the majority of cardiotoxicities induced by
MTTs are unexpectedly associated with the second- and third-generation kinase inhibitors;501 a new face on an old
problem. Fifth, the paradigm of precision oncology remains a theoretical promise or hypothesis rather than a real-time
reality in many areas of clinical oncology.479,495,502
5.3.2 Kinase inhibitors versus cancer driver or actionablemutations on efficacy
and cardiotoxicity/toxicity
Kinase inhibitors that are designed to target cancer “driver”mutations, which are identified by cancer genetic profiling,
are being challenged for their clinical endpoint—i.e., the clinical beneficial effects from targeted agents are not gener-
alizable to a large patient population.101,109,471,482,483,494 First, biologically, the “driver”-centric paradigm on tumori-
genesis is being challenged not only by the clinical reality but also by a novel paradigm.503–506 The novel paradigm
envisions that those traditionally considered “passenger”mutations (i.e., thosemutationswith no roles in carcinogene-
sis) affect the course of cancer progression.504–506 Further, cancer evolution and progression are a balance of “driver”
and “passenger” mutations, rather than being solely determined by “driver” mutations.505,506 In line with the novel
paradigm, the role of a targeted therapeutic approach is to interfere with an existing balance of “driver” and “pas-
senger” mutations of cancer and then to develop a new interaction network to build a new balance of “drivers” and
“passengers”. Such an iterative cycle can occur through an entire treatment course with different kinase inhibitors or
combined with other categories of anticancer drugs in real time. As observed in the clinic, most tumors can escape
from the inhibition of any single kinase, as manifested as a partial and/or non-durable response with these therapeu-
tics, and multiple target inhibitors are necessary to sort the effects.101,153,483,507,508 The balance between “drivers”
and “passengers” reflects the clinical reality, and this novel paradigm may encourage the clinical and pharmaceutical
communities to rethink and refine the current concept of MTT under the umbrella of precision oncology, with respect
to the pharmaceutical innovation against the effects on the clinical endpoint. Second, the emerging concept of “action-
ablemutations”, defined as thosemutations that are potentially responsive to a targeted therapy (actionability),509,510
remains a huge challenge with respect to the identification of such targetable mutations.494,509 From the perspective
of onco-pharmacology, themost significant success has been achieved in oncology by targetingmutationally activated
“oncogenic” driver kinases, includingBcr-Abl, EGFR, c-Kit, PDGFR,ALK, andb-RAF (Tables 1 and2).105,469 Todate, only
a small subset of the human kinome has been studied,104 and many potential candidate kinases for cancer therapies
remain unexplored.469,511 Consequently, the cardiac safety liabilities of those potential future kinase inhibitors in the
clinical endpoint are unknown. Third, with more than 518 protein kinases in the human kinome,108 including the car-
diac kinome,512 it remains largely ambiguous in relation to the target specificity or selectivity of individual kinases and
their biological roles in the cells or tissue-specific contexts, and most of the identified kinases remain largely unchar-
acterized or unexplored for their functions and tissue expressions,513 including the majority of kinases expressed in
the heart.514 Many molecular mechanisms relevant to cardiac disease are also relevant to tumor biology, suggesting
that cancer and cardiovascular disease have a shared biological mechanism.515 Indeed, numerous overlapping signal-
ing pathways that drive tumorigenesis are also essential for normal cardiac function.3,7,512,516 Unfortunately, these
molecular signaling pathways are often targeted in molecularly targeted cancer therapies.8,517 Fourth, promiscuous
targeting is a unique feature of ATP-competitive kinase inhibitors, and the potential is greater than almost any other
type of drugs regardless of multi-targeted or highly specific targeted kinase inhibitors.50,153,518 Multi-targeted agents
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are frequentlymore efficacious than selective agents,116 andpartial inhibitionof a small number of targets canbemore
efficient than the complete inhibition of a single target.519 However, a major concern using combination approaches is
the possibility of more uncontrollable and unpredictable toxicities on multiple organs/tissues than that observed with
single target approaches. Therefore, target selectivity/specificity represents the biggest challenge for drug design and
the development of kinase inhibitors116,483 because most inhibitors interact with the highly conserved ATP-binding
sites of kinases. Additionally, developing pharmacological agents that target only one of the more than 500 kinases
present in humans remains a formidable challenge.164
5.3.3 Effects of kinase inhibitors on the immune system and concerns for autoimmune
cardiovascular diseases
Kinases play pivotal roles in tumor immunity and tumor immune evasion; thus, they could serve as relevant therapeu-
tic intervention points far beyond various antibody-based therapies.520 However, it is important that a kinase inhibitor
does not co-target components of the immune system that are essential for mounting an immune response.101 Unfor-
tunately, some drugs may bind directly and reversibly to immune receptors, e.g., major histocompatibility complex or
TCR, thereby stimulating the cells in a manner similar to a pharmacological activation of other receptors.521 This con-
cept has been termed “pharmacological interactionwith immune receptors” or the “p-i concept”.521–523 In linewith the
importance of kinases in the regulation of an immune response as an intrinsic defensemechanism,524 many oncogenic
signaling pathways in tumor cells, such asMAPKor PI3K/AKT/mTOR, are also critical in the regulation of immune cells,
and those oncogenic signaling pathways are often targeted by anticancer kinase inhibitors.525 Thus, many targeted
agents might have “off-target” effects (either beneficial or detrimental) on immune cells beyond their intended effects
on the respective signaling pathways in cancer cells.526,527 Immunomodulatory effects of kinase inhibitors can act indi-
vidually onDCs, effectorT cells, and immunosuppressive cells or their combination.528 Indeed, sucheffects are induced
by some FDA-approved kinase inhibitors, e.g., temsirolimus, sorafenib, sunitinib, imatinib, and dasatinib.101,525,529 The
secondary pharmacological interaction of kinase inhibitors with the immune system have yet to be studied in detail in
cancer patients,525 and the exact in vivo mechanisms remain to be further clarified in human studies. This crosstalk
may open new possibilities for using either a stimulatory or inhibitory function of the immune system for defined
targeting.521 The consequences of these kinase inhibitors on the functionality of immune effector cells alter immune
cell infiltration (immune subset conditioning), increase the frequency and function of effector immune elements, and
decrease the number and function of immune suppressor cells.528,529 Although the regulation of immune cell signal-
ingwith kinase inhibitors has produced robust evidence, whether autoimmune cardiovascular diseases can be induced
by the pathway when patients are treated with kinase inhibitors remains unknown. Further studies are warranted to
determine the causal direction of this relationship.
5.3.4 Targeting non-coding cancer drivers by kinase inhibitors and concerns of cardiac safety
liabilities
Cancer may arise from the accumulation of multiple driver mutations.530 However, cancers harbor a large number
of molecular alterations, and targeting one or some of the many molecular alterations to achieve a clinically signifi-
cant, sustained effect might not be realistic for most tumors.479 In addition, the overwhelming majority of oncogenic
variants, both somatic and germline, occur in non-coding portions of the genome531 as opposed to protein-coding
regions, which have been incorporated into the paradigm of precision oncology in the clinic. The concept of MTT
developed to target protein-coding cancer drivers is being challenged by the emerging paradigm of non-coding cancer
drivers.531–533 The non-protein-coding cancer genome remains widely unexplored,532 but this field will have a pro-
found impact onmany disciplines beyond cancer research. For example, such genetic events noticed in cancer are also
observed in autoimmune disorders, in which approximately 90% of the causal variants are non-coding, and most map
to immune cell enhancer regions.534 Given the central role in cellular signaling of kinases in the heart and many other
organs aside from cancers, accumulating pharmacological and pathological evidence has revealed that kinases are also
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promising drug targets for numerous non-oncological indications.101,535–540 The successful approval of tofacitinib for
the treatment of arthritis is a typical example,536 although the exact mode of action of tofacitinib in the setting of
autoimmune disease has yet to be unraveled.537 The importance of cardiac safety liabilities with kinase inhibitors goes
beyond cancer treatment. Insights gained from the clinical endpoints of oncology show that an optimization of the
therapeutic equation (efficacy vs. toxicity) appears to be very hard to achieve in many cases with kinase inhibitors.116
It is highly important to use robust systemic approaches,154,541,542 including kinase panels543 and chemical
proteomics,544 for understanding chemical interactions with biological systems, characterizing drug-induced molec-
ular changes in affected cells and tissues of interest, and permitting kinome-wide analysis of candidate molecules.116
These strategiesmay allow researchers to startwith these theoretical approaches to initially identify virtual cardiotox-
icity by focusing on pathways that are common to all ormany cardiotoxicities.154,545 Then, amultitude of datawill help
reach a better characterization of “specific” tumor or disease signaling pathways that are unique to cancer cells or dis-
eases and do not significantly affect normal cells such as heart muscle.
6 CARDIOTOXICITY INDUCED BY ICIS AND T-CELL THERAPY
Immune therapies represent an advance in the fight against cancer. In a broad sense, this field encompasses a number
of treatment approaches that utilize distinct components of the immune system in the fight against cancer.44,546 The
main forms of immunotherapy strategies that are used or in active clinical development today include ICIs, therapeu-
tic monoclonal antibodies, cancer treatment vaccines, immune systemmodulators, and immune cell therapy (including
different forms of adoptive cell transfer (ACT), such as tumor-infiltrating lymphocytes (TILs) and CART). Currently at
the forefront of immunotherapy are ICIs and CART. Here, we focus on ICIs and CART cell therapy and their poten-
tial to induce cardiotoxicity. To date, clinical cardiotoxicity induced by ICIs and CART seems to be less frequently
reported compared with MTT and other categories of anticancer drugs. The clinical data remain limited because the
approved ICIs are still limited, and CART has not yet been approved. Thus, serious side effects such as cardiotoxicity
are still being documented. Nevertheless, clinical cardiotoxicity induced by ICIs12–28,546–550 and CART30–44 have been
reported (Table 3).
In the physiological situation, immune checkpoint proteins limit the strength and duration of immune responses
and normally act as a type of “off switch” that helps keep the T cells from attacking normal cells in the body,551
which in turn reduces autoimmunity and promotes self-tolerance.552–554 Recently approved ICIs that target recep-
tors that are involved in the immune escape of cancer cells, such as cytotoxic T lymphocyte-associated antigen-4
(CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death protein ligand-1 (PD-L1), are increas-
ingly being used for therapeutic benefit in a number of cancers.546 Thus far, the development of ICIs has focused on
these major targets.14 These therapeutic monoclonal antibodies interact with specific co-stimulatory or co-inhibitory
molecules that are expressed on the surface of activated T cells and strengthen the immune response against can-
cer cells and minimize tumor evasion from host immunity.555,556 ICIs work by blocking inhibitory pathways of T-
cell activation, leading to an immune response directed against tumors; thus, this activation represents a nonspe-
cific immunologic activation that can lead to immune-related adverse events (IRAEs).557 To date, FDA-approved
ICIs 26,27,547,548,550,558 include Ipilimumab (CTLA-4), Pembrolizumab (PD-1), Nivolumab (PD-1), Atezolizumab (PD-
L1), Avelumab (PD-L1), and Durvalumab (PD-L1). Based on the working principles, ICI-induced toxicity typically
involves autoimmune disorders,28,54,555,557,559 including autoimmune myocarditis.12–28,93,550 The importance of ICIs
in the heart has been addressed in preclinical data, and the data give some mechanistic insights into the clinical
observations of autoimmune myocarditis.560,561 In addition, although ICIs are an attractive concept in the ther-
apeutic development of cancer treatment, many cancer patients do not respond to treatments with ICIs, partly
because of the lack of tumor-infiltrating effector T cells562–565 or primary or acquired resistance due to various
mechanisms.565 The overall response rates against melanoma, bladder cancer, Hodgkin's lymphoma and non-small
cell lung cancer using ICIs is approximately 30%, and complete response rates (eradication of a patient's tumors)
are as low as 5%.566 Recently, macrophage activation syndrome (MAS), a very severe, new complication of ICIs with
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a 50% mortality rate, has been reported.567 More serious concerns have clearly been raised about the clinical use
of ICIs.
Immune cell therapy (T-cell based therapy) consists of several forms, TILs, cytotoxic T lymphocytes (CTLs), trans-
genic T-cell receptor (tgTCR) T cells and CART.196,568,569 CART is considered the best-in-class example that the
genetic engineering of T cells can lead to deep and durable responses in CD19+ B cell malignancies.73 The recep-
tors allow the modified T cells to attach to specific proteins on the surface of cancer cells, and the modified T cells
become activated and attack the cancer cells once bound.570 CD19 CART has demonstrated remarkable success
in treating hematologic cancers, prominently including acute and chronic B cell leukemias.571 Currently, a grow-
ing number of clinical trials have focused on solid tumors and targeted surface proteins including carcinoembry-
onic antigen, diganglioside GD2, mesothelin, interleukin 13 receptor 𝛼, human epidermal growth factor receptor
2, fibroblast activation protein, L1 cell adhesion molecule,568,571 and melanoma-associated antigen 3.32 However,
the clinical results in solid tumors have been much less encouraging.71,570 Historically, three generations of CAR
constructs have been developed, and the third-generation CARs are the most recent196,572 and contain more than
one additional co-stimulatory molecule. Recently, fourth-generation CAR T cells redirected for universal cytokine
killing (TRUCK) have been described and are designed to express and release transgenic products that accumulate
in the targeted tissue.572–575 However, despite tremendous efforts to date CART targeting, CD19 remains the best-
studied example205,570,576; CD19 is a cell surface molecule on B cells and B cell malignancies. The FDA granted a
‘breakthrough therapy’ designation to anti-CD19 CART on 1 July 2014.196,205 To date, the challenge for targeted
CART continues to be the identification of suitable epitopes to ensure on-target specificity.51,53,55,577 The identi-
fication of truly tumor-specific antigens has become the greatest general challenge in cancer immunotherapy572
because true tumor-specific antigens are rare, and many tumor-associated antigens are shared by both tumor and
normal tissues, resulting in off-tumor, on-target toxicity.53,578 Cardiotoxicity caused by CART has been reported
(Table 3),30–44 but the causes are diverse, and the mechanisms are not fully understood.30,31 In general, the unpre-
dictable specificities of targeted tumor antigens and cytokine release syndrome are recognized as two major factors
that are accountable for “on-target, off-tumor” toxicity in multiple organs, including cardiotoxicity.51,53,83,196,579–582
Conceptually, neoantigens are the antigens encoded by tumor-specific mutated genes (known as driver mutations)
and specifically expressed in the tumor; thus, neoantigens are theoretically ideal targets for cancer immunotherapy
because they are less likely to induce normal tissue toxicity (non-exclusive antigens).564,583 However, the identifica-
tion of neoantigens depends on targeting “driver” mutations first, and many questions remain unanswered regard-
ing how to precisely define and distinguish between “driver” mutations or clinically actionable mutations (responsive
to targeted therapies) from the much larger set of passenger alterations embedded in tumor DNA.494 The emerg-
ing concept of non-coding drivers adds additional challenges to precisely define or identify “neoantigens.” In addi-
tion, the use of host lymphodepletion-chemotherapy with immunosuppressive agents (e.g., cyclophosphamide) is
required to augment the antitumor effects of CART.584 Unfortunately, these concomitant therapies can lead to clinical
cardiotoxicity.585–588
The recent experienceswith severe, life-threatening episodes of cardiotoxicity associatedwith ICIs andCART gives
rise to some important concerns that are biologically and clinically relevant for future preclinical studies, oncology tri-
als, and clinical practice to limit the uncontrolled activation of immune responses. Immunotherapies have significant
potential, yet there is room for further improvement. The immune system is species-specific; thus, immunotherapy-
induced toxicity/cardiotoxicitymay not be readily predictable in animalmodels because of the differences in both gene
expression and amino acid sequences of peptides derived fromhomologous proteins.577 The insights derived from ani-
mal models are limited by significant functional differences of the cardiac and immune systems between animals and
humans. For instance, idiosyncratic drug reactions (drug- or individual human leukocyte antigen restriction-specific)
are unpredictable, occur only in certain susceptible patients and have a complex dose-dependent relationship.589 Fur-
thermore, the immune system is a complex network of organs, different cell types and molecules that interact among
themselves and with other organs, cells, and local and systemic factors. Thus, it is very difficult to predict the behavior
of the system from any of its components studied in isolation.212 Finally, antigen presentation is not a static event but
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spatiotemporally dynamic,564 which may lead to drug-mediated immunotoxicity due to unstable immunophenotypes
(immunophenotypic drift).31,55,590,591 Multi-organ toxicity resulting from ICIs and CARTmay reflect the complex sce-
narios of the immune system in vivo. These problems may be minimized by combining in vitro data with mechanistic
mathematical models, which describe intracellular metabolism, fluid-flow, substrate, hormone, and nutrient distribu-
tion and provide the opportunity tomimic the in vivo scenario.394,577
7 CONCLUSION AND OUTLOOK
Anticancer drug-induced toxicities occur because agents are not selective, or the targets are not unique to cancer
cells. The research gaps resulting from the problematic specificity/selectivity of drugs leave a bottleneck on effective
clinical management (curative care) because of uncontrollable toxicities on multiple organs. Improving the speci-
ficity/selectivity of drug target selection (druggable molecular targets and tumor-specific antigens) is considered the
singlemost important factor,592 and this strategywill substantiallyminimize the risk of potential cardiovascular safety
liabilities and other organ toxicity. The pharmaceutical industry may have to move toward more selective agents to
meet clinical challenges. In linewith themission “oncology drugs still a pipeline priority” (innovation drives the race), as
suggested by the US FDA,593 numerous approved anticancer drugs and those under investigation have been included
in pharmaceutical pipeline databases.594,595 Given the explosive rate of new anticancer drug development, there is an
urgent need for a synergistic improvement of preclinical studies, clinical trials, pharmacovigilance and post-marketing
surveillance as a whole, including an awareness of biosimilars in oncology. Cardiovascular toxicity has become a very
challenging issue during cancer therapy, while consensual guidelines remain lacking for its effective management.596
The development of novel therapeuticmodalities such as chronotherapy and chronoprevention using natural products
of antioxidants should be highly encouraged for both researchers and clinicians to simultaneously address clinical
cardiotoxicity and drug efficacy. Furthermore, working with multidisciplinary teams should be considered compulsory
to decrease morbidity and mortality from both cardiotoxicity and cancer itself,597 and multidisciplinary collaboration
is helpful to address the interdisciplinary differences and dilemmas in the meantime. Lastly, kinase inhibitors used
in patients with cancer have given a new face to cardiovascular medicine, providing unprecedented insights into the
functional roles played by numerous kinases in the cardiovascular system.2 This insight will aid in the fundamental
understanding of kinase inhibitors and their direct clinical applications in oncology, cardiology, and the cardio-oncology
interface.
ACKNOWLEDGMENTS
PPZ conceived the ideas, organized the study, and wrote the manuscript. JL and JMK reviewed and approved the sub-
mission.
REFERENCES
1. Moslehi JJ, DeiningerM. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin
Oncol. 2015;33(35):4210–4218.
2. Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ. Cardio-Oncology: how new tar-
geted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation. 2015;132(23):2248–
2258.
3. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res.
2010;106(1):21–34.
4. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.Nat Rev Cancer.
2007;7(5):332–344.
5. Svoboda M, Poprach A, Dobes S, Kiss I, Vyzula R. Cardiac toxicity of targeted therapies used in the treatment for solid
tumours: a review. Cardiovasc Toxicol. 2012;12(3):191–207.
ZHENGETAL. 351
6. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treat-
ments: epidemiology, detection, andmanagement. CA Cancer J Clin. 2016;66(4):309–325.
7. Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical
outcomes.Nat Rev Drug Discov. 2011;10(2):111–126.
8. Mellor HR, Bell AR, Valentin JP, Roberts RR. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol
Sci. 2011;120(1):14–32.
9. Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, Moslehi J. Cardiovascular complications of novel multiple
myeloma treatments. Circulation. 2016;133(9):908–912.
10. Stellitano A, Fedele R, Barilla S, Iaria A, Rao CM,MartinoM. Chemotherapy and cardiotoxicity in hematologic malignan-
cies: a Review. Curr Cancer Drug Targets. 2017;17(4):311–324.
11. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol.
2009;48(7):964–970.
12. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ.
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.
13. Laubli H, Balmelli C, BossardM, PfisterO,GlatzK, ZippeliusA. Acute heart failure due to autoimmunemyocarditis under
pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11.
14. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A,
Ederhy S, Feuillet S, FrancoisH, Lazarovici J, Le Pavec J, DeMartin E,MateusC,Michot JM, SamuelD, Soria JC, Robert C,
Eggermont A,Marabelle A.Management of immune checkpoint blockade dysimmune toxicities: a collaborative position
paper. AnnOncol. 2016;27(4):559–574.
15. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto
PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath
RK, de Schaetzen G, Suciu S, Testori A. Adjuvant ipilimumab versus placebo after complete resection of high-
risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–
530.
16. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC,
Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S,
Goldberg SM, Pardoll DM, Gupta A,Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced
cancer.N Engl J Med. 2012;366(26):2455–2465.
17. Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient
treatedwith ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4.
18. Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S. Late onset ipilimumab-induced pericarditis and pericardial effu-
sion: a rare but life threatening complication. Case Rep Oncol Med. 2015;2015:794842.
19. Gibson R, Delaune J, Szady A, Markham M. Suspected autoimmune myocarditis and cardiac conduction abnormalities
with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep. 2016;2016:pii: bcr2016216228.
20. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies.N Engl J Med. 2016;375(15):1457–1467.
21. Heinzerling L, Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. Curr Opin
Oncol. 2017;29(2):136–144.
22. Cheng F, Loscalzo J. Autoimmune cardiotoxicity of cancer immunotherapy. Trends Immunol. 2017;38(2):77–78.
23. Semper H,Muehlberg F, Schulz-Menger J, AlleweltM, Grohe C. Drug-inducedmyocarditis after nivolumab treatment in
a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer. 2016;99:117–119.
24. Kushnir I, Wolf I. Nivolumab-induced pericardial tamponade: a case report and discussion. Cardiology. 2017;136(1):49–
51.
25. Dasanu CA, Jen T, Skulski R. Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune
monoarthritis induced by ipilimumab use for metastatic melanoma. J Oncol Pharm Pract. 2017;23(3):231–234.
26. Atezolizumab. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761041lbl.pdf.
27. Alexander W. The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some
daunting adverse effects; new drugs, indications, and combinations continue to emerge. P T. 2016;41(3):185–191.
28. Teply BA, Lipson EJ. Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology
(Williston Park). 2014;28 Suppl 3:30–38.
29. WangDY, Okoye GD, Neilan TG, JohnsonDB,Moslehi JJ. Cardiovascular toxicities associatedwith cancer immunother-
apies. Curr Cardiol Rep. 2017;19(3):21.
352 ZHENGETAL.
30. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood.
2016;127(26):3321–3330.
31. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy.Mol Ther Oncolytics.
2016;3:16011.
32. LinetteGP, Stadtmauer EA,MausMV,RapoportAP, LevineBL, Emery L, Litzky L, BaggA,CarrenoBM,CiminoPJ, Binder-
Scholl GK, Smethurst DP, Gerry AB, PumphreyNJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakob-
sen BK, Hassan NJ, Kalos M, June CH. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in
myeloma andmelanoma. Blood. 2013;122(6):863–871.
33. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event
following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther.
2010;18(4):843–851.
34. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah
NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells
expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1
dose-escalation trial. Lancet. 2015;385(9967):517–528.
35. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent
antitumor effects and can establishmemory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
36. van den Berg JH, Gomez-Eerland R, van de Wiel B, Hulshoff L, van den Broek D, Bins A, Tan HL, Harper JV, Hassan NJ,
Jakobsen BK, Jorritsma A, Blank CU, Schumacher TN, Haanen JB. Case report of a fatal serious adverse event upon
administration of T cells transducedwith aMART-1-specific T-cell receptor.Mol Ther. 2015;23(9):1541–1550.
37. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric
antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1(1):26–31.
38. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD,
Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor
T cells for sustained remissions in leukemia.N Engl J Med. 2014;371(16):1507–1517.
39. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu
J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal
Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R.
Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med.
2014;6(224):224ra225.
40. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler
DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen
BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA. Donor-derived CD19-targeted
T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood.
2013;122(25):4129–4139.
41. Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu
TL, Feldman SA, IwamotoAT, Kurlander R,Maric I, GoyA, HansenBG,Wilder JS, Blacklock-Schuver B, HakimFT, Rosen-
berg SA, Gress RE, Kochenderfer JN. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce
remissions ofB-cellmalignancies that progress after allogeneic hematopoietic stem-cell transplantationwithout causing
graft-versus-host disease. J Clin Oncol. 2016;34(10):1112–1121.
42. Kochenderfer JN,DudleyME,KassimSH, Somerville RP,CarpenterRO, Stetler-StevensonM,Yang JC, PhanGQ,Hughes
MS, Sherry RM, RaffeldM, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE,WangML, ChenCC, Kranick SM,
Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-refractory diffuse large B-cell lymphoma
and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric
antigen receptor. J Clin Oncol. 2015;33(6):540–549.
43. Kochenderfer JN, DudleyME, Feldman SA,WilsonWH, Spaner DE,Maric I, Stetler-StevensonM, Phan GQ, HughesMS,
Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell
depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-
antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–2720.
44. NelsonMH, Paulos CM. Novel immunotherapies for hematologic malignancies. Immunol Rev. 2015;263(1):90–105.
45. Kang YJ, Molecular and cellular mechanisms of cardiotoxicity. Environ Health Perspect. 2001;109 Suppl 1:27–34.
46. Coviello JS, Cardiac side effects of targeted therapies. Semin Oncol Nurs. 2014;30(3):175–182.
47. Hedhli N, Russell KS. Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev. 2011;7(4):221–233.
ZHENGETAL. 353
48. Raschi E, De Ponti F. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-
oncology. Intern EmergMed. 2012;7(2):113–131.
49. Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G, Meuleman C, Besse B, Boccara F, Kahyat D, Cohen
A, Soria JC. Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and
cardiologists. Crit Rev Oncol Hematol. 2011; 80(3):369–379.
50. Hasinoff BB, Patel D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their
ability to damagemyocytes in vitro. Toxicol Appl Pharmacol. 2010;249(2):132–139.
51. van Loenen MM, de Boer R, Amir AL, Hagedoorn RS, Volbeda GL, Willemze R, van Rood JJ, Falkenburg JH,
Heemskerk MH. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A.
2010;107(24):10972–10977.
52. Liu S, Kurzrock R. Understanding toxicities of targeted agents: implications for anti-tumor activity and management.
Semin Oncol. 2015;42(6):863–875.
53. Gross G, Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting
off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol. 2016;56:59–83.
54. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update onmanagement of immune-related toxici-
ties. Transl Lung Cancer Res. 2015;4(5):560–575.
55. Jethwa H, Adami AA, Maher J. Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathol-
ogy: is now the right time? Clin Immunol. 2014;150(1):51–63.
56. Kizhedath A, Wilkinson S, Glassey J. Applicability of predictive toxicology methods for monoclonal antibody therapeu-
tics: status quo and scope. Arch Toxicol. 2017;91(4):1595–1612.
57. DyGK, Adjei AA. Understanding, recognizing, andmanaging toxicities of targeted anticancer therapies. CA Cancer J Clin.
2013;63(4):249–279.
58. Seruga B, Sterling L, Wang L, Tannock IF. Reporting of serious adverse drug reactions of targeted anticancer agents in
pivotal phase III clinical trials. J Clin Oncol. 2011;29(2):174–185.
59. RoslandGV,EngelsenAS.Novel points of attack for targeted cancer therapy.BasicClin Pharmacol Toxicol. 2015;116(1):9–
18.
60. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Can-
nady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA
Cancer J Clin. 2012;62(4):220–241.
61. Shah DR, Shah RR,Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.
Drug Saf. 2013;36(6):413–426.
62. Chen YM, Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. J ChinMed Assoc. 2017;80(1):7–14.
63. de Mello RA, Veloso AF, Esrom Catarina P, Nadine S, Antoniou G. Potential role of immunotherapy in advanced non-
small-cell lung cancer.Onco Targets Ther. 2017;10:21–30.
64. Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K. Immunotherapy for the treatment of
urothelial carcinoma. J Urol. 2017;197(1):14–22.
65. Du L, Herbst RS,Morgensztern D. Immunotherapy in lung cancer.Hematol Oncol Clin North Am. 2017;31(1):131–141.
66. Hude I, Sasse S, Engert A, Brockelmann PJ. The emerging role of immune checkpoint inhibition in malignant lymphoma.
Haematologica. 2017;102(1):30–42.
67. Mohamed H, Eltobgy M, Abdel-Rahman O. Immune checkpoints aberrations and malignant mesothelioma: assessment
of prognostic value and evaluation of therapeutic potentials. Anticancer Agents Med Chem. 2017. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/28042777.
68. Remon J, Besse B. Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. Curr Opin
Oncol. 2017;29(2):97–104.
69. Yu LY, Tang J, Zhang CM, ZengWJ, Yan H, Li MP, Chen XP. New immunotherapy strategies in breast cancer. Int J Environ
Res Public Health. 2017;14(1):pii: E68. https://doi.org/10.3390/ijerph14010068.
70. Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X. A review of the PD-1/PD-L1 checkpoint in bladder
cancer: frommediator of immune escape to target for treatment.Urol Oncol. 2017;35(1):14–20.
71. GuoY,WangY, HanW.Chimeric antigen receptor-modified T cells for solid tumors: challenges and prospects. J Immunol
Res. 2016;2016:3850839.
72. Kenderian SS, Porter DL, Gill S. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put
the CART before the horse. Biol BloodMarrow Transplant. 2017;23(2):235–246.
354 ZHENGETAL.
73. Ruella M, June CH. Chimeric antigen receptor T cells for B cell neoplasms: choose the right CAR for you. Curr Hematol
Malig Rep. 2016;11(5):368–384.
74. Smith C, Khanna R. Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized
medicine. Immunol Cell Biol. 2017;95(4):364–371.
75. Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in cancer patients receiving
chemotherapy or radiation. Curr Cardiol Rep. 2016;18(6):52.
76. Manrique CR, ParkM, Tiwari N, Plana JC, GarciaMJ. Diagnostic strategies for early recognition of cancer therapeutics-
related cardiac dysfunction. Clin Med Insights Cardiol. 2017;11:1179546817697983.
77. Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management
of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017;47(8):678–682.
78. Hamo CE, Bloom MW, Cardinale D, Ky B, Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR, Butler
J. Cancer therapy-related cardiac dysfunction and heart failure: part 2: prevention, treatment, guidelines, and future
directions. Circ Heart Fail. 2016;9(2):e002843.
79. Thavendiranathan P, NolanMT. An emerging epidemic: cancer and heart failure. Clin Sci (Lond). 2017;131(2):113–121.
80. Cautela J, LaleveeN, AmmarC, Ederhy S, PeyrolM,Debourdeau P, SerinD, LeDolley Y,Michel N,OrabonaM, Barraud J,
LaineM,Bonello L, Paganelli F, Barlesi F, ThunyF.Management and research in cancer treatment-related cardiovascular
toxicity: challenges and perspectives. Int J Cardiol. 2016;224:366–375.
81. Mailankody S, Prasad V. Implications of proposed medicare reforms to counteract high cancer drug prices. JAMA.
2016;316(3):271–272.
82. Mailankody S, PrasadV. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMAOncol. 2015;1(4):539–
540.
83. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev
Immunol. 2012;12(4):269–281.
84. Maude S, Barrett DM. Current status of chimeric antigen receptor therapy for haematological malignancies.Br J Haema-
tol. 2016;172(1):11–22.
85. ZhangW, CAR T-cell therapy: opportunities and challenges. Immunotherapy. 2016;8(3):245–247.
86. KalaitsidouM, Kueberuwa G, Schutt A, Gilham DE. CAR T-cell therapy: toxicity and the relevance of preclinical models.
Immunotherapy. 2015;7(5):487–497.
87. Camacho LH. Current status of biosimilars in oncology.Drugs. 2017;77(9):985–997.
88. Jacobs I, Ewesuedo R, Lula S, Zacharchuk C. Biosimilars for the treatment of cancer: a systematic review of published
evidence. BioDrugs. 2017;31(1):1–36.
89. Declerck P, Danesi R, Petersel D, Jacobs I. The language of biosimilars: clarification, definitions, and regulatory aspects.
Drugs. 2017;77(6):671–677.
90. Madonna R, Cadeddu C, Deidda M, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Spallarossa P, Tocchetti CG, Zito C,
Mercuro G. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a position paper of
the Italian working group on drug cardiotoxicity and cardioprotection.Heart Fail Rev. 2015;20(5):621–631.
91. Turner JR, Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use.
Expert Opin Drug Saf. 2017;16(4):481–492.
92. Larsen CM, Mulvagh SL. Cardio-oncology: what you need to know now for clinical practice and echocardiography. Echo
Res Pract. 2017;4(1):R33–R41.
93. Cheng F, Loscalzo J. Autoimmune cardiotoxicity of cancer immunotherapy. Trends Immunol. 2017;38(2):77–78.
94. Lenihan DJ, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell RF, Moslehi J, Oliveira GH, Murtagh G, Fisch
M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, Curigliano G, Lenneman CG, Magalhaes A,
Krone R, Porter C, Parasher S, Dent S, Douglas P, Carver J. Cardio-Oncology Training: a proposal from the interna-
tional cardioncology society and Canadian Cardiac Oncology Network for a new multidisciplinary specialty. J Card Fail.
2016;22(6):465–471.
95. Gujral DM, Lloyd G, Bhattacharyya S. Provision and clinical utility of cardio-oncology services for detection of cardiac
toxicity in cancer patients. J Am Coll Cardiol. 2016;67(12):1499–1500.
96. Givertz MM, Cancer and the heart: training subspecialists, optimizing care, and moving the field forward. J Card Fail.
2016;22(6):472–474.
ZHENGETAL. 355
97. Yang H, Qin C, Li YH, Tao L, Zhou J, Yu CY, Xu F, Chen Z, Zhu F, Chen YZ. Therapeutic target database update
2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res.
2016;44(D1):D1069–D1074.
98. Rask-Andersen M, Zhang J, Fabbro D, Schioth HB. Advances in kinase targeting: current clinical use and clinical trials.
Trends Pharmacol Sci. 2014;35(11):604–620.
99. Xu J,WangP, YangH, Zhou J, Li Y, Li X, XueW, YuC, Tian Y, Zhu F. Comparison of FDAapproved kinase targets to clinical
trial ones: insights from their systemprofiles anddrug-target interaction networks.BiomedRes Int. 2016;2016:2509385.
100. Qin C, Zhang C, Zhu F, Xu F, Chen SY, Zhang P, Li YH, Yang SY, Wei YQ, Tao L, Chen YZ. Therapeutic target database
update 2014: a resource for targeted therapeutics.Nucleic Acids Res. 2014;42(Database issue):D1118–D1123.
101. Levitzki A, Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxi-
col. 2013;53:161–185.
102. Roskoski R, Jr Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme
complexes. Pharmacol Res. 2016;103:26–48.
103. Carmi C, Mor M, Petronini PG, Alfieri RR. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
Biochem Pharmacol. 2012;84(11):1388–1399.
104. Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015;36(7):422–
439.
105. LiuQ, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, GrayNS. Developing irreversible inhibitors of the protein kinase
cysteinome. Chem Biol. 2013;20(2):146–159.
106. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy.N Engl J Med. 2005;353(2):172–187.
107. Govender J, Loos B, Marais E, Engelbrecht AM.Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: a
review of the protective role of melatonin. J Pineal Res. 2014;57(4):367–380.
108. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome.
Science. 2002;298(5600):1912–1934.
109. Roskoski R, Jr A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res.
2015;100:1–23.
110. ZhangH, Photiou A, Grothey A, Stebbing J, GiamasG. The role of pseudokinases in cancer.Cell Signal. 2012;24(6):1173–
1184.
111. PazinMJ,Williams LT. Triggering signaling cascades by receptor tyrosine kinases. Trends Biochem Sci. 1992;17(10):374–
378.
112. Bolen JB, Nonreceptor tyrosine protein kinases.Oncogene. 1993;8(8):2025–2031.
113. Lipovka Y, Konhilas JP. AMP-activated protein kinase signalling in cancer and cardiac hypertrophy. Cardiovasc Pharm
Open Access. 2015;4(3):154.
114. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors.Nat Rev Cancer. 2009;9(1):28–39.
115. WongKK, Engelman JA,Cantley LC. Targeting thePI3K signaling pathway in cancer.CurrOpinGenetDev. 2010;20(1):87–
90.
116. Fischer PM. Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview.Med Res
Rev. 2017;37(2):314–367.
117. Sutherland JJ, Gao C, Cahya S, Vieth M.What general conclusions can we draw from kinase profiling data sets? Biochim
Biophys Acta. 2013;1834(7):1425–1433.
118. FrezzaM, Schmitt S, DouQP. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.Curr
TopMed Chem. 2011;11(23):2888–2905.
119. Shaikh AY, Shih JA. Chemotherapy-induced cardiotoxicity. Curr Heart Fail Rep. 2012;9(2):117–127.
120. Roy R, Evens AM, Patton D, Gallot L, Larson A, Rademaker A, Cilley J, Spies S, Variakojis D, Gordon LI, Winter JN.
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular
non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. Leuk Lymphoma.
2013;54(3):497–502.
121. EnricoO, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C, Antonio S, Mario P. Unexpected cardiotoxicity in haematolog-
ical bortezomib treated patients. Br J Haematol. 2007;138(3):396–397.
122. SubediA, SharmaLR, ShahBK.Bortezomib-inducedacute congestive heart failure: a case report and reviewof literature.
Ann Hematol. 2014;93(10):1797–1799.
356 ZHENGETAL.
123. Xiao Y, Yin J,Wei J, Shang Z. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer:
a systematic review andmeta-analysis. PLoS One. 2014;9(1):e87671.
124. MaureaN, SpallarossaP, CadedduC,MadonnaR,MeleD,Monte I, NovoG, PagliaroP, PepeA, Tocchetti CG, ZitoC,Mer-
curoG. A recommended practical approach to themanagement of target therapy and angiogenesis inhibitors cardiotox-
icity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J
Cardiovasc Med (Hagerstown). 2016;17 Suppl 1:e93–e104.
125. Bortezomib. https://www.uptodate.com/contents/bortezomib-drug-information?source=search_result&search=Borte
zomib&selectedTitle=1~100.
126. Grandin EW, Ky B, Cornell RF, Carver J, LenihanDJ. Patterns of cardiac toxicity associatedwith irreversible proteasome
inhibition in the treatment of multiple myeloma. J Card Fail. 2015;21(2):138–144.
127. Danhof S, Schreder M, Rasche L, Strifler S, Einsele H, Knop S. ‘Real-life’ experience of preapproval carfilzomib-based
therapy inmyeloma - analysis of cardiac toxicity and predisposing factors. Eur J Haematol. 2016;97(1):25–32.
128. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S.
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
Haematologica. 2013;98(11):1753–1761.
129. Harvey RD, Incidence andmanagement of adverse events in patients with relapsed and/or refractory multiple myeloma
receiving single-agent carfilzomib. Clin Pharmacol. 2014;6:87–96.
130. Carfilzomib. https://www.uptodate.com/contents/carfilzomib-drug-information?source=search_result&search=Carfi
lzomib&selectedTitle=1~21.
131. Laubach JP,Moslehi JJ, Francis SA, SanMiguel JF, SonneveldP,Orlowski RZ,MoreauP,Rosinol L, FaberEA, Jr., Voorhees
P,MateosMV,MarquezL, FengH,DesaiA, vandeVeldeH,Elliott J, ShiH,DowE, JobanputraN,EsseltineDL,NiculescuL,
AndersonKC, Lonial S, RichardsonPG. A retrospective analysis of 3954patients in phase 2/3 trials of bortezomib for the
treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition
inmultiple myeloma. Br J Haematol. 2017;178(4):547–560.
132. Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D, Saldanha SC. Epigenetic therapy of cancer with histone deacetylase
inhibitors. J Cancer Res Ther. 2014;10(3):469–478.
133. Song SH, Han SW, Bang YJ. Epigenetic-based therapies in cancer: progress to date.Drugs. 2011;71(18):2391–2403.
134. Liu M, Zhou J, Chen Z, Cheng AS. Understanding the epigenetic regulation of tumours and their microenvironments:
opportunities and problems for epigenetic therapy. J Pathol. 2017;241(1):10–24.
135. Hronek J, Reed M. Nursing roles in cardiac safety: romidepsin in Patients with T-cell lymphoma. Oncol Nurs Forum.
2016;43(2):227–234.
136. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, Farra Y, Young D, Grever M. Cardiotoxicity of
histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res.
2006;12(13):3997–4003.
137. FedericoM, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J
Biomed Biotechnol. 2011;2011:475641.
138. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE. Cardiac studies in
patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762–
3773.
139. Romidepsin. https://www.uptodate.com/contents/romidepsin-drug-information?source=search_result&search=Romi
depsin&selectedTitle=1~10.
140. Laubach JP, San-Miguel JF,HungriaV,Hou J,MoreauP, Lonial S, Lee JH, EinseleH,AlsinaM,RichardsonPG.Deacetylase
inhibitors: an advance inmyeloma therapy? Expert Rev Hematol. 2017;10(3):229–237.
141. YeoW, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC,
To KF, TaoQ,MaBB, Chan AW, Tong JH, ErlichmanC, Chan AT, Goh BC. Epigenetic therapy using belinostat for patients
with unresectable hepatocellular carcinoma: amulticenter phase I/II studywith biomarker andpharmacokinetic analysis
of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol.
2012;30(27):3361–3367.
142. Belinostat. https://www.uptodate.com/contents/belinostat-drug-information?source=search_result&search=Belino
stat&selectedTitle=1~7.
143. Redic KA, Hough SM, Price EM. Clinical developments in the treatment of relapsed or relapsed and refractory multi-
ple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor. Onco Targets Ther. 2016;9:2783–
2793.
ZHENGETAL. 357
144. Panobinostat. https://www.uptodate.com/contents/panobinostat-drug-information?source=search_result&search=
Panobinostat&selectedTitle=1~12.
145. Eglen R, Reisine T. Drug discovery and the human kinome: recent trends. Pharmacol Ther. 2011;130(2):144–156.
146. Singh J, Petter RC, Baillie TA,Whitty A. The resurgence of covalent drugs.Nat Rev Drug Discov. 2011;10(4):307–317.
147. Landi L, Cappuzzo F. Irreversible EGFR-TKIs: dreaming perfection. Transl Lung Cancer Res. 2013;2(1):40–49.
148. Baillie TA, Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicol-
ogy. Chem Res Toxicol. 2006;19(7):889–893.
149. LieblerDC, Protein damage by reactive electrophiles: targets and consequences.ChemRes Toxicol. 2008;21(1):117–128.
150. Fasano M, Della Corte CM, Califano R, Capuano A, Troiani T, Martinelli E, Ciardiello F, Morgillo F. Type III or allosteric
kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs. 2014;23(6):809–821.
151. Dar AC, Shokat KM. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu
Rev Biochem. 2011;80:769–795.
152. Lamba V, Ghosh I. New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors. Curr
PharmDes. 2012;18(20):2936–2945.
153. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology.Nat Rev Cancer. 2010;10(2):130–
137.
154. Cross MJ, Berridge BR, Clements PJ, Cove-Smith L, Force TL, Hoffmann P, HolbrookM, Lyon AR, Mellor HR, Norris AA,
Pirmohamed M, Tugwood JD, Sidaway JE, Park BK. Physiological, pharmacological and toxicological considerations of
drug-induced structural cardiac injury. Br J Pharmacol. 2015;172(4):957–974.
155. Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res.
2013;113(6):709–724.
156. Weisner J, Gontla R, van der Westhuizen L, Oeck S, Ketzer J, Janning P, Richters A, Muhlenberg T, Fang Z, Taher A,
Jendrossek V, Pelly SC, Bauer S, van OtterloWA, Rauh D. Covalent-allosteric kinase inhibitors. Angew Chem Int Ed Engl.
2015;54(35):10313–10316.
157. Trametinib. https://www.uptodate.com/contents/trametinib-drug-information?source=search_result&search=Tramet
inib&selectedTitle=1~26.
158. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, MilhemM, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer
R, Trefzer U, Larkin JM, Utikal J, Dreno B, NyakasM,MiddletonMR, Becker JC, CaseyM, Sherman LJ,Wu FS, Ouellet D,
Martin AM, Patel K, Schadendorf D, Group MS. Improved survival with MEK inhibition in BRAF-mutated melanoma. N
Engl J Med. 2012;367(2):107–114.
159. KimKB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA,MillwardM,McArthurGA,HwuP, Gonzalez R,
Ott PA, LongGV,GardnerOS,OuelletD, XuY, DeMarini DJ, LeNT, Patel K, Lewis KD. Phase II study of theMEK1/MEK2
inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without
a BRAF inhibitor. J Clin Oncol. 2013;31(4):482–489.
160. Ibrutinib. https://www.uptodate.com/contents/ibrutinib-drug-information?source=search_result&search=Ibrutinib&
selectedTitle=1~36.
161. Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF,
Moslehi JJ, Brown JR. Ventricular arrhythmias and suddendeath in patients taking ibrutinib.Blood. 2017;129(18):2581–
2584.
162. SendurMA,Aksoy S, AltundagK.Cardiotoxicity of novelHER2-targeted therapies.CurrMedResOpin. 2013;29(8):1015–
1024.
163. Afatinib. https://www.uptodate.com/contents/afatinib-drug-information?source=search_result&search=Afatinib&
selectedTitle=1~15.
164. Gower CM, ChangME,Maly DJ. Bivalent inhibitors of protein kinases. Crit Rev BiochemMol Biol. 2014;49(2):102–115.
165. Bailey FP, Byrne DP, McSkimming D, Kannan N, Eyers PA. Going for broke: targeting the human cancer pseudokinome.
Biochem J. 2015;465(2):195–211.
166. Hammaren HM, Virtanen AT, Silvennoinen O. Nucleotide-binding mechanisms in pseudokinases. Biosci Rep.
2015;36(1):e00282.
167. Reiterer V, Eyers PA, Farhan H. Day of the dead: pseudokinases and pseudophosphatases in physiology and disease.
Trends Cell Biol. 2014;24(9):489–505.
168. Mondal D, Mathur A, Chandra PK. Tripping on TRIB3 at the junction of health, metabolic dysfunction and cancer.
Biochimie. 2016;124:34–52.
358 ZHENGETAL.
169. Eyers PA, Keeshan K, KannanN. Tribbles in the 21st century: The evolving roles of tribbles pseudokinases in biology and
disease. Trends Cell Biol. 2017;27(4):284–298.
170. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32(21):2601–
2613.
171. Baselga J, Swain SM.Novel anticancer targets: revisiting ERBB2 anddiscovering ERBB3.Nat Rev Cancer. 2009;9(7):463–
475.
172. Salazar M, Lorente M, Orea-Soufi A, Davila D, Erazo T, Lizcano J, Carracedo A, Kiss-Toth E, Velasco G. Oncosuppressive
functions of tribbles pseudokinase 3. Biochem Soc Trans. 2015;43(5):1122–1126.
173. Xie T, Lim SM, Westover KD, Dodge ME, Ercan D, Ficarro SB, Udayakumar D, Gurbani D, Tae HS, Riddle SM, Sim
T, Marto JA, Janne PA, Crews CM, Gray NS. Pharmacological targeting of the pseudokinase Her3. Nat Chem Biol.
2014;10(12):1006–1012.
174. Cowan-Jacob SW, JahnkeW, Knapp S. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation
and pseudokinases. Future Med Chem. 2014;6(5):541–561.
175. KarvonenH, NiininenW,Murumagi A, UngureanuD. Targeting ROR1 identifies new treatment strategies in hematolog-
ical cancers. Biochem Soc Trans. 2017;45(2):457–464.
176. Rebagay G, Yan S, Liu C, Cheung NK. ROR1 and ROR2 in human malignancies: potentials for targeted therapy. Front
Oncol. 2012;2:34.
177. BorcherdingN, KusnerD, LiuGH, ZhangW. ROR1, an embryonic proteinwith an emerging role in cancer biology. Protein
Cell. 2014;5(7):496–502.
178. Aghebati-Maleki L, Shabani M, Baradaran B, Motallebnezhad M, Majidi J, Yousefi M. Receptor tyrosine kinase-like
orphan receptor 1 (ROR-1): an emerging target for diagnosis and therapy of chronic lymphocytic leukemia. Biomed Phar-
macother. 2017;88:814–822.
179. ShabaniM,Naseri J, Shokri F. Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy.
Expert Opin Ther Targets. 2015;19(7):941–955.
180. AsemMS, Buechler S,Wates RB,Miller DL, StackMS.Wnt5a signaling in cancer. Cancers (Basel). 2016;8(9):79.
181. Dave H, Anver MR, Butcher DO, Brown P, Khan J, Wayne AS, Baskar S, Rader C. Restricted cell surface expression of
receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with thera-
peutic monoclonal antibodies. PLoS One. 2012;7(12):e52655.
182. Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, Mellstedt H. The receptor
tyrosine kinase ROR1–an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol. 2014;29:21–31.
183. RicheyEA, LyonsEA,Nebeker JR, ShankaranV,McKoy JM, LuuTH,NonzeeN, Trifilio S, SartorO,BensonAB, 3rd, Carson
KR, Edwards BJ, Gilchrist-Scott D, Kuzel TM, Raisch DW, Tallman MS, West DP, Hirschfeld S, Grillo-Lopez AJ, Bennett
CL. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and
ineffective drugs? J Clin Oncol. 2009;27(26):4398–4405.
184. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME, Jr., Ruccione K, Smithson WA, Robison LL. Late mortality expe-
rience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol.
2001;19(13):3163–3172.
185. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and manage-
ment. J Am Coll Cardiol. 2009;53(24):2231–2247.
186. Meacham LR, Chow EJ, Ness KK, Kamdar KY, Chen Y, Yasui Y, Oeffinger KC, Sklar CA, Robison LL, Mertens AC. Car-
diovascular risk factors in adult survivors of pediatric cancer–a report from the childhood cancer survivor study. Cancer
Epidemiol Biomarkers Prev. 2010;19(1):170–181.
187. Rose-Felker K, BorderWL, Hong BJ, ChowEJ. Cardio-oncology related to heart failure: pediatric considerations for car-
diac dysfunction.Heart Fail Clin. 2017;13(2):311–325.
188. ArmstrongGT, JoshiVM,NessKK,MarwickTH,ZhangN, SrivastavaD,GriffinBP,GrimmRA,Thomas J, PhelanD,Collier
P, Krull KR,MulrooneyDA, GreenDM,HudsonMM, Robison LL, Plana JC. Comprehensive echocardiographic detection
of treatment-related cardiacdysfunction in adult survivors of childhoodcancer: results fromtheSt. JudeLifetimeCohort
Study. J Am Coll Cardiol. 2015;65(23):2511–2522.
189. ArmstrongGT, Plana JC, ZhangN, SrivastavaD, GreenDM,Ness KK, Daniel Donovan F,MetzgerML, Arevalo A, Durand
JB, Joshi V,HudsonMM,Robison LL, FlammSD. Screening adult survivors of childhood cancer for cardiomyopathy: com-
parison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30(23):2876–2884.
190. Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood
cancers. Circ Res. 2011;108(5):619–628.
ZHENGETAL. 359
191. Lipshultz SE, CochranTR, FrancoVI,Miller TL. Treatment-related cardiotoxicity in survivors of childhood cancer.Nat Rev
Clin Oncol. 2013;10(12):697–710.
192. Lipshultz SE, Franco VI, Miller TL, Colan SD, Sallan SE. Cardiovascular disease in adult survivors of childhood cancer.
Annu RevMed. 2015;66:161–176.
193. Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA,
Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy DJ, Carrasco DR, Robinson
S, Moslehi J, Letai A. Developmental regulation of mitochondrial apoptosis by c-Myc governs age- and tissue-specific
sensitivity to cancer therapeutics. Cancer Cell. 2017;31(1):142–156.
194. Toro-Salazar OH, Gillan E, O'LoughlinMT, Burke GS, Ferranti J, Stainsby J, Liang B,MazurW, Raman SV, Hor KN. Occult
cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging. 2013;6(6):873–
880.
195. No authors listed. PD-1 inhibitor becomes “breakthrough therapy”. Cancer Discov. 2013;3(7):OF14.
196. Ataca P, ArslanO. Chimeric antigen receptor T cell therapy in hematology. Turk J Haematol. 2015;32(4):285–294.
197. Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol.
2016;13(1):25–40.
198. Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev.
2015;263(1):68–89.
199. Helleday T. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer:
beyond germline BRCAmutations. Ann Oncol. 2016;27(5):755–757.
200. Kim ES. Olmutinib: First global approval.Drugs. 2016;76(11):1153–1157.
201. Lim JS, Sundar R, Chenard-Poirier M, Lopez J, Yap TA. Emerging biomarkers for PD-1 pathway cancer therapy. Biomark
Med. 2017;11(1):53–67.
202. Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park).
2014;3(28 Suppl):39–48.
203. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in
melanoma. Clin Ther. 2015;37(4):764–782.
204. Mangini NS, Wesolowski R, Ramaswamy B, Lustberg MB, Berger MJ. Palbociclib: A novel cyclin-dependent kinase
inhibitor for hormone receptor-positive advanced breast cancer. Ann Pharmacother. 2015;49(11):1252–1260.
205. Miller BC, Maus MV. CD19-targeted CAR T cells: a new tool in the fight against B cell malignancies. Oncol Res Treat.
2015;38(12):683–690.
206. NicholsM. Newdirections for drug-resistant breast cancer: the CDK4/6 inhibitors. FutureMed Chem. 2015;7(12):1473–
1481.
207. SantarpiaM, Altavilla G, Rosell R. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged
non-small-cell lung cancer. Expert Rev Respir Med. 2015;9(3):255–268.
208. Skoulidis F, Papadimitrakopoulou VA. Personalized medicine tackles clinical resistance: alectinib in ALK-positive non-
small cell lung cancer progressing on first-generation ALK inhibitor. Clin Cancer Res. 2016;22(21):5177–5182.
209. KesselheimAS,Woloshin S, EddingsW, Franklin JM, Ross KM, Schwartz LM. Physicians′ knowledge about FDA approval
standards and perceptions of the “breakthrough therapy” designation. JAMA. 2016;315(14):1516–1518.
210. Krishnamurti T, Woloshin S, Schwartz LM, Fischhoff B. A randomized trial testing US Food and Drug Administration
“Breakthrough” language. JAMA InternMed. 2015;175(11):1856–1858.
211. Casartelli A, LanzoniA,Comelli R,CrivellenteF,DefazioR,Dorigatti R, FasdelliN, Faustinelli I, PagliaruscoS, Tontodonati
M, Cristofori P. A novel and integrated approach for the identification and characterization of drug-induced cardiac tox-
icity in the dog. Toxicol Pathol. 2011;39(2):361–371.
212. LageA,CrombetT.Control of advanced cancer: the road to chronicity. Int J EnvironRes PublicHealth. 2011;8(3):683–697.
213. Wickramasinghe CD, Nguyen KL, Watson KE, Vorobiof G, Yang EH. Concepts in cardio-oncology: definitions, mecha-
nisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity. Future Oncol. 2016;12(6):855–870.
214. Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P. The Repurposing Drugs in Oncology (ReDO)
Project. Ecancermedicalscience. 2014;8:442.
215. PantziarkaP,Cairns L.Recyclingexistingdrugs for cancer therapy: delivering lowcost cancer care.Ecancermedicalscience.
2014;8:ed40.
216. FlorescuM, CintezaM, VinereanuD. Chemotherapy-induced Cardiotoxicity.Maedica (Buchar). 2013;8(1):59–67.
360 ZHENGETAL.
217. Dolci A,Dominici R,CardinaleD, SandriMT, PanteghiniM.Biochemicalmarkers for predictionof chemotherapy-induced
cardiotoxicity: systematic reviewof the literature and recommendations for use.AmJClin Pathol. 2008;130(5):688–695.
218. Broder H, Gottlieb RA, Lepor NE. Chemotherapy and cardiotoxicity. Rev Cardiovasc Med. 2008;9(2):75–83.
219. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs
J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE,
Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging
evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography
and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063–1093.
220. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol.
2010;7(10):564–575.
221. BillinghamME, Mason JW, BristowMR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes.
Cancer Treat Rep. 1978;62(6):865–872.
222. BristowMR, Thompson PD,Martin RP,Mason JW, BillinghamME, HarrisonDC. Early anthracycline cardiotoxicity.Am J
Med. 1978;65(5):823–832.
223. Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl
Cardiol. 2012;19(2):377–388.
224. SandhuH,MaddockH.Molecular basis of cancer-therapy-induced cardiotoxicity: introducingmicroRNAbiomarkers for
early assessment of subclinical myocardial injury. Clin Sci (Lond). 2014;126(6):377–400.
225. Zajicek G. Cancer as a systemic disease.Med Hypotheses. 1978;4(3):193–207.
226. Murphy KT. The pathogenesis and treatment of cardiac atrophy in cancer cachexia. Am J Physiol Heart Circ Physiol.
2016;310(4):H466–H477.
227. McLean AS, Huang SJ, Salter M. Bench-to-bedside review: the value of cardiac biomarkers in the intensive care patient.
Crit Care. 2008;12(3):215.
228. Witteles RM. Biomarkers as predictors of cardiac toxicity from targeted cancer therapies. J Card Fail. 2016;22(6):459–
464.
229. WeberM, HammC. Role of B-type natriuretic peptide (BNP) andNT-proBNP in clinical routine.Heart. 2006;92(6):843–
849.
230. Shah KS, Yang EH, Maisel AS, Fonarow GC. The role of biomarkers in detection of cardio-toxicity. Curr Oncol Rep.
2017;19(6):42.
231. Michos ED, Wilson LM, Yeh HC, Berger Z, Suarez-Cuervo C, Stacy SR, Bass EB. Prognostic value of cardiac troponin
in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-
analysis. Ann InternMed. 2014;161(7):491–501.
232. PavoN,RadererM,HulsmannM,NeuholdS,AdlbrechtC, StrunkG,GoliaschG,GisslingerH, StegerGG,HejnaM,Kostler
W, Zochbauer-Muller S, Marosi C, Kornek G, Auerbach L, Schneider S, Parschalk B, Scheithauer W, Pirker R, Drach J,
Zielinski C, Pacher R. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
Heart. 2015;101(23):1874–1880.
233. Lyon AR. Disparate worlds drawing closer together: cardiovascular biomarkers predict cancer outcomes in treatment-
naive patients.Heart. 2015;101(23):1853–1854.
234. Wang X, Raulji P, Mohapatra SS, Patel R, Hellermann G, Kong X, Vera PL, Meyer-Siegler KL, Coppola D, Mohapatra S.
Natriuretic peptide receptor a as a novel target for prostate cancer.Mol Cancer. 2011;10:56.
235. Wieshammer S, Dreyhaupt J, Muller D, Momm F, Jakob A. Limitations of N-terminal Pro-B-type natriuretic peptide
in the diagnosis of heart disease among cancer patients who present with cardiac or pulmonary symptoms. Oncology.
2016;90(3):143–150.
236. Thavendiranathan P, Poulin F, Lim KD, Plana JC,Woo A, Marwick TH. Use of myocardial strain imaging by echocardiog-
raphy for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J
Am Coll Cardiol. 2014;63(25 Pt A):2751–2768.
237. Bottinor WJ, Migliore CK, Lenneman CA, Stoddard MF. Echocardiographic assessment of cardiotoxic effects of cancer
therapy. Curr Cardiol Rep. 2016;18(10):99.
238. Chen-Scarabelli C, McRee C, Leesar MA, Hage FG, Scarabelli TM. Comprehensive review on cardio-oncology: role of
multimodality imaging. J Nucl Cardiol. 2016;24(3):906–935.
239. Bezerra HG, Costa RA, Reiber JH, Rybicki FJ, Schoenhagen P, Stillman AA, De Sutter J, Van de Veire NR. Cardiovascular
imaging 2013 in the International Journal of Cardiovascular Imaging. Int J Cardiovasc Imaging. 2014;30(4):683–695.
ZHENGETAL. 361
240. Collier P, Phelan D, Klein A. A test in context: myocardial strain measured by speckle-tracking echocardiography. J Am
Coll Cardiol. 2017;69(8):1043–1056.
241. Nguyen KL, Hu P, Ennis DB, Shao J, Pham KA, Chen JJ. Cardiac MRI: a translational imaging tool for characterizing
anthracycline-inducedmyocardial remodeling. Curr Oncol Rep. 2016;18(8):48.
242. Jeong D, Patel A, Francois CJ, Gage KL, Fradley MG. Cardiac magnetic resonance imaging in oncology. Cancer Control.
2017;24(2):147–160.
243. Pitekova B, Ravi S, Shah SV,Mladosievicova B, Heitner S, FerencikM. The role of imagingwith cardiac computed tomog-
raphy in cardio-oncology patients. Curr Cardiol Rep. 2016;18(9):87.
244. DraznerMH. The progression of hypertensive heart disease. Circulation. 2011;123(3):327–334.
245. Lessick J, Sideman S, Azhari H, Shapiro E, Weiss JL, Beyar R. Evaluation of regional load in acute ischemia by three-
dimensional curvatures analysis of the left ventricle. Ann Biomed Eng. 1993;21(2):147–161.
246. Beyar R, Weiss JL, Shapiro EP, Graves WL, Rogers WJ, Weisfeldt ML. Small apex-to-base heterogeneity in radius-to-
thickness ratio by three-dimensional magnetic resonance imaging. Am J Physiol. 1993;264(1 Pt 2):H133–140.
247. CooleyD, A.What is concentric remodeling of the left ventriclewith adequate systolic function? Ask a TexasHeart Insti-
tute Doctor. 2014. http://www.texasheart.org/HIC/HeartDoctor/answer_3342.cfm
248. Pugliese NR, Fabiani I, La Carrubba S, Conte L, Antonini-Canterin F, Colonna P, Caso P, Benedetto F, Santini V, Carerj
S, Romano MF, Citro R, Di Bello V. Italian Society of Cardiovascular E. Classification and prognostic evaluation of left
ventricular remodeling in patients with asymptomatic heart failure. Am J Cardiol. 2017;119(1):71–77.
249. KonstamMA,KramerDG,PatelAR,MaronMS,Udelson JE. Left ventricular remodeling in heart failure: current concepts
in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4(1):98–108.
250. Udelson JE, KonstamMA. Ventricular remodeling fundamental to the progression (and regression) of heart failure. J Am
Coll Cardiol. 2011;57(13):1477–1479.
251. Seo Y, Ishizu T, Aonuma K. Current status of 3-dimensional speckle tracking echocardiography: a review from our expe-
riences. J Cardiovasc Ultrasound. 2014;22(2):49–57.
252. Avelar E, Strickland CR, Rosito G. Role of imaging in cardio-oncology. Curr Treat Options Cardiovasc Med. 2017;19(6):46.
253. Luis SA, Yamada A, Khandheria BK, Speranza V, Benjamin A, Ischenko M, Platts DG, Hamilton-Craig CR, Haseler
L, Burstow D, Chan J. Use of three-dimensional speckle-tracking echocardiography for quantitative assessment of
global left ventricular function: a comparative study to three-dimensional echocardiography. J Am Soc Echocardiogr.
2014;27(3):285–291.
254. Lin ACW, Strugnell W, Riley R, Schmitt B, Zenge M, Schmidt M, Morris NR, Hamilton-Craig C. Higher resolution
cine imaging with compressed sensing for accelerated clinical left ventricular evaluation. J Magn Reson Imaging.
2017;45(6):1693–1699.
255. Madore B, HogeWS, Chao TC, ZientaraGP, Chu R. Retrospectively gated cardiac cine imagingwith temporal and spatial
acceleration.Magn Reson Imaging. 2011;29(4):457–469.
256. Malayeri AA, JohnsonWC, Macedo R, Bathon J, Lima JA, Bluemke DA. Cardiac cine MRI: quantification of the relation-
ship between fast gradient echo and steady-state free precession for determination of myocardial mass and volumes. J
Magn Reson Imaging. 2008;28(1):60–66.
257. Nakano S, Takahashi M, Kimura F, Senoo T, Saeki T, Ueda S, Tanno J, Senbonmatsu T, Kasai T, Nishimura S. Cardiac mag-
netic resonance imaging-basedmyocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated
with trastuzumab: a pilot study to evaluate the feasibility of themethod. Cardiol J. 2016;23(3):270–280.
258. Bengel FM. Clinical cardiovascular molecular imaging. J Nucl Med. 2009;50(6):837–840.
259. Wollenweber T, Bengel FM. Cardiacmolecular imaging. Semin Nucl Med. 2014;44(5):386–397.
260. Dobrucki LW, Sinusas AJ. PET and SPECT in cardiovascular molecular imaging.Nat Rev Cardiol. 2010;7(1):38–47.
261. SinusasAJ.Molecular imaging in nuclear cardiology: translating research concepts into clinical applications.QJNuclMed
Mol Imaging. 2010;54(2):230–240.
262. Saraste A, Nekolla SG, Schwaiger M. Cardiovascular molecular imaging: an overview. Cardiovasc Res. 2009;83(4):643–
652.
263. Sosnovik DE, Nahrendorf M, Weissleder R. Targeted imaging of myocardial damage. Nat Clin Pract Cardiovasc Med.
2008;2(5 Suppl):S63–S70.
264. Kasama S, Toyama T, Kurabayashi M. Usefulness of cardiac sympathetic nerve imaging using (123)Iodine-
Metaiodobenzylguanidine Scintigraphy for Predicting sudden cardiac death in patients with heart failure. Int Heart J.
2016;57(2):140–144.
362 ZHENGETAL.
265. Bengel FM, Thackeray JT. Altered cardiac innervation predisposes to ventricular arrhythmia: targeted positron emission
tomography identifies risk in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63(2):150–152.
266. Thackeray JT, Bengel FM. Assessment of cardiac autonomic neuronal function using PET imaging. J Nucl Cardiol.
2013;20(1):150–165.
267. Wollenweber T, Bengel FM. Molecular imaging to predict ventricular arrhythmia in heart failure. J Nucl Cardiol.
2014;21(6):1096–1109.
268. Guimaraes SL, Brandao SC, Andrade LR,Maia RJ,Markman Filho B. Cardiac sympathetic hyperactivity after chemother-
apy: early sign of cardiotoxicity. Arq Bras Cardiol. 2015;105(3):228–234.
269. StokkelMP, deWit-van der Veen LJ, Boekhout A. I-123-MIBGmyocardial imaging in trastuzumab-based cardiotoxicity:
the first experience.Nucl Med Commun. 2013;34(1):19–24.
270. Swiger KJ, Singh J, Lenihan DJ. Cardiomyopathic toxicity from chemotherapy: is there an opportunity for preemptive
intervention? Curr Treat Options Cardiovasc Med. 2017;19(3):20.
271. Kang J, Chang JH,Wilson BC, Veilleux I, Bai Y, DaCosta R, Kim K, Ha S, Lee JG, Kim JS, Lee SG, Kim SM, Lee HJ, Ahn YB,
Han S, Yoo Y, Song TK. A prototype hand-held tri-modal instrument for in vivo ultrasound, photoacoustic, and fluores-
cence imaging. Rev Sci Instrum. 2015;86(3):034901.
272. Wang LV, Yao J. A practical guide to photoacoustic tomography in the life sciences. Nat Methods. 2016;13(8):627–
638.
273. Valluru KS,Willmann JK. Clinical photoacoustic imaging of cancer.Ultrasonography. 2016;35(4):267–280.
274. Wang S, Lin J, Wang T, Chen X, Huang P. Recent Advances in photoacoustic imaging for deep-tissue biomedical applica-
tions. Theranostics. 2016;6(13):2394–2413.
275. Yao J, Xia J,Wang LV. Multiscale functional andmolecular photoacoustic tomography.Ultrason Imaging. 2016;38(1):44–
62.
276. Zhang YS, Wang LV, Xia Y. Seeing through the surface: non-invasive characterization of biomaterial-tissue interactions
using photoacoustic microscopy. Ann Biomed Eng. 2016;44(3):649–666.
277. Zhou Y, Yao J,Wang LV. Tutorial on photoacoustic tomography. J Biomed Opt. 2016;21(6):61007.
278. Sivasubramanian K, PramanikM. High frame rate photoacoustic imaging at 7000 frames per second using clinical ultra-
sound system. Biomed Opt Express. 2016;7(2):312–323.
279. DongB, SunC,ZhangHF.Optical detectionof ultrasound inphotoacoustic imaging. IEEETransBiomedEng. 2017;64(1):4–
15.
280. Miao Q, Pu K. Emerging Designs of activatable photoacoustic probes for molecular imaging. Bioconjug Chem.
2016;27(12):2808–2823.
281. LiuC,GongX, LinR, Liu F, Chen J,WangZ, Song L, Chu J. Advances in imaging techniques and genetically encodedprobes
for photoacoustic imaging. Theranostics. 2016;6(13):2414–2430.
282. Lemaster JE, Jokerst JV. What is new in nanoparticle-based photoacoustic imaging? Wiley Interdiscip Rev Nanomed
Nanobiotechnol. 2017;9(1):https://doi.org/10.1002/wnan.1404
283. Hu S. Emerging concepts in functional andmolecular photoacoustic imaging. Curr Opin Chem Biol. 2016;33:25–31.
284. JeonM, Kim J, KimC.Multiplane spectroscopic whole-body photoacoustic imaging of small animals in vivo.Med Biol Eng
Comput. 2016;54(2–3):283–294.
285. Wang LV, Hu S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science. 2012;335(6075):1458–
1462.
286. Wang LV.Multiscale photoacoustic microscopy and computed tomography.Nat Photonics. 2009;3(9):503–509.
287. Wang D, Wu Y, Xia J. Review on photoacoustic imaging of the brain using nanoprobes. Neurophotonics.
2016;3(1):010901.
288. Li R,Wang P, Lan L, Lloyd FP, Jr., Goergen CJ, Chen S, Cheng JX. Assessing breast tumormargin bymultispectral photoa-
coustic tomography. Biomed Opt Express. 2015;6(4):1273–1281.
289. Xia W, Piras D, Singh MK, van Hespen JC, van Leeuwen TG, Steenbergen W, Manohar S. Design and evaluation of a
laboratory prototype system for 3D photoacoustic full breast tomography. Biomed Opt Express. 2013;4(11):2555–2569.
290. PramanikM, KuG, Li C,Wang LV. Design and evaluation of a novel breast cancer detection system combining both ther-
moacoustic (TA) and photoacoustic (PA) tomography.Med Phys. 2008;35(6):2218–2223.
ZHENGETAL. 363
291. Maeda A, Bu J, Chen J, Zheng G, DaCosta RS. Dual in vivo photoacoustic and fluorescence imaging of HER2 expres-
sion inbreast tumors for diagnosis,margin assessment, and surgical guidance.Mol Imaging. 2015;14(1):7290201400043.
https://doi.org/10.2310/7290.2014.00043.
292. ZhangM, KimHS, Jin T, Yi A, MoonWK. Ultrasound-guided photoacoustic imaging for the selective detection of EGFR-
expressing breast cancer and lymph nodemetastases. Biomed Opt Express. 2016;7(5):1920–1931.
293. Chen BZ, Yang JG, Wu D, Zeng DW, Yi Y, Yang N, Jiang HB. Photoacoustic imaging of cerebral hypoperfusion during
acupuncture. Biomed Opt Express. 2015;6(9):3225–3234.
294. Nasiriavanaki M, Xia J, Wan H, Bauer AQ, Culver JP, Wang LV. High-resolution photoacoustic tomography of resting-
state functional connectivity in themouse brain. Proc Natl Acad Sci U S A. 2014;111(1):21–26.
295. Dahal S, Cullum BM. Characterization of multiphoton photoacoustic spectroscopy for subsurface brain tissue diagnosis
and imaging. J Biomed Opt. 2016;21(4):47001.
296. van Es P, Biswas SK, BernelotMoensHJ, SteenbergenW,Manohar S. Initial results of finger imaging using photoacoustic
computed tomography. J Biomed Opt. 2014;19(6):060501.
297. Erpelding TN, Kim C, PramanikM, Jankovic L, Maslov K, Guo Z, Margenthaler JA, PashleyMD,Wang LV. Sentinel lymph
nodes in the rat: noninvasive photoacoustic and US imaging with a clinical US system. Radiology. 2010;256(1):102–110.
298. Taruttis A, Herzog E, Razansky D, Ntziachristos V. Real-time imaging of cardiovascular dynamics and circulating gold
nanorods withmultispectral optoacoustic tomography.Opt Express. 2010;18(19):19592–19602.
299. Kang D, Huang Q, Li Y. Noninvasive photoacoustic measurement of the composite indicator dilution curve for cardiac
output estimation. Biomed Opt Express. 2015;6(2):536–543.
300. Laufer J, Norris F, Cleary J, Zhang E, Treeby B, Cox B, Johnson P, Scambler P, LythgoeM, Beard P. In vivo photoacoustic
imaging of mouse embryos. J Biomed Opt. 2012;17(6):061220.
301. Song KH,Wang LV. Noninvasive photoacoustic imaging of the thoracic cavity and the kidney in small and large animals.
Med Phys. 2008;35(10):4524–4529.
302. Dean-Ben XL, Ford SJ, Razansky D. High-frame rate four dimensional optoacoustic tomography enables visualization of
cardiovascular dynamics andmouse heart perfusion. Sci Rep. 2015;5:10133.
303. Horiguchi A, Tsujita K, Irisawa K, Kasamatsu T, Hirota K, Kawaguchi M, Shinchi M, Ito K, Asano T, Shinmoto H, Tsuda H,
IshiharaM. A pilot study of photoacoustic imaging system for improved real-time visualization of neurovascular bundle
during radical prostatectomy. Prostate. 2016;76(3):307–315.
304. Tang S, Chen J, Samant P, Stratton K, Xiang L. Transurethral photoacoustic endoscopy for prostate cancer: a simulation
study. IEEE Trans Med Imaging. 2016;35(7):1780–1787.
305. Schwarz M, Buehler A, Aguirre J, Ntziachristos V. Three-dimensional multispectral optoacoustic mesoscopy reveals
melanin and blood oxygenation in human skin in vivo. J Biophotonics. 2016;9(1–2):55–60.
306. Valluru KS,Wilson KE,Willmann JK. Photoacoustic imaging in oncology: translational preclinical and early clinical expe-
rience. Radiology. 2016;280(2):332–349.
307. Diot G, Dima A, Ntziachristos V. Multispectral opto-acoustic tomography of exercised muscle oxygenation. Opt Lett.
2015;40(7):1496–1499.
308. LiuY,Nie L, ChenX. Photoacousticmolecular imaging: frommultiscale biomedical applications towards early-stage ther-
anostics. Trends Biotechnol. 2016;34(5):420–433.
309. V KS, Hong XJ, VMM,MB, Tin A. Progress in anterior chamber angle imaging for glaucoma risk prediction - a review on
clinical equipment, practice and research.Med Eng Phys. 2016;38(12):1383–1391.
310. Bourantas CV, Jaffer FA, Gijsen FJ, van Soest G, Madden SP, Courtney BK, Fard AM, Tenekecioglu E, Zeng Y, van
der Steen AFW, Emelianov S, Muller J, Stone PH, Marcu L, Tearney GJ, Serruys PW. Hybrid intravascular imaging:
recent advances, technical considerations, and current applications in the study of plaque pathophysiology. Eur Heart
J. 2017;38(6):400–412.
311. McNally LR,MezeraM,MorganDE, Frederick PJ, Yang ES, Eltoum IE, GrizzleWE. Current and emerging clinical applica-
tions ofMultispectral Optoacoustic Tomography (MSOT) in oncology. Clin Cancer Res. 2016;22(14):3432–3439.
312. Wang LV, Gao L. Photoacoustic microscopy and computed tomography: from bench to bedside. Annu Rev Biomed Eng.
2014;16:155–185.
313. La Riviere P.WE-H-206-00: advances in preclinical imaging.Med Phys. 2016;43(6):3847–3848.
314. Yao J, Wang LV. Breakthrough in Photonics 2013: photoacoustic tomography in biomedicine. IEEE Photonics J.
2014;6(2):pii: 0701006.
364 ZHENGETAL.
315. Wang L. WE-H-206-01: Photoacoustic tomography: multiscale imaging from organelles to patients by ultrasonically
beating the optical diffusion limit.Med Phys. 2016;43(6):3847–3848.
316. Holotta M, Grossauer H, Kremser C, Torbica P, Volkl J, Degenhart G, Esterhammer R, Nuster R, Paltauf G, Jaschke W.
Photoacoustic tomography of ex vivomouse hearts withmyocardial infarction. J Biomed Opt. 2011;16(3):036007.
317. Zhang C, Cheng YJ, Chen J,Wickline S,Wang LV. Label-free photoacousticmicroscopy ofmyocardial sheet architecture.
J Biomed Opt. 2012;17(6):060506.
318. WangL,MaslovK,XingW,Garcia-UribeA,WangLV.Video-rate functional photoacousticmicroscopyat depths. J Biomed
Opt. 2012;17(10):106007.
319. Zemp RJ, Song L, Bitton R, Shung KK,Wang LV. Realtime photoacoustic microscopy of murine cardiovascular dynamics.
Opt Express. 2008;16(22):18551–18556.
320. Taruttis A, Claussen J, Razansky D, Ntziachristos V. Motion clustering for deblurring multispectral optoacoustic tomog-
raphy images of themouse heart. J Biomed Opt. 2012;17(1):016009.
321. RobinsonWH, Lindstrom TM, Cheung RK, Sokolove J. Mechanistic biomarkers for clinical decision making in rheumatic
diseases.Nat Rev Rheumatol. 2013;9(5):267–276.
322. Ritchlin CT. An integrative approach to biomarker development in psoriatic arthritis. J Rheumatol Suppl. 2015;93:43–
47.
323. AntoineDJ, Dear JW, Lewis PS, Platt V, Coyle J,MassonM, ThanacoodyRH, Gray AJ,WebbDJ,Moggs JG, BatemanDN,
Goldring CE, Park BK. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute
liver injury at first presentation to hospital.Hepatology. 2013;58(2):777–787.
324. WangW, Shi Q, MattesWB,Mendrick DL, Yang X. Translating extracellular microRNA into clinical biomarkers for drug-
induced toxicity: from high-throughput profiling to validation. BiomarkMed. 2015;9(11):1177–1188.
325. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of
microRNAs in living cells. J Biol Chem. 2010;285(23):17442–17452.
326. Iguchi H, Kosaka N, Yoshioka Y, Ochiya T. Secretory microRNAs as a versatile communication tool. Commun Integr Biol.
2010;3(5):478–481.
327. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007;59(9–
10):828–851.
328. Levi F,OkyarA. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. ExpertOpin
Drug Deliv. 2011;8(12):1535–1541.
329. Lin SY, Kawashima Y. Current status and approaches to developing press-coated chronodelivery drug systems. J Control
Release. 2012;157(3):331–353.
330. Mirza Aami M, Shakeel F, Iqbal Z. An overview of the regulatory and developmental strategies of chronotherapeutics.
Therapeutic Innovation & Regulatory Science. 2016;50(4):450–454.
331. Levi F. The circadian timing system, a coordinator of life processes. Implications for the rhythmic delivery of cancer ther-
apeutics. Conf Proc IEEE EngMed Biol Soc. 2006;Suppl:6736–6739.
332. Fu L, Kettner NM. The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci. 2013;119:221–
282.
333. SukumaranS,AlmonRR,DuBoisDC, JuskoWJ.Circadian rhythms in geneexpression: relationship tophysiology, disease,
drug disposition and drug action. Adv Drug Deliv Rev. 2010;62(9–10):904–917.
334. Bordyugov G, Westermark PO, Korencic A, Bernard S, Herzel H. Mathematical modeling in chronobiology. Handb Exp
Pharmacol. 2013;217:335–357.
335. Okamura H. Suprachiasmatic nucleus clock time in the mammalian circadian system. Cold Spring Harb Symp Quant Biol.
2007;72:551–556.
336. Kaur G, Phillips C, Wong K, Saini B. Timing is important in medication administration: a timely review of chronotherapy
research. Int J Clin Pharm. 2013;35(3):344–358.
337. Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Levi FA. The circadian timing system in clinical oncology.
AnnMed. 2014;46(4):191–207.
338. Sewlall S, Pillay V, Danckwerts MP, Choonara YE, Ndesendo VM, du Toit LC. A timely review of state-of-the-art
chronopharmaceuticals synchronizedwith biological rhythms. Curr Drug Deliv. 2010;7(5):370–388.
339. YouanBB.Chronopharmaceutical drug delivery systems: hurdles, hype or hope.AdvDrugDeliv Rev. 2010;62(9–10):898–
903.
ZHENGETAL. 365
340. Ballesta A, Innominato PF, Dallmann R, RandDA, Levi FA. Systems chronotherapeutics. Pharmacol Rev. 2017;69(2):161–
199.
341. Traynor K, Newton DW, Hrushesky WJ, Reiter RJ. A pharmacist's primer on chronotherapeutics. Am Pharm.
1992;NS32(3):77–83.
342. Mandal AS, Biswas N, Karim KM, Guha A, Chatterjee S, Behera M, Kuotsu K. Drug delivery system based on
chronobiology–a review. J Control Release. 2010;147(3):314–325.
343. Tran TH, Lee BJ. On-off pulsed oral drug-delivery systems: a possible tool for drug delivery in chronotherapy. Ther Deliv.
2011;2(9):1199–1214.
344. Sewlall S, Pillay V, Danckwerts MP, Choonara YE, Ndesendo VM, du Toit LC. A timely review of state-of-the-art
chronopharmaceuticals synchronizedwith biological rhythms. Curr Drug Deliv. 2010;7(5):370–388.
345. Singh R, Sharma PK, Malviya R. Circadian cycle and chronotherapeutics: recent trend for the treatment of various bio-
logical disorders. Recent Pat Drug Deliv Formul. 2012;6(1):80–91.
346. Librodo P, BuckleyM, LukM, Bisso A. Chronotherapeutic drug delivery. J Infus Nurs. 2015;6(38 Suppl):S18–S23.
347. Levi F, Karaboue A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, Hauteville D, Guettier C, Adam R, Bouchahda
M. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer
(mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol. 2011;67(2):339–
348.
348. Ohdo S. Chronopharmaceutics: pharmaceutics focused on biological rhythm. Biol Pharm Bull. 2010;33(2):159–167.
349. Altinok A, Levi F, Goldbeter A. A cell cycle automaton model for probing circadian patterns of anticancer drug delivery.
Adv Drug Deliv Rev. 2007;59(9-10):1036–1053.
350. Altinok A, Levi F, Goldbeter A. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs
5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci. 2009;36(1):20–38.
351. Innominato PF, Giacchetti S, Moreau T, Smaaland R, Focan C, Bjarnason GA, Garufi C, Iacobelli S, Tampellini M, Tumolo
S, Carvalho C, Karaboue A, Levi F, Group AIC. Prediction of survival by neutropenia according to delivery schedule
of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC
05963). Chronobiol Int. 2011;28(7):586–600.
352. Grimaldi B. Therapeutic implications of cancer-specific clocks. Ann Pharmacol Pharm. 2017;2(4):1–2.
353. DeMei C, Ercolani L, Parodi C, Veronesi M, Lo Vecchio C, Bottegoni G, Torrente E, Scarpelli R, Marotta R, Ruffili R, Mat-
tioli M, Reggiani A, Wade M, Grimaldi B. Dual inhibition of REV-ERBbeta and autophagy as a novel pharmacological
approach to induce cytotoxicity in cancer cells.Oncogene. 2015;34(20):2597–2608.
354. Sajan J, Cinu TA, Chacko AJ, Litty J, Jaseeda T. Chronotherapeutics and chronotherapeutic drug delivery systems. Trop J
Pharm Res. 2009;8(5):467–475.
355. Levi F, Okyar A. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics.Opin Drug
Deliv. 2011;8(12):1535–1541.
356. Ohdo S, Koyanagi S,MatsunagaN, HamdanA.Molecular basis of chronopharmaceutics. J Pharm Sci. 2011;100(9):3560–
3576.
357. Altun A, Ugur-Altun B.Melatonin: therapeutic and clinical utilization. Int J Clin Pract. 2007;61(5):835–845.
358. ZmrzljakUP, RozmanD. Circadian regulation of the hepatic endobiotic and xenobitoic detoxification pathways: the time
matters. Chem Res Toxicol. 2012;25(4):811–824.
359. Arif IS, Hooper CL, Greco F, Williams AC, Boateng SY. Increasing doxorubicin activity against breast cancer cells using
PPARgamma-ligands and by exploiting circadian rhythms. Br J Pharmacol. 2013;169(5):1178–1188.
360. Doroshaw JH. Anthracyclin antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by
NADHdehydrogenase. Cancer Res. 1983;43(10):4543–4551.
361. Kaiserova H, Simunek T, SterbaM, den Hartog GJ, Schroterova L, Popelova O, Gersl V, Kvasnickova E, Bast A. New iron
chelators in anthracycline-induced cardiotoxicity. Cardiovasc Toxicol. 2007;7(2):145–150.
362. VenegasC,García JA, EscamesG,Ortiz F, LopezA,DoerrierC,Garcia-Corzo L, Lopez LC, Reiter RJ, Acuna-CastroviejoD.
Extrapineal melatonin: analysis of its subcellularr distribution and daily fluctuations. J Pineal Res. 2012;52(2):217–227.
363. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G. Decreased toxicity
and increased efficacy of cancer chemotherapy using the pineal hormonemelatonin in metastatic solid tumour patients
with poor clinical status. Eur J Cancer. 1999;35(12):1688–1692.
364. Lucius K, Trukova K. Integrative therapies and cardiovascular disease in the breast cancer population: a review, part 1.
Integr Med (Encinitas). 2015;14(4):22–29.
366 ZHENGETAL.
365. Piasek A, Bartoszek A, Namiesnik J. [Phytochemicals that counteract the cardiotoxic side effects of cancer
chemotheraSpy] Substancje pochodzenia roslinnegoprzeciwdzialajace kardiotoksycznosci towarzyszacej chemioterapii
nowotworow. Postepy HigMed Dosw (Online). 2009;63:142–158.
366. Gandhi BR, Mundada AS, Gandhi PP. Chronopharmaceutics: as a clinically relevant drug delivery system. Drug Deliv.
2011;18(1):1–18.
367. Hradetzky D. Transdermal drug delivery devices for chronotherapy.Med Device Technol. 2008;19(3):45–47.
368. Lin SY. Chronotherapeutic approach to design a thermoresponsive membrane for transdermal drug delivery. Curr Drug
Deliv. 2004;1(3):249–263.
369. Sutradhar KB, Sumi CD. Implantablemicrochip: the futuristic controlled drug delivery system.Drug Deliv. 2016;23(1):1–
11.
370. Hamidi M, Azadi A, Rafiei P, Ashrafi H. A pharmacokinetic overview of nanotechnology-based drug delivery systems: an
ADME-oriented approach. Crit Rev Ther Drug Carrier Syst. 2013;30(5):435–467.
371. Balmayor ER, Azevedo HS, Reis RL. Controlled delivery systems: from pharmaceuticals to cells and genes. Pharm Res.
2011;28(6):1241–1258.
372. Sharma A, Madhunapantula SV, Robertson GP. Toxicological considerations when creating nanoparticle-based drugs
and drug delivery systems. Expert Opin DrugMetab Toxicol. 2012;8(1):47–69.
373. Patra CN, Swain S, Sruti J, Patro AP, Panigrahi KC, Beg S, Rao ME. Osmotic drug delivery systems: basics and design
approaches. Recent Pat Drug Deliv Formul. 2013;7(2):150–161.
374. Sunil SA, Srikanth MV, Rao NS, Uhumwangho MU, Latha K, Murthy KV. Chronotherapeutic drug delivery systems: an
approach to circadian rhythms diseases. Curr Drug Deliv. 2011;8(6):622–633.
375. Aragao-Santiago L, Bohr A, Delaval M, Dalla-Bona AC, Gessler T, Seeger W, Beck-Broichsitter M. Innovative formula-
tions for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome. Curr Pharm
Des. 2016;22(9):1147–1160.
376. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and chal-
lenges. Ther Deliv. 2014;5(9):1007–1024.
377. Robitzki AA, Kurz R. Biosensing and drug delivery at the microscale: novel devices for controlled and responsive drug
delivery.Handb Exp Pharmacol. 2010;197:87–112.
378. Bale S, KhuranaA, ReddyAS, SinghM,GoduguC.OverviewonTherapeutic Applications ofMicroparticulateDrugDeliv-
ery Systems. Crit Rev Ther Drug Carrier Syst. 2016;33(4):309–361.
379. Cooper DL, Conder CM, Harirforoosh S. Nanoparticles in drug delivery: mechanism of action, formulation and clinical
application towards reduction in drug-associated nephrotoxicity. Expert Opin Drug Deliv. 2014;11(10):1661–1680.
380. GongC,Qi T,Wei X,QuY,WuQ, Luo F,Qian Z. Thermosensitive polymeric hydrogels as drug delivery systems.CurrMed
Chem. 2013;20(1):79–94.
381. Patil SS, Shahiwala A. Patented pulsatile drug delivery technologies for chronotherapy. Expert Opin Ther Pat.
2014;24(8):845–856.
382. Doherty KR, Wappel RL, Talbert DR, Trusk PB, Moran DM, Kramer JW, Brown AM, Shell SA, Bacus S. Multi-parameter
in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol.
2013;272(1):245–255.
383. van Hasselt J, Hansen J, Xiong Y, Shim Y, Pickard A, Jayaraman G, Hu B, Mahajan M, Gallo J, Sobie E, Birtwistle M,
Azeloglu E, Iyengar R. Clinically-weighted transcriptomic signatures for protein kinase inhibitor associated cariotoxic-
ity. BioRxiv. 2016. http://www.biorxiv.org/content/early/2016/09/19/075754.
384. Gwathmey JK, Davidoff AJ. Pathophysiology of cardiomyopathies: Part II. Drug-induced and other interventions. Curr
Opin Cardiol. 1994;9(3):369–378.
385. Barr J, Vazquez-Chantada M, Alonso C, Perez-Cormenzana M, Mayo R, Galan A, Caballeria J, Martin-Duce A, Tran A,
Wagner C, Luka Z, Lu SC, Castro A, Le Marchand-Brustel Y, Martinez-Chantar ML, Veyrie N, Clement K, Tordjman J,
Gual P, Mato JM. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse
model serum reveals putative biomarkers associatedwith the progression of nonalcoholic fatty liver disease. J Proteome
Res. 2010;9(9):4501–4512.
386. Palomo L, Casal E, Royo F, Cabrera D, van-Liempd S, Falcon-Perez JM. Considerations for applying metabolomics to the
analysis of extracellular vesicles. Front Immunol. 2014;5:651.
387. FriedmanRC, FarhKK, BurgeCB, Bartel DP.MostmammalianmRNAs are conserved targets ofmicroRNAs.GenomeRes.
2009;19(1):92–105.
ZHENGETAL. 367
388. Heijne WH, Kienhuis AS, van Ommen B, Stierum RH, Groten JP. Systems toxicology: applications of toxicogenomics,
transcriptomics, proteomics andmetabolomics in toxicology. Expert Rev Proteomics. 2005;2(5):767–780.
389. Schnackenberg LK, Beger RD. Metabolomic biomarkers: their role in the critical path. Drug Discov Today Technol.
2007;4(1):13–16.
390. Chaudhari U, Nemade H, Gaspar JA, Hescheler J, Hengstler JG, Sachinidis A. MicroRNAs as early toxicity signa-
tures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol. 2016;90(12):3087–
3098.
391. Xi B,Wang T, Li N, OuyangW, ZhangW,Wu J, Xu X,WangX, Abassi YA. Functional cardiotoxicity profiling and screening
using the xCELLigence RTCA cardio system. J Lab Autom. 2011;16(6):415–421.
392. Sharma A, Burridge PW,McKeithanWL, Serrano R, Shukla P, Sayed N, Churko JM, Kitani T,WuH, HolmstromA,Matsa
E, Zhang Y, Kumar A, Fan AC, Del Alamo JC,Wu SM,Moslehi JJ, MercolaM,Wu JC. High-throughput screening of tyro-
sine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med. 2017;9(377):eaaf2584.
https://doi.org/10.1126/scitranslmed.aaf2584
393. Penaranda A, Cantalapiedra IR, Bragard J, Echebarria B. Cardiac dynamics: a simplified model for action potential prop-
agation. Theor Biol MedModel. 2012;9:50. https://doi.org/10.1186/1742-4682-9-50.
394. Williams DP, Shipley R, Ellis MJ, Webb S, Ward J, Gardner I, Creton S. Novel in vitro and mathematical models for the
prediction of chemical toxicity. Toxicol Res (Camb). 2013;2(1):40–59.
395. Pawar S, Mahajan K, Vavia P. In vivo anticancer efficacy and toxicity studies of a novel polymer conjugate N-
acetyl glucosamine (NAG)-PEG-doxorubicin for targeted cancer therapy. AAPS PharmSciTech. 2017. https://doi.org/
10.1208/s12249-017-0787-0 [Epub ahead of print].
396. Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with
ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992;52(1):194–201.
397. Ali M, KamjooM, Thomas HD, Kyle S, Pavlovska I, BaburM, Telfer BA, Curtin NJ,Williams KJ. The clinically active PARP
inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving
tumor perfusion and radiation response inmice.Mol Cancer Ther. 2011;10(12):2320–2329.
398. Bellamy WT, Peng YM, Odeleye A, Ellsworth L, Xu MJ, Grogan TM, Weinstein RS. Cardiotoxicity in the SCID mouse
following administration of doxorubicin and cyclosporin A. Anticancer Drugs. 1995;6(6):736–743.
399. Cao J, Cui S, Li S, Du C, Tian J, Wan S, Qian Z, Gu Y, ChenWR,Wang G. Targeted cancer therapy with a 2-deoxyglucose-
based adriamycin complex. Cancer Res. 2013;73(4):1362–1373.
400. D'AvinoC, Paciello R, RiccioG, CoppolaC, Laccetti P,MaureaN, Raines RT,De LorenzoC. Effects of a second-generation
humananti-ErbB2 ImmunoRNaseon trastuzumab-resistant tumors and cardiac cells.Protein EngDes Sel.2014;27(3):83–
88.
401. FedeleC, RiccioG,MalaraAE,D'AlessioG,De LorenzoC.Mechanismsof cardiotoxicity associatedwith ErbB2 inhibitors.
Breast Cancer Res Treat. 2012;134(2):595–602.
402. Mukherjee A, Dutta S, Sanyal U. Evaluation of antitumor efficacy and toxicity of novel 6-nitro-2-(3-chloropropyl)-1H-
benz[de]isoquinoline-1,3-dione in vivo inmouse. J Cancer Res Ther. 2013;9(3):442–446.
403. Nasr M, Nafee N, Saad H, Kazem A. Improved antitumor activity and reduced cardiotoxicity of epirubicin using
hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur J Pharm
Biopharm. 2014;88(1):216–225.
404. Ryu JS, Lee HS, Hong YS, Lee JJ, Sohn UD, Kim TY. In vivo antitumor efficacy and cardiotoxicity of novel anthracycline
ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin). Cancer Chemother Pharmacol. 2006;57(6):811–818.
405. Santucci L, Mencarelli A, Renga B, Ceccobelli D, Pasut G, Veronese FM, Distrutti E, Fiorucci S. Cardiac safety and antitu-
moral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anticancer Drugs. 2007;18(9):1081–1091.
406. Zhou ZY, Wan LL, Yang QJ, Han YL, Li D, Lu J, Guo C. Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug
resistance but increases cardiotoxicity of doxorubicin in aMDR xenograft model. Toxicol Lett. 2016;259:124–132.
407. Fulbright JM, Egas-Bejar DE, HuhWW,Chandra J. Analysis of redox and apoptotic effects of anthracyclines to delineate
a cardioprotective strategy. Cancer Chemother Pharmacol. 2015;76(6):1297–1307.
408. Goyal V, Bews H, Cheung D, Premecz S, Mandal S, Shaikh B, Best R, Bhindi R, Chaudhary R, Ravandi A, Thliveris J, Sin-
gal PK, Niraula S, Jassal DS. The cardioprotective role of N-Acetyl cysteine amide in the prevention of doxorubicin and
trastuzumab-mediated cardiac dysfunction. Can J Cardiol. 2016;32(12):1513–1519.
409. Liu Y, Nguyen P, Baris TZ, Poirier MC. Molecular analysis of mitochondrial compromise in rodent cardiomy-
ocytes exposed long term to nucleoside reverse transcriptase inhibitors (NRTIs). Cardiovasc Toxicol. 2012;12(2):123–
134.
368 ZHENGETAL.
410. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. Cardioprotective effects of zofenopril, a
new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol.
2001;414(1):71–78.
411. ZhuH, Luo P, Fu Y,Wang J, Dai J, Shao J, Yang X, Chang L,WengQ, Yang B, HeQ. Dihydromyricetin prevents cardiotoxi-
city and enhances anticancer activity induced by adriamycin.Oncotarget. 2015;6(5):3254–3267.
412. Zhu W, Zhang W, Shou W, Field LJ. P53 inhibition exacerbates late-stage anthracycline cardiotoxicity. Cardiovasc Res.
2014;103(1):81–89.
413. MilanDJ, PetersonTA,Ruskin JN,PetersonRT,MacRaeCA.Drugs that induce repolarization abnormalities causebrady-
cardia in zebrafish. Circulation. 2003;107(10):1355–1358.
414. Boukens BJ, Rivaud MR, Rentschler S, Coronel R. Misinterpretation of the mouse ECG: ‘musing the waves of Mus mus-
culus’. J Physiol. 2014;592(21):4613–4626.
415. Shin JT, Fishman MC. From Zebrafish to human: modular medical models. Annu Rev Genomics Hum Genet. 2002;3:311–
340.
416. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, Collins JE, Humphray S, McLaren K, Matthews L,
McLaren S, Sealy I, CaccamoM, Churcher C, Scott C, Barrett JC, Koch R, Rauch GJ,White S, ChowW, Kilian B, Quintais
LT, Guerra-Assuncao JA, ZhouY, GuY, Yen J, Vogel JH, Eyre T, Redmond S, Banerjee R, Chi J, Fu B, Langley E,Maguire SF,
Laird GK, LloydD, Kenyon E, Donaldson S, Sehra H, Almeida-King J, Loveland J, Trevanion S, JonesM, Quail M,Willey D,
Hunt A, Burton J, Sims S, McLay K, Plumb B, Davis J, Clee C, Oliver K, Clark R, Riddle C, Elliot D, Threadgold G, Harden
G, Ware D, Begum S, Mortimore B, Kerry G, Heath P, Phillimore B, Tracey A, Corby N, Dunn M, Johnson C, Wood J,
Clark S, Pelan S, Griffiths G, SmithM, Glithero R, Howden P, Barker N, Lloyd C, Stevens C, Harley J, Holt K, Panagiotidis
G, Lovell J, Beasley H, Henderson C, Gordon D, Auger K, Wright D, Collins J, Raisen C, Dyer L, Leung K, Robertson L,
Ambridge K, Leongamornlert D, McGuire S, Gilderthorp R, Griffiths C, Manthravadi D, Nichol S, Barker G,Whitehead S,
Kay M, Brown J, Murnane C, Gray E, Humphries M, Sycamore N, Barker D, Saunders D, Wallis J, Babbage A, Hammond
S, Mashreghi-Mohammadi M, Barr L, Martin S, Wray P, Ellington A, Matthews N, Ellwood M, Woodmansey R, Clark G,
Cooper J, Tromans A, Grafham D, Skuce C, Pandian R, Andrews R, Harrison E, Kimberley A, Garnett J, Fosker N, Hall R,
Garner P, Kelly D, Bird C, Palmer S, Gehring I, Berger A, Dooley CM, Ersan-Urun Z, Eser C, Geiger H, Geisler M, Karotki
L, Kirn A, Konantz J, Konantz M, Oberlander M, Rudolph-Geiger S, Teucke M, Lanz C, Raddatz G, Osoegawa K, Zhu B,
Rapp A,Widaa S, Langford C, Yang F, Schuster SC, Carter NP, Harrow J, Ning Z, Herrero J, Searle SM, Enright A, Geisler
R, Plasterk RH, LeeC,WesterfieldM, de Jong PJ, Zon LI, Postlethwait JH,Nusslein-VolhardC,Hubbard TJ, Roest Crollius
H, Rogers J, Stemple DL. The zebrafish reference genome sequence and its relationship to the human genome. Nature.
2013;496(7446):498–503.
417. MacRae CA, Peterson RT. Zebrafish as tools for drug discovery.Nat Rev Drug Discov. 2015;14(10):721–731.
418. LinKY, ChangWT, Lai YC, Liau I. Toward functional screening of cardioactive and cardiotoxic drugswith zebrafish in vivo
using pseudodynamic three-dimensional imaging. Anal Chem. 2014;86(4):2213–2220.
419. Stainier DY, FishmanMC. The zebrafish as a model system to study cardiovascular development. Trends Cardiovasc Med.
1994;4(5):207–212.
420. Leong IU, Skinner JR, Shelling AN, Love DR. Zebrafish as a model for long QT syndrome: the evidence and the means of
manipulating zebrafish gene expression. Acta Physiol (Oxf). 2010;199(3):257–276.
421. Shin JT, Pomerantsev EV,Mably JD,MacRae CA. High-resolution cardiovascular function confirms functional orthology
of myocardial contractility pathways in zebrafish. Physiol Genomics. 2010;42(2):300–309.
422. Vornanen M, Hassinen M. Zebrafish heart as a model for human cardiac electrophysiology. Channels (Austin).
2016;10(2):101–110.
423. Wlodarchak N, Tariq R, Striker R. Comparative analysis of the human and zebrafish kinomes: focus on the development
of kinase inhibitors. Trends Cell Mol Biol. 2015;10:49–75.
424. Rakshambikai R, Srinivasan N, Gadkari RA. Repertoire of protein kinases encoded in the genome of zebrafish shows
remarkably large population of PIM kinases. J Bioinform Comput Biol. 2014;12(1):1350014.
425. VerkerkAO,RemmeCA.Zebrafish: a novel research tool for cardiac (patho) electrophysiology and ion channel disorders.
Front Physiol. 2012;3:255.
426. Burns CG,MilanDJ, Grande EJ, RottbauerW,MacRaeCA, FishmanMC.High-throughput assay for small molecules that
modulate zebrafish embryonic heart rate.Nat Chem Biol. 2005;1(5):263–264.
427. Chi NC, Shaw RM, Jungblut B, Huisken J, Ferrer T, Arnaout R, Scott I, Beis D, Xiao T, Baier H, Jan LY, Tristani-Firouzi M,
Stainier DY. Genetic and physiologic dissection of the vertebrate cardiac conduction system. PLoS Biol. 2008;6(5):e109.
ZHENGETAL. 369
428. Lin E, CraigC, LamotheM, SarunicMV,BegMF, TibbitsGF. Construction anduse of a zebrafish heart voltage and calcium
optical mapping system, with integrated electrocardiogram and programmable electrical stimulation. Am J Physiol Regul
Integr Comp Physiol. 2015;308(9):R755–R768.
429. Asnani A, Peterson RT. The zebrafish as a tool to identify novel therapies for human cardiovascular disease. Dis Model
Mech. 2014;7(7):763–767.
430. Zheng PP, Severijnen LA, van derWeidenM,Willemsen R, Kros JM. A crucial role of caldesmon in vascular development
in vivo. Cardiovasc Res. 2009;81(2):362–369.
431. Zheng PP, Severijnen LA, Willemsen R, Kros JM. Images in cardiovascular medicine. Functional cardiac phenotypes in
zebrafish caldesmonmorphants: a digital motion analysis. Circulation. 2009;120(17):e145–e146.
432. Zheng PP, Romme E, van der Spek PJ, Dirven CM, Willemsen R, Kros JM. Glut1/SLC2A1 is crucial for the development
of the blood-brain barrier in vivo. Ann Neurol. 2010;68(6):835–844.
433. Tsutsui H, Higashijima S,Miyawaki A, Okamura Y. Visualizing voltage dynamics in zebrafish heart. J Physiol. 2010;588(Pt
12):2017–2021.
434. Cheng H, Kari G, Dicker AP, Rodeck U, KochWJ, Force T. A novel preclinical strategy for identifying cardiotoxic kinase
inhibitors andmechanisms of cardiotoxicity. Circ Res. 2011;109(12):1401–1409.
435. McGrath P, Li CQ. Zebrafish: a predictive model for assessing drug-induced toxicity. Drug Discov Today. 2008;13(9-
10):394–401.
436. Zhu JJ, XuYQ,He JH, YuHP,HuangCJ,Gao JM,DongQX,XuanYX, Li CQ.Human cardiotoxic drugs deliveredby soaking
andmicroinjection induce cardiovascular toxicity in zebrafish. J Appl Toxicol. 2014;34(2):139–148.
437. Akle V, Stankiewicz AJ, Kharchenko V, Yu L, Kharchenko PV, Zhdanova IV. Circadian kinetics of cell cycle progression in
adult neurogenic niches of a diurnal vertebrate. J Neurosci. 2017;37(7):1900–1909.
438. Ben-Moshe Z, Foulkes NS, Gothilf Y. Functional development of the circadian clock in the zebrafish pineal gland. Biomed
Res Int. 2014;2014:235781.
439. Cahill GM, Hurd MW, Batchelor MM. Circadian rhythmicity in the locomotor activity of larval zebrafish. Neuroreport.
1998;9(15):3445–3449.
440. Dang Y, Wang J, Giesy JP, Liu C. Responses of the zebrafish hypothalamic-pituitary-gonadal-liver axis PCR array to
prochloraz are dependent on timing of sampling. Aquat Toxicol. 2016;175:154–159.
441. Dekens MP, Santoriello C, Vallone D, Grassi G, Whitmore D, Foulkes NS. Light regulates the cell cycle in zebrafish. Curr
Biol. 2003;13(23):2051–2057.
442. Dickmeis T, Lahiri K, NicaG, ValloneD, SantorielloC,NeumannCJ, HammerschmidtM, FoulkesNS. Glucocorticoids play
a key role in circadian cell cycle rhythms. PLoS Biol. 2007;5(4):e78.
443. Hirayama J, Cardone L, Doi M, Sassone-Corsi P. Common pathways in circadian and cell cycle clocks: light-dependent
activation of Fos/AP-1 in zebrafish controls CRY-1a andWEE-1. Proc Natl Acad Sci U S A. 2005;102(29):10194–10199.
444. Idda ML, Bertolucci C, Vallone D, Gothilf Y, Sanchez-Vazquez FJ, Foulkes NS. Circadian clocks: lessons from fish. Prog
Brain Res. 2012;199:41–57.
445. IddaML, Kage E, Lopez-Olmeda JF,MracekP, FoulkesNS, ValloneD. Circadian timing of injury-induced cell proliferation
in zebrafish. PLoS One. 2012;7(3):e34203.
446. Moore HA,Whitmore D. Circadian rhythmicity and light sensitivity of the zebrafish brain. PLoS One. 2014;9(1):e86176.
447. NocheRR, Lu PN,Goldstein-Kral L, GlasgowE, Liang JO. Circadian rhythms in the pineal organ persist in zebrafish larvae
that lack ventral brain. BMCNeurosci. 2011;12:7.
448. Smadja Storz S, Tovin A, Mracek P, Alon S, Foulkes NS, Gothilf Y. Casein kinase 1delta activity: a key element in the
zebrafish circadian timing system. PLoS One. 2013;8(1):e54189.
449. Tovin A, Alon S, Ben-Moshe Z, Mracek P, Vatine G, Foulkes NS, Jacob-Hirsch J, Rechavi G, Toyama R, Coon SL, Klein DC,
Eisenberg E, Gothilf Y. Systematic identification of rhythmic genes reveals camk1gb as a new element in the circadian
clockwork. PLoS Genet. 2012;8(12):e1003116.
450. Uchida Y, Hirayama J, NishinaH. A common origin: signaling similarities in the regulation of the circadian clock andDNA
damage responses. Biol Pharm Bull. 2010;33(4):535–544.
451. Vallone D, Gondi SB, Whitmore D, Foulkes NS. E-box function in a period gene repressed by light. Proc Natl Acad Sci U S
A. 2004;101(12):4106–4111.
452. VansteenselMJ,Michel S,Meijer JH. Organization of cell and tissue circadian pacemakers: a comparison among species.
Brain Res Rev. 2008;58(1):18–47.
370 ZHENGETAL.
453. Vatine G, Vallone D, Gothilf Y, Foulkes NS. It's time to swim! Zebrafish and the circadian clock. FEBS Lett.
2011;585(10):1485–1494.
454. Whitmore D, Cermakian N, Crosio C, Foulkes NS, Pando MP, Travnickova Z, Sassone-Corsi P. A clockwork organ. Biol
Chem. 2000;381(9-10):793–800.
455. Xiao B, Cui LQ, Ding C, Wang H. Effects of lithium and 2,4-dichlorophenol on zebrafish: circadian rhythm disorder and
molecular effects. Zebrafish. 2017;14(3):209–215.
456. Guerra-Varela J, Cabezas-Sainz P, Yebra-Pimentel E, Gutierrez-Lovera C, Cedron VP, Otero Obarrio MA, Sciara AA,
Rodriguez N, Araujo J, Millan A, Sanchez L. “A zebra in the water”: inspiring science in Spain. Zebrafish. 2016;13(4):241–
247.
457. Doke SK, Dhawale SC. Alternatives to animal testing: a review. Saudi Pharm J. 2015;23(3):223–229.
458. Strahle U, Scholz S, Geisler R, Greiner P, Hollert H, Rastegar S, Schumacher A, Selderslaghs I,Weiss C,Witters H, Braun-
beck T. Zebrafish embryos as an alternative to animal experiments–a commentary on the definition of the onset of pro-
tected life stages in animal welfare regulations. Reprod Toxicol. 2012;33(2):128–132.
459. Kacew S. Confounding factors in toxicity testing. Toxicology. 2001;160(1-3):87–96.
460. Kennedy-Lydon T, Rosenthal N. Cardiac regeneration: epicardial mediated repair. Proc Biol Sci. 2015;
282(1821):20152147.
461. Masters M, Riley PR. The epicardium signals the way towards heart regeneration. Stem Cell Res. 2014;13(3 Pt B):683–
692.
462. Challa AK, Chatti K. Conservation and early expression of zebrafish tyrosine kinases support the utility of zebrafish as a
model for tyrosine kinase biology. Zebrafish. 2013;10(3):264–274.
463. Hall AM,OrlowSJ. Degradation of tyrosinase induced by phenylthiourea occurs followingGolgimaturation. Pigment Cell
Res. 2005;18(2):122–129.
464. Wang WD, Wang Y, Wen HJ, Buhler DR, Hu CH. Phenylthiourea as a weak activator of aryl hydrocarbon receptor
inhibiting 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced CYP1A1 transcription in zebrafish embryo. Biochem Pharmacol.
2004;68(1):63–71.
465. Sarmah S, Marrs JA. Zebrafish as a vertebrate model system to evaluate effects of environmental toxicants on cardiac
development and function. Int J Mol Sci. 2016;17(12):2123.
466. Sabeh MK, Kekhia H, Macrae CA. Optical mapping in the developing zebrafish heart. Pediatr Cardiol. 2012;33(6):916–
922.
467. Ferl GZ, Theil FP, Wong H. Physibodies: a minireview on physiologically based pharmacokineyic models of small
molecules and therapeutic antibodies: a minreview on fundamental concepts and applications. Biopharm Drug Dispos.
2016;37(2):75–92.
468. Gibiansky L, Gibiansky E. Target-mediated drug disposition model and its approximations for antibody-drug conjugates.
J Pharmacokinet Pharmacodyn. 2014;41(1):35–47.
469. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell. 2011;145(1):19–24.
470. MacConaill LE, Lindeman NI, Rollins BJ. Brave-ish New World–what's needed to make precision oncology a practical
reality. JAMAOncol. 2015;1(7):879–880.
471. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin
Cancer Res. 2009;15(24):7471–7478.
472. Gharwan H, Groninger H. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin
Oncol. 2016;13(4):209–227.
473. KurianAW,FrieseCR.Precisionmedicine inbreast cancer care: anearly glimpseof impact. JAMAOncol.2015;1(8):1109–
1110.
474. Rubin R. A precisionmedicine approach to clinical trials. JAMA. 2016;316(19):1953–1955.
475. Blumenthal GM, Mansfield E, Pazdur R. Next-generation sequencing in oncology in the era of precision medicine. JAMA
Oncol. 2016;2(1):13–14.
476. Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A,
Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C,
JanewayKA.Multicenter feasibility study of tumormolecular profiling to inform therapeutic decisions in advanced pedi-
atric solid tumors: the individualized cancer therapy (iCat) study. JAMAOncol. 2016;2(5):608–615.
477. Horlings HM, Shah SP, Huntsman DG. Using somatic mutations to guide treatment decisions: context matters. JAMA
Oncol. 2015;1(3):275–276.
ZHENGETAL. 371
478. Pasche B, Absher D. Whole-genome sequencing: a step closer to personalized medicine. JAMA. 2011;305(15):1596–
1597.
479. Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016;17(2):e81–
e86.
480. Gibbs JB.Mechanism-based target identification and drug discovery in cancer research. Science.2000;287(5460):1969–
1973.
481. Abrams J, Conley B, MooneyM, Zwiebel J, Chen A,Welch JJ, Takebe N, Malik S, McShane L, Korn E, WilliamsM, Staudt
L, Doroshow J. National Cancer Institute's precision medicine initiatives for the new national clinical trials network. Am
Soc Clin Oncol Educ Book. 2014:71–76.
482. Asic K. Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to tar-
geted therapies. Crit Rev Oncol Hematol. 2016;97:178–196.
483. ShoshanMC, Linder S. Target specificity and off-target effects as determinants of cancer drug efficacy. Expert Opin Drug
Metab Toxicol. 2008;4(3):273–280.
484. HolohanC,Van Schaeybroeck S, LongleyDB, JohnstonPG.Cancer drug resistance: an evolving paradigm.Nat RevCancer.
2013;13(10):714–726.
485. Hammerman PS, Janne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in
non-small cell lung cancer. Clin Cancer Res. 2009;15(24):7502–7509.
486. Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic
myeloid leukemia. Clin Cancer Res. 2009;15(24):7519–7527.
487. JannePA,GrayN, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.Nat RevDrug
Discov. 2009;8(9):709–723.
488. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-basedmechanisms of cytotoxic chemotherapy: implications for the
design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15–25.
489. Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, Wong N, Lafarga V, Calvo JA, Panzarino NJ, John
S, Day A, Crespo AV, Shen B, Starnes LM, de Ruiter JR, Daniel JA, Konstantinopoulos PA, Cortez D, Cantor SB,
Fernandez-Capetillo O, Ge K, Jonkers J, Rottenberg S, Sharan SK, Nussenzweig A. Replication fork stability confers
chemoresistance in BRCA-deficient cells.Nature. 2016;535(7612):382–387.
490. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding
genes or promoter regions, epigenetic changes andmicroRNAs.Drug Resist Updat. 2007;10(1–2):59–67.
491. Duesberg P, Stindl R, Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes:
chromosome reassortments catalyzed by aneuploidy. Proc Natl Acad Sci U S A. 2001;98(20):11283–11288.
492. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung ade-
nocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med.
2005;2(3):e73.
493. Joyner MJ, Paneth N, Ioannidis JP. What happens when underperforming big ideas in research become entrenched?
JAMA. 2016;316(13):1355–1356.
494. ChauNG, Lorch JH. Exceptional Responders inspire change: lessons for drug development from thebedside to the bench
and back.Oncologist. 2015;20(7):699–701.
495. Prasad V. Perspective: the precision-oncology illusion.Nature. 2016;537(7619):S63.
496. Subbiah IM, Subbiah V. Exceptional responders: in search of the science behind the miracle cancer cures. Future Oncol.
2015;11(1):1–4.
497. Takebe N, McShane L, Conley B. Biomarkers: exceptional responders-discovering predictive biomarkers. Nat Rev Clin
Oncol. 2015;12(3):132–134.
498. Mullard A. Learning from exceptional drug responders.Nat Rev Drug Discov. 2014;13(6):401–402.
499. Poh A. In search of exceptional responders. Cancer Discov. 2015;5(1):8.
500. Sheridan C. Cancer centers zero in on exceptional responders.Nat Biotechnol. 2014;32(8):703–704.
501. Damrongwatanasuk R, Fradley MG. Cardiovascular complications of targeted therapies for chronic myeloid leukemia.
Curr Treat Options Cardiovasc Med. 2017;19(4):24.
502. BergerMF, Van Allen EM. Delivering on the promise of precision cancer medicine.GenomeMed. 2016;8(1):110.
503. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts
SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C,
Ambrogio L, Nickerson E, Shefler E, Cortes ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L,
372 ZHENGETAL.
HeimanDI, Fennell T, ImielinskiM,Hernandez B, Hodis E, Baca S, DulakAM, Lohr J, LandauDA,WuCJ,Melendez-Zajgla
J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Lee RS, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie
K, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sun-
yaev S, Lander ES, Getz G. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature.
2013;499(7457):214–218.
504. Zhao J, Cheng F, Wang Y, Arteaga CL, Zhao Z. Systematic prioritization of druggable mutations in approximately 5000
genomes across 16 cancer types using a structural genomics-based approach.Mol Cell Proteomics. 2016;15(2):642–656.
505. McFarland CD, Korolev KS, Kryukov GV, Sunyaev SR, Mirny LA. Impact of deleterious passenger mutations on cancer
progression. Proc Natl Acad Sci U S A. 2013;110(8):2910–2915.
506. McFarlandCD,Mirny LA, Korolev KS. Tug-of-war between driver and passengermutations in cancer and other adaptive
processes. Proc Natl Acad Sci U S A. 2014;111(42):15138–15143.
507. Carragher NO, Unciti-Broceta A, Cameron DA. Advancing cancer drug discovery towards more agile development of
targeted combination therapies. Future Med Chem. 2012;4(1):87–105.
508. Groenendijk FH, Bernards R. Drug resistance to targeted therapies: deja vu all over again.Mol Oncol. 2014;8(6):1067–
1083.
509. Carr TH, McEwen R, Dougherty B, Johnson JH, Dry JR, Lai Z, Ghazoui Z, Laing NM, Hodgson DR, Cruzalegui F,
Hollingsworth SJ, Barrett JC. Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer.
2016;16(5):319–329.
510. Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell. 2012;148(3):409–
420.
511. Rask-Andersen M, Masuram S, Schioth HB. The druggable genome: evaluation of drug targets in clinical trials suggests
major shifts in molecular class and indication. Annu Rev Pharmacol Toxicol. 2014;54:9–26.
512. Fuller SJ, Osborne SA, Leonard SJ, HardymanMA, Vaniotis G, Allen BG, Sugden PH, Clerk A. Cardiac protein kinases: the
cardiomyocyte kinome and differential kinase expression in human failing hearts. Cardiovasc Res. 2015;108(1):87–98.
513. FedorovO,Muller S, Knapp S. The (un)targeted cancer kinome.Nat Chem Biol. 2010;6(3):166–169.
514. Lal H, Kolaja KL, Force T. Cancer genetics and the cardiotoxicity of the therapeutics. J Am Coll Cardiol. 2013;61(3):267–
274.
515. Blaes A, Prizment A, Koene RJ, Konety S. Cardio-oncology related to heart failure: common risk factors between cancer
and cardiovascular disease.Heart Fail Clin. 2017;13(2):367–380.
516. ChenMH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer ther-
apeutics. Circulation. 2008;118(1):84–95.
517. Force T, KuidaK,NamchukM, ParangK, Kyriakis JM. Inhibitors of protein kinase signaling pathways: emerging therapies
for cardiovascular disease. Circulation. 2004;109(10):1196–1205.
518. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. Comprehensive
analysis of kinase inhibitor selectivity.Nat Biotechnol. 2011;29(11):1046–1051.
519. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design.
Trends Pharmacol Sci. 2005;26(4):178–182.
520. Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest.
2015;125(5):1780–1789.
521. PichlerWJ, Beeler A, KellerM, LerchM, Posadas S, Schmid D, Spanou Z, Zawodniak A, Gerber B. Pharmacological inter-
action of drugs with immune receptors: the p-i concept. Allergol Int. 2006;55(1):17–25.
522. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin
Allergy Clin Immunol. 2002;2(4):301–305.
523. Pichler WJ. The p-i concept: pharmacological interaction of drugs with immune receptors. World Allergy Organ J.
2008;1(6):96–102.
524. Handley ME, Rasaiyaah J, Chain BM, Katz DR. Mixed lineage kinases (MLKs): a role in dendritic cells, inflammation and
immunity? Int J Exp Pathol. 2007;88(2):111–126.
525. Ott PA, Adams S. Small-molecule protein kinase inhibitors and their effects on the immune system: implications for can-
cer treatment. Immunotherapy. 2011;3(2):213–227.
526. Mohty M, Blaise D, Olive D, Gaugler B. Imatinib: the narrow line between immune tolerance and activation. Trends Mol
Med. 2005;11(9):397–402.
ZHENGETAL. 373
527. Seggewiss R, Price DA, Purbhoo MA. Immunomodulatory effects of imatinib and second-generation tyrosine kinase
inhibitors on T cells and dendritic cells: an update. Cytotherapy. 2008;10(6):633–641.
528. Seliger B,MassaC, Rini B, Ko J, Finke J. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.
TrendsMol Med. 2010;16(4):184–192.
529. Kwilas AR, Donahue RN, Tsang KY, Hodge JW. Immune consequences of tyrosine kinase inhibitors that synergize with
cancer immunotherapy. Cancer Cell. Microenviron. 2015;2(1):pii: e677.
530. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. Science.
2013;339(6127):1546–1558.
531. Khurana E, Fu Y, Chakravarty D, Demichelis F, Rubin MA, Gerstein M. Role of non-coding sequence variants in cancer.
Nat Rev Genet. 2016;17(2):93–108.
532. Weinhold N, Jacobsen A, Schultz N, Sander C, LeeW. Genome-wide analysis of noncoding regulatory mutations in can-
cer.Nat Genet. 2014;46(11):1160–1165.
533. Mularoni L, SabarinathanR,Deu-Pons J, Gonzalez-PerezA, Lopez-BigasN.OncodriveFML: a general framework to iden-
tify coding and non-coding regions with cancer driver mutations.Genome Biol. 2016;17(1):128.
534. Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, Shoresh N, Whitton H, Ryan RJ, Shishkin AA,
Hatan M, Carrasco-Alfonso MJ, Mayer D, Luckey CJ, Patsopoulos NA, De Jager PL, Kuchroo VK, Epstein CB, Daly
MJ, Hafler DA, Bernstein BE. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature.
2015;518(7539):337–343.
535. Ben-Bassat H, Klein BY. Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des. 2000;6(9):933–
942.
536. Kontzias A, Laurence A, Gadina M, O'Shea JJ. Kinase inhibitors in the treatment of immune-mediated disease. F1000
Med Rep. 2012;4:5.
537. Patterson H, Nibbs R, McInnes I, Siebert S. Protein kinase inhibitors in the treatment of inflammatory and autoimmune
diseases. Clin Exp Immunol. 2014;176(1):1–10.
538. Belmonte SL, Blaxall BC. G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res.
2011;109(3):309–319.
539. SatohK, FukumotoY, ShimokawaH.Rho-kinase: important new therapeutic target in cardiovascular diseases.AmJPhys-
iol Heart Circ Physiol. 2011;301(2):H287–H296.
540. Dhalla NS, Muller AL. Protein kinases as drug development targets for heart disease therapy. Pharmaceuticals (Basel).
2010;3(7):2111–2145.
541. Mardinoglu A, Nielsen J. Systemsmedicine andmetabolic modelling. J InternMed. 2012;271(2):142–154.
542. Kell DB. The virtual human: towards a global systems biology of multiscale, distributed biochemical network models.
IUBMB Life. 2007;59(11):689–695.
543. Goldstein DM, Gray NS, Zarrinkar PP. High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug
Discov. 2008;7(5):391–397.
544. Patricelli MP, Szardenings AK, Liyanage M, Nomanbhoy TK, WuM,Weissig H, Aban A, Chun D, Tanner S, Kozarich JW.
Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry. 2007;46(2):350–358.
545. Scheiber J, Chen B, Milik M, Sukuru SC, Bender A, Mikhailov D, Whitebread S, Hamon J, Azzaoui K, Urban L, Glick M,
Davies JW, Jenkins JL. Gaining insight into off-targetmediated effects of drug candidateswith a comprehensive systems
chemical biology analysis. J Chem Inf Model. 2009;49(2):308–317.
546. Jain V, Bahia J, Mohebtash M, Barac A. Cardiovascular complications associated with novel cancer immunotherapies.
Curr Treat Options Cardiovasc Med. 2017;19(5):36.
547. Avelumab. https://www.uptodate.com/contents/avelumab-drug-information?source=search_result&search=Bavencio
&selectedTitle=1~12. 2017.
548. Avelumab. https://www.bavencio.com/en_US/for-patients-and-caregivers.html. 2017.
549. Durvalumab. https://www.uptodate.com/contents/durvalumab-drug-information?source=search_result&search=
Imfinzi&selectedTitle=1~11. 2017.
550. Varricchi G, Marone G, Mercurio V, Galdiero MR, Bonaduce D, Tocchetti CG. Immune checkpoint inhibitors and car-
diac toxicity: an emerging issue. Curr Med Chem. 2017. https://doi.org/10.2174/0929867324666170407125017 [Epub
ahead of print].
551. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Holle-
becque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C,
374 ZHENGETAL.
Robert C, Soria JC,Marabelle A, LambotteO. Immune-related adverse eventswith immune checkpoint blockade: a com-
prehensive review. Eur J Cancer. 2016;54:139–148.
552. Li Y, Li F, Jiang F, Lv X, Zhang R, Lu A, Zhang G. A mini-review for cancer immunotherapy: molecular understanding of
PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci. 2016;17(7).
553. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–
242.
554. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci.
2011;1217:45–59.
555. Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G. Immune checkpoint blockade in cancer treatment: a
double-edged sword cross-targeting the host as an “innocent bystander”. Toxins (Basel). 2014;6(3):914–933.
556. Romano E, Romero P. The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing
theCD8T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors.
J Immunother Cancer. 2015;3:15.
557. Cappelli LC, Shah AA, Bingham CO, 3rd. Immune-related adverse effects of cancer immunotherapy- implications for
rheumatology. RheumDis Clin North Am. 2017;43(1):65–78.
558. Atezolizumab. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm.
559. KongYC, Flynn JC.Opportunistic autoimmunedisorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and
anti-PD-1. Front Immunol. 2014;5:206.
560. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, HaraM,Matsumori A, Sasayama S,Mizoguchi A, Hiai H,Minato N, Honjo
T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319–322.
561. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T.
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med.
2003;9(12):1477–1483.
562. Kyi C, PostowMA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014;588(2):368–376.
563. Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and
immune checkpoint inhibitors. Cancer Biol Med. 2015;12(3):201–208.
564. GadAZ, El-Naggar S,AhmedN.Realismandpragmatism indeveloping aneffective chimeric antigen receptorT-cell prod-
uct for solid cancers. Cytotherapy. 2016;18(11):1382–1392.
565. O'Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat
Rev. 2017;52:71–81.
566. News. ‘Immunoswitch’ particles may be key to more effective cancer immunotherapy. 2017. https://www.
drugtargetreview.com/news/23754/immunoswitch-particles-may-key-effective-cancer-immunotherapy/?utm_medium
=email&utm_campaign=DTR%20-%20Newsletter%2023%202017&utm_content=DTR%20-%20Newsletter%2023%
202017+CID_baf709250c33534ce98ca5b551a0fceb&utm_source=Email%20marketing&utm_term=Immunoswitch%
20particles%20may%20be%20key%20to%20more%20effective%20cancer%20immunotherapy.
567. Malissen N, Lacotte J, Du-Thanh A, Gaudy-Marqueste C, Guillot B, Grob JJ. Macrophage activation syndrome: a new
complication of checkpoint inhibitors. Eur J Cancer. 2017;77:88–89.
568. Fousek K, Ahmed N. The evolution of T-cell therapies for solid malignancies. Clin Cancer Res. 2015;21(15):3384–
3392.
569. Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy
using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer
J. 2012;18(2):160–175.
570. Newick K, O'Brien S,Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu RevMed. 2017;68:139–152.
571. Gill S,MausMV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in themaking. Blood Rev. 2016;30(3):157–
167.
572. Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rah-
man RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M.
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol.
2015;34(2):154–187.
573. Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst.
2016;108(7):pii: djv439.
574. ChmielewskiM, AbkenH. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154.
ZHENGETAL. 375
575. Han EQ, Li XL, Wang CR, Li TF, Han SY. Chimeric antigen receptor-engineered T cells for cancer immunotherapy:
progress and challenges. J Hematol Oncol. 2013;6:47.
576. Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lym-
phoblastic leukemia. Blood. 2015;125(26):4017–4023.
577. CameronBJ, Gerry AB, Dukes J, Harper JV, KannanV, Bianchi FC, Grand F, Brewer JE, GuptaM, PlesaG, Bossi G, Vuide-
potA, PowleslandAS, LeggA,AdamsKJ, BennettAD, PumphreyNJ,WilliamsDD,Binder-SchollG,Kulikovskaya I, Levine
BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK.
Identification of a Titin-derivedHLA-A1-presented peptide as a cross-reactive target for engineeredMAGEA3-directed
T cells. Sci Transl Med. 2013;5(197):197ra103.
578. King J,Waxman J, Stauss H. Advances in tumour immunotherapy.QJM. 2008;101(9):675–683.
579. Maude SL, Barrett D, TeacheyDT, Grupp SA.Managing cytokine release syndrome associatedwith novel T cell-engaging
therapies. Cancer J. 2014;20(2):119–122.
580. Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist.
2016;21(5):608–617.
581. ZhangE, XuH.Anew insight in chimeric antigen receptor-engineeredT cells for cancer immunotherapy. JHematol Oncol.
2017;10(1):1.
582. Shank BR, Do B, Sevin A, Chen SE, Neelapu SS, Horowitz SB. Chimeric Antigen receptor T cells in hematologicmalignan-
cies. Pharmacotherapy. 2017;37(3):334–345.
583. Lu YC, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol. 2016;28(1):22–27.
584. Saida Y, Watanabe S, Tanaka T, Baba J, Sato K, Shoji S, Igarashi N, Kondo R, Okajima M, Koshio J, Ichikawa K, Nozaki K,
IshikawaD, Koya T,Miura S, Tanaka J, KagamuH, YoshizawaH,Nakata K, Narita I. Critical roles of chemoresistant effec-
tor and regulatory T cells in antitumor immunity after lymphodepleting chemotherapy. J Immunol. 2015;195(2):726–
735.
585. de JongeME,HuitemaAD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide.Clin Pharmacokinet.
2005;44(11):1135–1164.
586. Dhesi S, Chu MP, Blevins G, Paterson I, Larratt L, Oudit GY, Kim DH. Cyclophosphamide-induced cardiomy-
opathy: a case report, review, and recommendations for management. J Investig Med High Impact Case Rep.
2013;1(1):2324709613480346.
587. Mehta J, Singhal S, Or R. Cyclophosphamide-induced cardiomyopathy during bone marrow transplantation for severe
aplastic anemia. J Assoc Physicians India. 1994;42(2):159–160.
588. Taniguchi I. Clinical significance of cyclophosphamide-induced cardiotoxicity. InternMed. 2005;44(2):89–90.
589. DiMaggio PA, Jr., Subramani A, Judson RS, Floudas CA. A novel framework for predicting in vivo toxicities from in vitro
data using optimalmethods for dense and sparsematrix reordering and logistic regression. Toxicol Sci.2010;118(1):251–
265.
590. Ngo NT, Brodie C, Giles C, Horncastle D, KlammerM, Lampert IA, Rahemtulla A, Naresh KN. The significance of tumour
cell immunophenotype inmyeloma and its impact on clinical outcome. J Clin Pathol. 2009;62(11):1009–1015.
591. Crow J, Youens K, Michalowski S, Perrine G, Emhart C, Johnson F, Gerling A, Kurtzberg J, Goodman BK, Sebastian S,
RehderCW,DattoMB.Donor cell leukemia inumbilical cordblood transplant patients: a case studyand literature review
highlighting the importance of molecular engraftment analysis. J Mol Diagn. 2010;12(4):530–537.
592. Csermely P, Korcsmaros T, Kiss HJ, London G, Nussinov R. Structure and dynamics of molecular networks: a novel
paradigm of drug discovery: a comprehensive review. Pharmacol Ther. 2013;138(3):333–408.
593. Buffery D. The 2015 oncology drug pipeline: innovation drives the race to cure cancer. Am Health Drug Benefits.
2015;8(4):216–222.
594. Listing CD. https://www.cancer.gov/about-cancer/treatment/drugs. NCI Database.
595. Wang H, Yin Y, Wang P, Xiong C, Huang L, Li S, Li X, Fu L. Current situation and future usage of anticancer drug
databases. Apoptosis. 2016;21(7):778–794.
596. Jovenaux L, Cautela J, Resseguier N, Pibarot M, Taouqi M, Orabona M, Pinto J, Peyrol M, Barraud J, Laine M, Bonello L,
Paganelli F, Barlesi F, Thuny F. Practices in management of cancer treatment-related cardiovascular toxicity: a cardio-
oncology survey. Int J Cardiol. 2017;241:387–392.
597. Lopez-Fernandez T, Martin Garcia A, Santaballa Beltran A, Montero Luis A, Garcia Sanz R, Mazon Ramos P, Velasco
Del Castillo S, Lopez de Sa Areses E, Barreiro-Perez M, Hinojar Baydes R, Perez de Isla L, Valbuena Lopez SC, Dal-
mau Gonzalez-Gallarza R, Calvo-Iglesias F, Gonzalez Ferrer JJ, Castro Fernandez A, Gonzalez-Caballero E, Mitroi
376 ZHENGETAL.
C, Arenas M, Virizuela Echaburu JA, Marco Vera P, Iniguez Romo A, Zamorano JL, Plana Gomez JC, Lopez Sendon
Henchel JL. Cardio-onco-hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol (Engl Ed).
2017;70(6):474–486.
SUPPORTING INFORMATION
Additional Supporting Informationmay be found online in the supporting information tab for this article.
How to cite this article: Zheng P-P, Li J, Kros JM. Breakthroughs in modern cancer therapy and elu-
sive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Med Res Rev. 2018;38:325–376.
https://doi.org/10.1002/med.21463
